The affective response to CO2 in healthy volunteers : an instance of a primal emotion

Citation for published version (APA):

Colasanti, A. (2012). *The affective response to CO2 in healthy volunteers : an instance of a primal emotion*. [Doctoral Thesis, Maastricht University]. Maastricht University.
<https://doi.org/10.26481/dis.20121025ac>

Document status and date:
Published: 01/01/2012

DOI:
[10.26481/dis.20121025ac](https://doi.org/10.26481/dis.20121025ac)

Document Version:
Publisher's PDF, also known as Version of record

Please check the document version of this publication:

- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

[Link to publication](#)

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

www.umlib.nl/taverne-license

Take down policy

If you believe that this document breaches copyright please contact us at:

repository@maastrichtuniversity.nl

providing details and we will investigate your claim.

Alessandro Colasanti

**The affective response to CO₂ in healthy volunteers:
an instance of a primal emotion**

Cover: The dawn of man. Drawing based on a scene of the movie ‘2001: A Space Odyssey’ (1968).

© Alessandro Colasanti, London, 2012

Design: Alessandro Colasanti

Print: Smikhouse Maastricht

From the School of Mental Health and Neuroscience,
Maastricht University, The Netherlands, 2012

The affective response to CO₂ in healthy volunteers:
an instance of a primal emotion

Dissertation

To obtain the degree of DOCTOR at the Maastricht University
on the authority of the Rector Magnificus, Prof dr. L.L.G Soete
in accordance with the decision of the Board of Deans,
to be defended in public
on Thursday, the 25th of October 2012, at 12:00 hours

by

Alessandro Colasanti

Supervisor:

Prof. dr. Eric J.L. Griez

Co-supervisor:

Dr. Koen R.J. Schruers

Assessment Committee:

Prof. dr. Harry Steinbusch (Chairman)

Prof. dr. David J. Nutt

Prof. dr. Inez Myin-Germeys

Prof. dr. Giampaolo Perna

Dr. Rob van Diest

The research presented in this thesis was conducted at the Academic Anxiety Center Maastricht, Mondrian Zorggroep, School for Mental Health and Neuroscience, Maastricht University, Maastricht, The Netherlands.

per sara,

per mio padre

Paranymphs:

Gabriel Esquivel

Christopher Rieder

Contents

Introduction

Chapter 1. On the psychotropic effects of Carbon Dioxide

Chapter 2. Carbon Dioxide inhalation induces dose dependent and age-related negative affectivity

Chapter 3. Carbon Dioxide-induced emotion and respiratory symptoms in healthy volunteers

Chapter 4. Multidimensional characterization of respiratory symptoms in CO₂-elicited panic in healthy volunteers

Chapter 5. Effects of tryptophan depletion and tryptophan loading on the affective response to high dose CO₂ challenge in healthy volunteers

Chapter 6. The affective response to CO₂: a true primal emotion?

Summary and concluding remarks

Samenvatting en conclusies

Introduction

Aim of the thesis

The inhalation of high concentrations of carbon dioxide (CO₂) triggers a powerful instinctual response in humans characterized by the rapid occurrence of an intense urge for air and a sudden increase in ventilation. The aim of the present thesis is to experimentally characterize the emotional response to inhalation of CO₂ in humans.

In experimental settings, it is possible to administer CO₂ to human subjects in a safe, standardized, and reliable manner. By studying the subjective response to CO₂ in a laboratory context, it is possible to experimentally reproduce and characterize the emotional response associated to a basic instinct for life, such as air hunger. That response represents an instance of a “primal” emotion.

This experimental paradigm provides researchers in affective neuroscience and experimental psychopathology with an important opportunity to understand how affective responses rooted in instinctual behaviours may inform about the psychopathological states observed in psychiatric disorders. In fact, there have been theories suggesting that panic attacks originate from a phylogenetically ancient, innate, instinctual response aimed to protect the organism against asphyxia. In the studies reported in the present thesis, we analyze the phenomenology and pharmacology of CO₂-induced emotion, and we test the hypothesis that the instinctual responses to CO₂ inhalation in healthy human subjects share closely related features with panic attacks.

Background

Instincts are inherent inclinations of an organism toward a particular behaviour with high survival value. In animals, as well as in humans, when strongly aroused, instincts incorporate an imperious sensation and a compelling specific intention. The subjective element that coalesces these physiologic entities has been defined as a primal (or primordial) emotion by the physiologist Derek Denton (Denton, 2006). Indeed, instincts and emotions are closely bound. William James (James, 1918) stated that “in speaking of instincts, it has been

impossible to keep them separate from the emotional excitements which go with them [...] They shade imperceptively into each other”.

Primal emotions, such as hunger for air, hunger for minerals or for food, thirst, pain, or sexual arousal, are all generated by vegetative systems and dictated by chemical events sensed by interoceptors. When aroused, these emotions completely occupy the stream of the consciousness. They serve a homeostatic function and are genetically programmed to guard the physicochemical constancy of the internal environment of the body (Denton, 2006).

Air hunger is a form of primal emotion, programmed to protect the organism against the risk of impending suffocation and acidosis, and aimed to restore the acid-base balance and oxygen supply by cueing breathing (Liotti *et al*, 2001). Air hunger is characterized by the conscious perception of an urge to breathe, which arises when pulmonary ventilation is insufficient for the metabolic needs of the organism (Lansing *et al*, 2009). Air hunger, specifically, is believed to result from a mismatch of afferent information between respiratory drive and ventilation, and is therefore dependent on afferents originating from brainstem, informing about the automatic drive to breathe and related motor activity, and afferents from lungs, informing about the amount of pulmonary ventilation (Lansing *et al*, 2009).

Different interoceptors are involved in the origin of air hunger, including central and peripheral CO_2/H^+ chemoceptors, which project to brainstem nuclei, mechanoreceptors of the chest wall, and a number of pulmonary receptors such as vagal receptors, stretch receptors, type-J receptors in the walls of alveoli and capillaries, and irritant receptors in the upper airways and the tracheobronchial walls (von Leupoldt and Dahme, 2005). A classic stimulus to induce air hunger is the administration of CO_2 -enriched air mixtures; however other ventilatory stimuli, such as hypoxia and metabolic acidosis, can trigger air hunger by stimulating the brainstem reflex ventilatory drive. The level of air hunger is related to the level of ventilatory drive irrespective of the ventilatory stimulus and regardless of whether this arises from central or peripheral chemoreceptor afferent activity, suggesting that air hunger is directly dependent on the reflex respiratory drive (Moosavi *et al*, 2003). Although it is not the only stimulus capable to induce air hunger, acute hypercapnia per se is a

powerful way to evoke air hunger, even in absence of the afferent contribution from respiratory muscles, as demonstrated by an experiment showing that totally curarized, and mechanically ventilated, human subjects reported severe air hunger during hypercapnia (Banzett *et al*, 1990).

In experimental psychiatry, the acute administration of CO₂ has been widely used for more than 25 years as tool to experimentally reproduce panic attacks in patients affected by Panic Disorder (PD) (Griez and Schruers, 1998). CO₂-challenges are relatively easy and non-invasive procedures, the two most common techniques of CO₂ administration consisting in either a single or double vital capacity inhalation of 35% CO₂ or 5-20 minute inhalation of 5-7.5% CO₂ through continuous exposure (Verburg *et al*, 2001). The assessments of the subjective response among the studies have classically used self-report measures based on the physiological and psychological panic symptoms defined by the Diagnostic and Statistical Manual of Mental Disorder, 4th edition (DSM-IV-TR) criteria for panic attack (Verburg *et al*, 2001).

The interest of researchers in experimental anxiety in the panicogenic properties of CO₂ arose from the well-established finding that a proportion of patients affected by PD are hypersensitive to CO₂, relative to healthy individuals and patients suffering from other psychopathological conditions (Griez *et al*, 1990a). When PD patients undergo a CO₂-challenge, they experience an emotion closely resembling the panic attacks that occur naturally, out of the blue, as a consequence of their condition. First-degree relatives of PD patients share, to a lesser extent, an increased sensitivity to CO₂ (van Beek and Griez, 2000). These findings have indicated that the vulnerability to CO₂ could represent a genetic trait marker of panic susceptibility, and stimulated the use of the CO₂-challenge as an experimental model of panic, eventually contributing to the formulation of several influential theories of the etiology of PD.

One of these theories was proposed by Donald Klein in 1993 (Klein, 1993; Preter and Klein, 2008), based on the hypersensitivity to CO₂ observed in PD patients, and accounted for a large number of experimental findings. He proposed that panic originates from the maladaptive response of a deranged inborn suffocation detector, sensitive to CO₂. When the

suffocation monitor erroneously detects excessively increased CO₂ concentrations, it alerts the organism to the threat of impending asphyxia, eventually leading to a behavioural and emotional response characterized by an urge for breathing and acute panic. Klein, in other words, proposed that panic attacks were false alarms of suffocation, occurring in individuals with a dysfunctional CO₂ suffocation detector (Klein, 1993; Preter *et al*, 2008).

This theory postulates the existence of an innate suffocation detector as part of the physiologic repertoire of human organism. The idea that panic attacks originate from a hard-wired, innate, instinctual response programmed to protect the organism against asphyxia fits perfectly with the concept of primal emotions previously described. The feeling of panic would correspond to the subjective feeling of air hunger, which completely occupies the stream of consciousness when CO₂ levels are excessively raised. If the hypothesis is true, every individual with no vulnerability to panic would experience a panic-like feeling when exposed to sufficiently high CO₂ doses. The CO₂-induced subjective response should be comparable to clinical panic, both in terms of phenomenological features and pharmacological modulation. Furthermore, the panic-like feeling evoked by CO₂ should closely correlate with the feeling of air hunger.

Based on these assumptions, the objective of the present thesis is to investigate the response to exposure to high-doses of CO₂ in healthy volunteers, aiming to answer the following research questions:

1. Does CO₂ induce acute emotional distress, resembling panic, in healthy volunteers when CO₂ doses are adequately increased?
2. Is the phenomenology of response to CO₂ similar in healthy subjects and patients with PD?
3. Is the emotional response to CO₂ specifically associated to respiratory sensations?
4. Does the manipulation of the serotonin system, which modulates clinical panic, influence the response to CO₂?

Finally, we try to answer the question: Does CO₂ really evoke a true emotion?

Outline

In chapter 1 we present a comprehensive review of the literature on the human response to exposure of exogenous CO₂ and its psychopharmacological properties. In the first half of the 20th century, CO₂ has been used as an anaesthetic and therapeutic agent, while in the last 25 years it became widely used in experimental psychiatric research as an experimental model of panic. Early human physiology studies and reports of cases of CO₂ poisoning and intoxications provide clues of the subjective effects of breathing CO₂ at different concentrations in humans, and indicate that the prolonged exposure at doses higher than 10% is associated with an intense emotional distress. The review also provides a complete summary of the studies on the genetics and pharmacology of the response to CO₂ in humans and animals, and includes an overview of the main mechanisms underlying CO₂-induced affective responses. It concludes with the evolutionary-inspired hypothesis that CO₂ might act as an agent of a primal emotion serving a homeostatic function, in the control of respiration and acid-base balance.

Due to ethical and methodological limits, it's not possible to test the affective response to prolonged exposure to CO₂ at doses higher than those used in the above-mentioned early physiology studies. However, documenting a dose-response relationship using very short exposures to CO₂ may provide a safe and easier solution to extrapolate information about the response to extreme concentrations. In the study reported in chapter 2, we investigated the acute emotional response to increasing concentration of CO₂ in 64 healthy subjects, who underwent a double inhalation of four gas mixtures containing respectively 0, 9, 17.5 and 35% CO₂ in a cross-over, randomized design. We demonstrated that CO₂ challenges induced a dose dependent negative affect compliant with the DSM-IV definition of panic attack. Approximately one third of the subjects experienced a short-lived panic attack with the highest CO₂ concentration. These data indicate that CO₂ induces acute emotional distress, resembling panic, in healthy volunteers when CO₂ doses are adequately increased.

To investigate the phenomenology of CO₂-induced emotional response, in chapter 3 we report the results of a factor analysis study of the CO₂ challenge-induced panic symptoms, using 4 different CO₂ concentrations. Three clusters of symptoms were extracted:

respiratory, cognitive, and neurovegetative, which correspond closely to the clusters of symptoms occurring in PD patients during their spontaneous attacks. Furthermore, the respiratory symptoms induced by CO₂ were the best correlate of the emotional distress evoked by the challenge at the highest doses. These findings underlie the specificity of respiratory symptoms in the phenomenology of the emotional response to CO₂, and fit numerous epidemiological and clinical evidences indicating that panic and respiration are closely related.

In chapter 4, we characterized the emotional response to CO₂ using a multidimensional instrument that measures the sensorial and affective components of respiratory discomfort. All the dimensions of respiratory discomfort were affected by the challenge. We found that the rating of respiratory discomfort was strongly correlated to the intensity of the CO₂ – induced panic feeling, showing a higher predictive power relative to that of all non-respiratory DSM-IV panic symptoms, and was able to accurately discriminate between responders and non-responders to the CO₂ challenge. By demonstrating that a scale rating respiratory discomfort could be successfully applied as a tool to evaluate the subjective response to CO₂, we provided support to the idea that respiratory symptoms are a central phenomenon in experimental panic induced by CO₂.

It has been reported that in PD the manipulation of serotonin precursor tryptophan alters the vulnerability to experimentally induced panic. In the study reported in chapter 5, we aimed to investigate the effects of tryptophan depletion and tryptophan loading on CO₂ induced panic response in healthy volunteers. We found that CO₂-induced subjective distress and air hunger were significantly lower after tryptophan depletion, and that the subjective distress was positively correlated to the availability of serotonin precursors. These findings go in the opposite direction relative to the results observed in PD patients; however they are in line with preclinical data indicating a role for the serotonergic system in promoting the aversive respiratory sensations to hypercapnic stimuli (Severson *et al*, 2003). The differences observed in our study, compared to previous findings in PD patients, might depend on an altered serotonergic modulatory function in PD patients compared to healthy subjects.

In chapter 6, we apply the criteria proposed by Cabanac for the definition of emotion to the findings of our studies, in order to test if the subjective response to CO₂ truly complies with the definition of emotion. Finally, we discuss other influential authors' views on primal emotions. To conclude, we summarize our findings and suggest future directions for further research.

Chapter I

On the psychotropic effects of Carbon Dioxide

Alessandro Colasanti ^{1,2}, Gabriel Esquivel ¹, Koen J. Schruers ¹, Eric J Griez ¹

¹ *Department of Psychiatry and Neuropsychology, Faculty of Health, Medicine and Life Sciences Research Institute Mental Health and Neuroscience, Maastricht University, NL*

² *Centre for Neuropsychopharmacology, Division of Brain Sciences, Imperial College London, UK*

Published as: Colasanti A, Esquivel G, Schruers K, Griez EJ. On the psychotropic properties of carbon dioxide. *Curr Pharm Des.* 2012 May 24.

Abstract

It has been well established that the inhalation of Carbon Dioxide (CO₂) can induce in humans an emotion closely replicating spontaneous panic attacks, as defined by current psychiatry nosology. The purpose of this review is to provide a critical summary of the data regarding CO₂'s psychopharmacological properties and underlying mechanisms. The authors review the literature on the human and animal response for the exposure of exogenous CO₂ focusing on five points of interest: 1) the early history of the use of CO₂ as an anesthetic and therapeutic agent, 2) the subjective effects of breathing CO₂ at different concentrations in humans, 3) the use of CO₂ in experimental psychiatric research as an experimental model of panic, 4) the pharmacological modulation of CO₂-induced responses, and 5) the putative neurobiological mechanisms underlying the affective state induced by CO₂. The authors conclude with an evolutionary-inspired notion that CO₂ might act as an agent of a primal emotion serving a homeostatic function, in the control of respiration and acid-base balance.

Keywords

Carbon dioxide; panic disorder; anxiety; fear; primal emotion; CO₂ challenge; respiration; human models.

Chapter I - Table of Contents

1. CO₂ from an early anaesthetic agent to an experimental tool in anxiety research	21
2. Subjective and objective effects of CO₂ in healthy humans.....	24
2. 1 Psychotropic effects of CO ₂ following accidental exposure	25
2.1.1 CO ₂ poisoning	25
2.1.2 CO ₂ and panic hazards in scuba divers	26
2. 2 Experimental studies	27
3. CO₂ challenge as an experimental model of panic attacks	29
3.1 Validation of CO ₂ as an experimental model of panic attacks	30
3.2 Genetics of CO ₂ sensitivity	31
3.3 Sensitivity to CO ₂ in the normal population.....	32
4 Pharmacological modulation of the affective response to CO₂	36
4.1 Studies in healthy volunteers.....	36
4.2 Studies in Panic Disorder Patients.....	37
4.3 Studies in animal models.....	38
5. Putative mechanisms of CO₂-induced affective states	38
5.1 Neural response to CO ₂ inhalation involves limbic and paralimbic activations	39
5.2 Midbrain serotonergic neurons are CO ₂ chemosensitive.....	40
5.3 Amygdala is a CO ₂ -chemosensor that elicits fear responses	40
6. CO₂ as the agent of a primal emotion	41
6.1 Rostral extension of CO ₂ sensitivity	41
6.2 Grounds for a suffocation alarm.....	42
6.3 A particular instance of primal emotion	43
7. Conclusions	43

1. CO₂ from an early anaesthetic agent to an experimental tool in anxiety research

First known references to what is now called carbon dioxide (CO₂) originated by the work of Helmont (1577-1644), who identified CO₂ and Black (1728-1799), who isolated CO₂ from chalk by acid and established that was identical to the air produced in animal respiration and that could have toxic effects (Davison, 1965; Foregger, 1957). In 1777, Lavoisier (1743–1794) proposed that inhaled oxygen (O₂) was transformed in the body to CO₂ and that respired air, containing low levels of O₂ and increased CO₂ concentration, was unfit for rebreathing. The first experiment shedding light on the effects derived from inhaling CO₂ was carried out by Hickman (1800-1830), who observed that putting small animals under a glass bell, they became initially restless and breathing hard until respiration arrested. Immediately thereafter, the experimenter could cut the animals' ear without they were showing any sign of pain. After the operation the animals recovered. Hickman suggested that the unconsciousness induced by inhalation of CO₂ to produce what he called “suspended animation” could be used to provide pain-free surgical procedures (Hickman, 1965). The anesthetic properties of CO₂ were formally recognized only a century later, in the early XX century. When anesthesia began to be accepted as a part of the surgical routine, the technique employed was generally asphyxial rebreathing. Anesthetic procedures were brief and patients usually were able to tolerate the asphyxial assaults (Morris, 2002). Leake and Waters (1929) studied the effects of mixtures of CO₂ with O₂ on rabbits and dogs, and performed some preliminary studies on man; they confirmed Hickman's reports and supported his statement that CO₂ produced unconsciousness. The same authors (Leake, 1929; Loevenhart, 1929) separately participated in administration of repeated inhalations from 10 to 40% CO₂ to psychiatric patients as a form of shock therapy in treatment of “dementia precox”, “manic depressive insanity”, and “involutional melancholia”, obtaining striking effects in patients who had been mute or inaccessible for years. The results were attributed to CO₂-induced cerebral stimulation. The positive effects however were short-lived and disappeared within 2 to 25 minutes following the inhalations (Loevenhart, 1929).

Even if the interest of research in its anxiogenic properties raised only in the last 25 years (see section 3), CO₂ was shown to be eliciting anxiety in vulnerable individuals since 1919, when Drury showed that CO₂ caused CO₂-induced hyperventilation and feeling of breathlessness in soldiers affected by the irritable heart syndrome, an early diagnostic entity similar to Panic Disorder (PD), at a lower inspired CO₂ concentrations than in control subjects. The finding was replicated 30 years later in patients with anxiety neurosis, when it was shown that the prolonged rebreathing of CO₂-enriched gas mixtures induced symptoms resembling those of their anxiety, particularly during so-called “anxiety attacks” (Cohen and White, 1951).

In spite of these early suggestions, the psychotropic properties of CO₂ remained almost unrecognised until the middle eighties. For almost seventy years since Drury’s reports, the use of CO₂ inhalation in psychiatry has been confined to rare and peculiar therapeutic techniques used in the 1950s as the Meduna’s “Carbon Dioxide therapy” and La Verne’s “Rapid coma technique” (Laverne, 1953; Meduna, 1955). These authors described the use of prolonged exposure to very high concentration of CO₂, respectively mixtures containing 30% and 70% CO₂ in patients with conversion symptoms, anxiety neurosis, personality disorders, and addiction disorders. The rationale of the techniques is still unclear. The treatment was based on an organic theory claiming that “neurosis” was caused by abnormally low threshold of stimulation and CO₂ treatment was intended to raise the threshold of stimulation to the normal level of resistance to noxious stimuli. Meduna’s technique consisted in repeated inhalations of 30% CO₂ -70% O₂ until induction of coma, while La Verne used 70% CO₂ in order to obtain a more rapid loss of consciousness. During CO₂ therapy subjects lost consciousness after 8-10 deep breaths of 30% CO₂, but in some cases forced administration of CO₂ was continued until 80 inhalations. During the initial phase the patient experienced a large increase in respiration rate and in respiration volume, a sense of panicky breathlessness, flushing of the face, and perspiration. Many patients felt that they were choking and raised their hands to remove the mask or to turn their heads. Some patients fought violently, kicked and screamed at top of their voices. Obviously the first complication was the fact that it could reinforce anxiety in patients with overt anxiety and in those who fear the treatment, and the reinforcement of anxiety was usually proportionate to the length

of the treatment. In the assessment of the psychodynamic factors responsible of the effectiveness of the treatment, it was stated that CO₂ inhalation definitely provoked feelings of smothering and of a literal threat to life, thus causing a stress situation which required an active effort to be handled (Rogers, 1955).

In the late '50s, CO₂ was turned into possible adjunct to psychiatric treatment based on the behaviorist concept of "reciprocal inhibition", which refers to the complete or partial suppression of anxiety responses to specific stimuli as a consequence of the immediate evocation of other responses physiologically antagonistic to anxiety. The technique, proposed by Wolpe (Wolpe, 1958), aimed to condition a new behavioral response, evoked by CO₂, which would have been able to replace the anxiety response. CO₂ was used for this purpose, and 20 cases of pervasive anxiety successfully treated by CO₂ were reported. After Wolpe's seminal work, other experiments were carried out to test the assumption that CO₂ inhalation has such an anxiolytic effect. Although these reports were consistent with the earlier findings, indicating that CO₂ reduced anxiety, refined replications of those studies by Griez & van den Hout in the early '80s repeatedly indicated that inspiring CO₂ in itself was not anxiety-reducing at all (Griez and van den Hout, 1982; van den Hout and Griez, 1982).

A different use of CO₂ inhalation was made by Orwin (Orwin, 1973) who treated situational phobic patients with the so-called technique "respiratory relief". CO₂ mixtures were introduced because of their properties of respiratory stimulation: it was believed that intensifying the need to breathe would have resulted in an augmented respiratory relief. The basic hypothesis was that a respiratory relief, satisfying an intense need to breathe, would inhibit the degree of anxiety provoked by the simultaneous presentation of the phobic stimulus.

Shortly after these preliminary suggestions, the interest of anxiety researchers in CO₂ began to shift from its putative anxiolytic properties to the current use of CO₂ as a panicogenic agent (see section 3).

2. Subjective and objective effects of CO₂ in healthy humans

CO₂ is the fourth most abundant gas in the earth's atmosphere. It is a colorless, odorless, non-irritating gas present in normal air at the concentration of 0.027-0.036%. It is faintly acidic-tasting and non-flammable at room temperature. CO₂ is formed during metabolism in humans and animals, in fermentation and decomposition and during the burning of fossil fuels. It is also available in solid and liquid forms.

Short exposures to concentrations lower than 2% have no noticeable effects on man. The symptoms depend on the concentration and the period of the exposure. Up to 4-6% CO₂ the only effects are a marked increase in ventilation, and mild dizziness and headache. At 6% of CO₂ dyspnea appears, the respiration can be difficult, distressing and increasingly anguished for some individuals. Then tachycardia, asthenia, visual disturbances, worsening of headache, dizziness, and confusion may occur. At 8% dyspnea becomes severe (Arena and Drew, 1986). The effects become more marked when at least 10% of the gas is present in the air. Tinnitus, tremor, profuse perspiration, increased blood pressure, abnormal eye movements can occur. Some individuals cannot tolerate concentrations above 10% for more than 5-10 minutes. Others can support it much better and there are cases of 1 hour exposure at concentrations near 10% CO₂ without evident harm (De Coninck, 1963). After prolonged exposures to 12% CO₂ dyspnea is extreme, accompanied by drowsiness, muscle twitching, vomit, photophobia and retinal degeneration. Prolonged exposures (more than 5 minutes) to higher concentrations (above 17%) result in CO₂ intoxications, characterized by stupor, loss of consciousness, convulsions, and eventually death.

In this section, we report the effects of different doses of CO₂, derived from accidental or occupational exposures and experimental procedures. In reviewing the literature we pay attention to any clue for anxiety, panic and extreme discomfort caused by breathing CO₂. We focus on the behavioural and psychological dimension and try to extrapolate data about these dimensions if they are not explicitly investigated in the studies.

2.1 Psychotropic effects of CO₂ following accidental exposure

2.1.1 CO₂ poisoning

Cases of CO₂ poisoning are described in the literature (Langford, 2005). Massive CO₂ poisoning occurred in occasion of two catastrophic events in 1984 and 1986, both occurred in Cameroon, Africa, when emissions up to 10⁹ m³ of gases were released from volcanic lakes. It was concluded that the gas was nearly all CO₂ and the poisonings could be attributed to it (Kling *et al*, 1987). Exogenous CO₂ may also be recovered from lime or cement kilns, flue gases, fermentation processes, and natural gas wells. It is also used for preserving foods, especially during transportations. Exposures may occur in mines, caves, tunnels, wells, holds of ships, tanks or any place where fermentation processes have formed CO₂. The use of dry ice and CO₂ fire extinguishers also offers exposures. A US environmental Protection Agency study investigated deaths resulting from the discharge of CO₂ fire extinguishing systems between 1975 and 2000; a total of 51 incidents occurred, with 72 deaths and 145 injuries (EPA, 2000). The course of the acute poisoning described in case reports (Gill *et al*, 2002; Romeo *et al*, 2002; Troisi, 1957; Williams, 1958) consists in a rapid loss of consciousness accompanied by minor symptoms as giddiness, pain in the legs, and pain and dryness of the throat. In these cases it was concluded that the percentage of CO₂ in the inspired air could have been between 15% and 30%. In an interesting report (Kreiss *et al*, 2003), a man and a woman reported episodic shortness of breath, confusion, poor concentration, light-headedness, dizziness, headache, blurry vision and fatigue every time they went down in the basement of their house. Their symptoms always resolved within minutes of returning upstairs, however basement-related symptoms persisted for two years, until the woman went to a hospital emergency department on two consecutive mornings with shortness of breath, rapid heart rate, and panic. The air sampled in the basement showed CO₂ concentrations of 10-12%.

Another example of CO₂ hazard is in general aviation, where CO₂ is used in fire-extinguishing system and in form of dry ice. Cases have been reported where firing of false alarms caused releases of CO₂ in the aircraft, resulting in partial incapacitation of the crew and eventually crashes. In a review (Gibbons, 1977) of CO₂ hazards in general aviation, it is

stated that CO₂ can have definite adverse effect on passengers and flight crew, and that possible panic, and associated performance decrements, that might occur from sudden, rapid, uncontrollable breathing could also lead to an aircraft accident.

2.1.2 CO₂ and panic hazards in scuba divers

CO₂ build-up constitutes a significant potential hazard which may lead to diving accidents and fatalities (Edmonds, 1992). CO₂ can accumulate insidiously in the diver, who intentionally holds the breath intermittently (skip breathing) in a mistaken attempt to conserve air. Moreover, divers may hypoventilate unintentionally if a tight wetsuit or buoyancy compensator jacket restricts chest wall expansion, or if ventilation is inadequate in response to physical exertion as when swimming against a strong current. Strenuous exercise can increase the rate of CO₂ production by more than 10-fold, resulting in a transient elevation in arterial CO₂ pressure (Pa CO₂) of more than 60 mm Hg. Furthermore, increased gas density at depth increases the work of breathing and thus the effort required to vent accumulated CO₂. When diving with any closed or semi-closed circuit rebreathing apparatus, part or all of the diver's exhaled breathing gas is recirculated and rebreathed after CO₂ is removed via a CO₂-absorbent material. Inadequate CO₂ absorption is possible with improper packing or saturation of the absorbent (Edmonds, 1992). A further risk occurs when the diver who runs out of air, removes the regulator, and takes repeated breaths from a trapped gas pocket that has formed under the roof of a cave, then rapidly developing hypercapnia.

In more than 60% of scuba diving fatalities, the cause is listed as drowning. Drowning is usually caused by specific problems, as lack of air, entanglement, air embolism, narcosis, and panic. There is considerable evidence that the occurrence of panic contribute to a substantial number of diving accidents and fatalities (Morgan, 1995). Air embolism, a common cause of diving fatalities, may also result from a rapid ascent due to panic (Sweeney, 1993). Mortality associated with diving is not restricted to the novice divers: it has been reported that more than half of a sample of experienced divers have experienced panic or near-panic behaviour while diving on one or more occasions (Morgan, 1995). While Brown has stated that emotional instability or "panic plays a big role in many, if not most,

diving accidents” (Brown, 1982), Graver had claimed that panic “[...]is the diver’s worst enemy” (Graver, 1993).

Morgan and Raven have shown that trait anxiety can accurately predict the majority of those individuals who will experience respiratory distress while wearing the Self-Contained Breathing Apparatus (SCBA) and performing heavy exercise (Morgan, 1995). According to Morgan, respiratory responses to exercise and CO₂ are influenced by psychopathology, and individuals classified as “hyperventilators” or “hypoventilators” appear to be particularly vulnerable to problems associated to the use of SCBA (Morgan, 1983). There is evidence that individuals who become certified scuba divers, score in the low range on measures of state and trait anxiety. Moreover, there is evidence that individuals who discontinue involvement in scuba diving, display significantly higher trait anxiety than those who continue (Morgan, 1995).

In summary, there is agreement that panic behaviour is one of the primary reasons for scuba diving injuries or fatalities, and there is evidence that certain individuals are more likely to panic while scuba diving than others. The idea that panic amongst divers might be a consequence of increased CO₂ is appealing, as it has been well demonstrated that CO₂ load is a frequent occurrence during scuba diving. The fact that divers have been shown to be at risk for performance impairment, immediately after a period of CO₂ retention load (Henning *et al*, 1990), provides further support to that hypothesis.

2.2 Experimental studies

Ethical issues determine a limitation in the CO₂ doses suitable for experimental studies. Up to 20 minutes of 7.5% CO₂ and a few breaths of 35% CO₂ are absolutely safe procedures, which have been used in psychiatric research for two decades without any unexpected adverse event. They will be described in chapter 3.

The effects of prolonged exposures to higher doses, as more than 7.5% CO₂, can be only extrapolated from reports of human physiology experiments. In fact, many experimental studies were conducted in the past to explore the physiological response to CO₂ in humans, testing the highest tolerable concentrations of CO₂.

In an early study, Brown (Brown, 1930) studied 7 male subjects with percentages of CO₂ ranging from 5.5% to 12.4% and O₂ ranging from 14.4% to 39.7%. He stated that these concentrations were “so excessive as to be intolerable within a comparatively short time”. The exposure periods showed considerable variations: from 3 to 10 minutes with 7.5% and 8.8% of CO₂ and from 0,75 to 2 minutes with 10.4% and 12.4%. Subjective symptoms were panting, dyspnea, dizziness, sensation of flushing, sweating of the face, drowsiness, headache, sense of impending collapse, irritation of the throat and choking sensation. One subject actually collapsed at 12.4% CO₂ and other two reported the sensation of impending loss of consciousness. High O₂ compared to low O₂ did not minimize the effects. In 1946, Dripps and Comroe (Dripps and Comroe, 1947) administered inhalations of 7.6 and 10.4 % CO₂ to 44 male young subjects for a period of time ranging from 2,5 to 6 minutes at 10.4 % CO₂ and from 2.5 to 8.5 minutes at 7.6 % CO₂. The symptoms most frequently noted during inhalation of 10.4 % CO₂ were dizziness, dyspnea and faintness. In less than a half of the total of the subjects also sweating, restlessness, headache, fullness in head were reported. Other symptoms noted were: general discomfort, exhaustion, palpitation, substernal pain, muscle tremors, tingling, irritation of the nose, cold extremities, mental clouding, dimness of vision, analgesia, unawareness of the surrounding, and a sensation described “as being in the first stage of nitrous oxide anaesthesia”. In 1960, in a study by Sechzer *et al.* (1960), 12 healthy male volunteers inspired concentrations of CO₂ in O₂ ranging from 7% and 14% for periods of 10- 20 minutes. Several subjects described the experience as “horrible”, “unbearable”, “like strangling” or “suffocating”. Others experienced a fear of calamity or a feeling of impending death. Profuse sweating, restlessness, headache, chills and excitement were reported, and visual and auditory hallucinations also occurred in few cases. Some subjects vomited into the mouthpiece, others lost consciousness. In 1965, an experiment (Brackett *et al.*, 1965) was performed in a large environmental chamber: 7 human volunteers were exposed to a 7% CO₂ and then to a 10% CO₂ atmosphere in a room where the CO₂ tension was automatically maintained at the desired level. All the subjects were able to tolerate the 7% CO₂ atmosphere for as long as it was requested (40 to 90 minutes), but all of them reported dyspnea, headache, and burning of the eyes. Mental status seemed unaffected. During exposure to 10% CO₂ atmosphere the subjects reported extreme hyperventilation and dyspnea, restlessness and confusion. Progressive listlessness also occurred. For these reasons

the period of exposure was discontinued after 15-25 minutes. A study on cognitive performance (Sayers *et al*, 1987) conducted in 10 healthy subjects, compared the effects of a 20 minutes inhalation of different CO₂ concentrations (0- 4.5- 5.5- 6.5- 7.5)% and a 80 minutes inhalation of 6.5% CO₂. A greater impairment of cognitive performance was seen while subjects breathed 6.5% and 7.5% CO₂ compared to 0%, 4.5% and 5.5% CO₂. Exposure to 7.5% CO₂ caused marked discomfort in all cases and one subject withdrew before completing the tests. In another study (Maresh *et al*, 1997) on 32 healthy volunteers, 6% and 8% CO₂ inhalations were compared, and a feeling of derealization or depersonalisation was reported only in the 8% CO₂ condition. The subjects were able to perceive a difference between the two concentrations, although shortness of breath, sweating, heart palpitations, pressure in the chest, tingling, and dizziness occurred in both the conditions. Two subjects removed their mouthpiece and walked out from the experiment during the 8% CO₂ condition.

3. CO₂ challenge as an experimental model of panic attacks

The current interest in the use of CO₂ as a probe of experimental anxiety originates in 1984 by simultaneous observations that CO₂ triggers an immediate feeling of anxiety, which resembles naturally occurring panic, in subjects with a diagnosis of PD (Gorman *et al*, 1984; Van den Hout and Griez, 1984). Not only is the inhalation of CO₂ an efficient means of provoking panic and anxiety in individuals affected by PD, but it also is a relatively easy and non-invasive procedure, since the induced symptoms, while intense, are very short-lived. Based on this, CO₂-induced panic has become a subject of much research over the last decades and has contributed to the formulation of several influential theories on the aetiology of PD.

Different methodological approaches have been used to demonstrate that exposure to high concentration of CO₂ tends to produce intense bodily sensations and panic attacks, significantly more often in individuals with PD than in individuals with other disorders or in healthy controls. The two most common techniques of CO₂ administration are: 1) single or double vital capacity inhalation of 35% CO₂ through a self-administration mask (Verburg *et*

al, 2001); 2) 5-20 minutes inhalation of 5-7.5% CO₂ through continuous exposure to a steady-state level in a respiratory canopy, or through Read rebreathing method via mouthpiece (Papp *et al*, 1997). The assessments of the subjective response among the studies differ on whether they have used a self-report measure, a behavioural definition of panic, or an observation of the participant by the experimenter (Rassovsky and Kushner, 2003). While many instruments developed for this purpose tend to survey both physiological and psychological panic symptoms defined by the Diagnostic and Statistical Manual of Mental Disorder, 4th edition (DSM-IV-TR) (APA, 2000) criteria, there is wide variation in terms of the minimum symptom intensity threshold required to define a panic attack.

3.1 Validation of CO₂ as an experimental model of panic attacks

There is substantial variability among the studies in the rates of CO₂-induced panic attacks, both in individuals with PD and in controls. However, the pattern of the overall findings described below indicates that inhaling high doses of CO₂ is a validated method to induce panic.

After CO₂ inhalation PD patients experience panic attacks characterized by similar symptoms to those occurring in real life panic attacks (Gorman *et al*, 1984; Van den Hout *et al*, 1984). PD patients are more sensitive to CO₂ challenges than healthy controls (Fyer *et al*, 1987; Griez *et al*, 1990a; Griez *et al*, 1987b; Perna *et al*, 1994a; Woods *et al*, 1988; Woods *et al*, 1986). Furthermore, PD patients are more sensitive to CO₂ challenges than patients affected by other anxiety disorders, like Obsessive Compulsive Disorder (Griez *et al*, 1990a; Perna *et al*, 1995b; Zandbergen *et al*, 1991), General Anxiety Disorder (Holt and Andrews, 1989; Perna *et al*, 1999a; Verburg *et al*, 1995a), Specific and Situational Phobias (Rapee *et al*, 1992; Verburg *et al*, 1994), and other subjects with high level of anxiety (Gorman *et al*, 1988; Griez *et al*, 1990b). PD patients are also more sensitive to CO₂ challenges than patients affected by Major Depressive Disorder (Kent *et al*, 2001; Perna *et al*, 1995a; Verburg *et al*, 1998a) and Eating Disorders (Perna *et al*, 2004c). Specifically, PD patients with prominent respiratory symptoms appear to be more sensitive to CO₂ compared to PD patients with predominant non-respiratory symptoms (Biber and Alkin, 1999; Nardi *et al*, 2002; Valenca *et al*, 2002). Also, history of accidental suffocation and presence of premenstrual distress are

associated with a higher sensitivity to CO₂ inhalation (Monkul *et al*, 2010; Nillni *et al*, 2010).

Some exception to the specificity of CO₂ hyperreactivity has been observed: an intermediate sensitivity to CO₂ was observed in social phobia (Antony *et al*, 1997; Blechert *et al*, 2010; Caldirola *et al*, 1997; Gorman *et al*, 1990; Papp *et al*, 1993; Schutters *et al*, 2012), Premenstrual Mood Disorder (Gorman *et al*, 2001; Harrison *et al*, 1989; Kent *et al*, 2001) and Post-Traumatic Stress Disorder (Muhtz *et al*, 2011) but see (Talesnik *et al*, 2007), thus suggesting a possible shared underlying pathophysiology of those disorders with PD; moreover, preliminary findings suggest the presence of a certain vulnerability to CO₂ in Bipolar Disorder (MacKinnon *et al*, 2007; Mackinnon *et al*, 2009) and extreme sensitivity to CO₂ in Schizophrenic patients (Savitz *et al*, 2011).

3.2 Genetics of CO₂ sensitivity

A family history of PD conveys a liability to experience anxiety with CO₂ exposure. Studies on healthy individuals with family histories of PD suggest that a panic reaction to high-dose CO₂ is a trait marker for PD, in fact individuals with a family history of PD, but no personal history of panic attacks, respond to CO₂ inhalation with more anxiety than do individuals who lack a family history (Cavallini *et al*, 1999; Coryell, 1997; Coryell *et al*, 2001; Coryell *et al*, 2006; Perna *et al*, 1999b; Perna *et al*, 1995c; van Beek *et al*, 2000). Moreover, patients who panic with CO₂ inhalation appear to have a relatively familial form of the illness (Perna *et al*, 1996) and studies of twins from the general population have shown the response to be heritable (Battaglia *et al*, 2007; Battaglia *et al*, 2008; Bellodi *et al*, 1998). Furthermore, the genetic factors that lead to react intensively to a hypercapnic stimulus coincide at a considerable extent with those that influence liability to naturally occurring panic (Battaglia *et al*, 2007). Taken together, these findings suggest that CO₂ hypersensitivity runs in families as an endophenotype of liability to PD, albeit relatively independent of the full clinical manifestations of the syndromes of PD (Battaglia and Ogliari, 2005).

A polymorphism analysis across the exons of the lactate dehydrogenase (LDH) genes suggested that LDH polymorphisms might contribute to the variability to CO₂ respiratory challenge and discriminate well subjects at high risk for PD from low-risk control subjects.

Furthermore, the fear reaction to CO₂ administration appeared to be moderated by a polymorphism in the serotonin transporter (SERT) gene in healthy volunteers (Schmidt *et al*, 2000), however in PD patients no differences for measures of CO₂ reactivity among the SERT genotype groups were observed (Perna *et al*, 2004d). Recently, in a study from our laboratory using different dosages of CO₂, Schruers and coauthors confirmed that healthy individuals with the LL genotype of the SERT display a stronger fear reaction to CO₂, and showed this was particularly evident at intermediate CO₂ dosages (Schruers *et al*, 2011). Instead, at high dosages, or in particularly vulnerable individuals like in Perna's study, the administered stimulus was probably so powerful that a genetic effect causing increased vulnerability to CO₂ could no longer be detected.

3.3 Sensitivity to CO₂ in the normal population

As suggested by genetic studies (Coryell *et al*, 2001), subjective sensitivity to inhaled CO₂ seems to lay on a continuum distributed in the population. At one extreme of the CO₂ sensitivity continuum there are PD patients, especially those with prominent respiratory symptoms (Nardi *et al*, 2006a) and history of suffocation (Monkul *et al*, 2010). At the other extreme, there are patients affected by the majority of other disorders and healthy controls, especially without familial history of PD (see Table 1). A study by Battaglia and Perna (Battaglia and Perna, 1995) was aimed to set an ideal threshold of discrimination between patients and controls in terms of sensitivity to CO₂ challenges, by using receiver operating characteristic analysis of the responses of PD patients and healthy controls undergoing a single breath 35% CO₂ challenge. The increment of 26% of subjective anxiety proved to be the ideal threshold to separate PD patients from healthy controls.

Although weaker than in PD patients, however, a certain degree of CO₂ vulnerability can be evidenced in healthy individuals, if CO₂ dosage is sufficiently increased. Recent evidences have supported this view: a double-blind study by Bailey *et al*. (Bailey *et al*, 2005) on 20 healthy volunteers, with 20 minutes inhalation of 7.5% CO₂, showed significant increases, compared to placebo, in several affective dimensions, namely fear, anxiety, tension, sensation of threat, irritability, worry, feeling like leaving the room. The procedure significantly decreased feeling of being happy and relaxed. Poma and coauthors (Poma *et al*,

2005), with 7% CO₂ for 20 minutes, found similar results and further demonstrated a good test-retest reliability. In a single blind study on a small sample of healthy subjects (Kaye *et al*, 2004), showed a dose-response relationship with a single breath of 5, 25, and 35% CO₂ on subjective reports of anxiety, fear, breathlessness, difficulty in concentrating, and dizziness.

A study from our group (Griez *et al*, 2007) recently showed that CO₂ dose-dependently induced a condition complying with the formal criteria of panic in current psychiatric nosology. Sixty-four healthy subjects underwent a double inhalation of four mixtures containing respectively 0, 9, 17.5 and 35% CO₂, following a double blind, cross-over, and randomized design. Affective responses were assessed using an electronic visual analogue scale and a panic symptom questionnaire. The assessments were strictly based on the current nosologic criteria for panic. The healthy volunteers experienced a significant dose-dependent sense of “fear” or “discomfort” while reporting substantial panic symptomatology. Cognitive items from the symptom list as “derealization” and “fear of losing control” showed significant increases linked to the doses of inhaled CO₂. This finding demonstrates that CO₂ dose-dependently activates a condition identical to panic in healthy volunteers, regardless of any constitutional predisposition to psychiatric pathology. Moreover, older subjects displayed less behavioural vulnerability to CO₂, compared to younger individuals, consistent with the decline of natural PA's and the progressive blunting of panic symptomatology observed in PD patients when they grow older. Interestingly, two recent studies demonstrated higher vulnerability to CO₂ in females relative to male volunteers. These findings are in line with literature documenting sex-specific differences in panic psychopathology (Bunaciu *et al*, 2011; Nillni *et al*, 2012).

A factor structure analysis of the CO₂-induced panic symptoms in healthy volunteers (Colasanti *et al*, 2008) identified clusters of symptoms, respiratory, cognitive and neurovegetative, which were similar to those extracted in naturally-occurring panic in PD patients (Briggs *et al*, 1993; Meuret *et al*, 2006). This suggests a close similarity between natural panic attacks and the experimental CO₂ model in healthy volunteers. Interestingly, respiratory symptoms were found to be the strongest correlates of the subjective emotional response to CO₂ inhalation (Colasanti *et al*, 2008). Furthermore, it was found that a

multidimensional rating of CO₂-induced respiratory discomfort was able to discriminate between responders and non-responders to the CO₂ challenge, with a higher predictive power relative to that of all non-respiratory DSM-IV panic symptoms (unpublished data). The idea that the panic-like subjective internal state induced by CO₂ goes along with respiratory sensations fits clinical and epidemiological evidences that panic and respiration are closely linked (Goodwin and Pine, 2002; Nardi *et al*, 2009). Consistent with these evidences, a higher sensitivity to CO₂ inhalation is found in patients with respiratory symptoms and history of suffocation (Abrams *et al*, 2006; Biber *et al*, 1999; Monkul *et al*, 2010; Nardi *et al*, 2006a; Valenca *et al*, 2002). Furthermore, an interesting case report described a panic reaction to the inhalation of 35% CO₂ associated to dissociative symptoms and flashbacks in a healthy man with a history of near-drowning (Muhtz *et al*).

Recent studies investigated the effects of CO₂ on neurocognitive mechanisms underlying anxiety in healthy volunteers. In one study, the authors reported an experiment during which healthy participants underwent an emotional variant of the antisaccade test, a tool to assess the selective attention to environmental threats, during 20 minutes inhalations of both 7.5% CO₂ and normal air (Garner *et al*, 2011). CO₂ inhalation, compared to normal air inhalation, induced erroneous eye movements toward negative stimuli, suggesting that subjects were more readily orientated toward threat stimuli when exposed to CO₂ relative to normal air exposure. This effect was observed also in subjects who did not report subjective anxiety in response to CO₂, suggesting that the hypervigilance towards threat was independent of changes in subjective mood. In another study using a tracking task with a reaction time component and a complex target identification task in healthy volunteers, the inhalation of 7.5% CO₂ produced effects on task performance which were consistent with anxiety (Diaper *et al*, 2012).

Table 1) Continuum of sensitivity to single or double breath CO₂ challenges across the population.

Study Population	CO ₂ challenge	CO ₂ -induced panic attack assessment	Panic rate	Ref.
16 PD Resp. subtype	35%CO ₂ S.B.	4 PA s. + 1 cognitive s. + panic resembling real-life PA + agreement of 2 MD	93.7%	Valenca <i>et al</i> , 2002
28 PD Resp. subtype	35%CO ₂ S.B.	Fear or panic + 4 PA s. + 1 cognitive s.	79%	Biber <i>et al</i> , 1999
23 PD Non-resp. subtype	35%CO ₂ S.B.	Fear or panic + 4 PA s. + 1 cognitive s.	48%	Biber <i>et al</i> , 1999
32 PD	35%CO ₂ S.B.	4 PA s. + 1 cognitive s.	46.9%	Monkul <i>et al</i> , 2010
11 FDR	35%CO ₂ S.B.	Fear or panic + 4 PA s. + 1 cognitive s.	45.5%	Coryell, 1997
50 FDR	35%CO ₂ S.B.	4 PA s. + increase in anxiety score>25/100	44%	van Beek <i>et al</i> , 2000
11 PD Non-resp. subtype	35%CO ₂ S.B.	4 PA s. + 1 cognitive s. + panic resembling real-life PA + agreement of 2 MD	43.4%	Valenca <i>et al</i> , 2002
64 HV	35%CO ₂ D.B.	4 PA s. + mean of the peak fear /discomfort score during placebo +2 SD	37%	Griez <i>et al</i> , 2007
32 FDR	35%CO ₂ S.B.	4 PA s. + 1 cognitive s.	36.7%	Monkul <i>et al</i> , 2010
50 HV (low risk)	35%CO ₂ S.B.	4 PA s. + increase in anxiety score>25/100	24%	van Beek <i>et al</i> , 2000
34 HV (low risk)	35%CO ₂ S.B.	4 PA s. + 1 cognitive s.	23.5%	Monkul <i>et al</i> , 2010
23 FDR	35%CO ₂ S.B.	Fear or panic + 4 PA s. + 1 cognitive s.	21.7%	Perna <i>et al</i> , 1995c
64 HV	17.5% CO ₂ D.B.	4 PA s. + mean of the peak fear /discomfort score during placebo +2 SD	14%	Griez <i>et al</i> , 2007
64 HV	9% CO ₂ D.B.	4 PA s. + mean of the peak fear /discomfort score during placebo +2 SD	6%	Griez <i>et al</i> , 2007
44 HV (low risk)	35% CO ₂ S.B.	Fear or panic + 4 PA s. + 1 cognitive s.	2.3%	Perna <i>et al</i> , 1995c
15 HV (low risk)	35%CO ₂ S.B.	Fear or panic + 4 PA s. + 1 cognitive s.	0%	Coryell, 1997

Table 1. The highest sensitivity to CO₂ challenges is observed in Panic Disorder patients with prominent respiratory symptoms. At the other extreme, there are healthy controls, especially without familial history of Panic Disorder. First Degree relatives of Panic Disorder patients display an intermediate sensitivity. Although weaker than in Panic Disorder patients and their first-degree relatives, a moderate degree of CO₂ vulnerability can be evidenced in healthy individuals, if CO₂ dosage is sufficiently increased (i.e. double breath 35% CO₂ challenge). PD: Panic Disorder; PA s.: panic attack symptoms; FDR: first-degree relatives of Panic Disorder patients; HV: healthy volunteers; low risk: no familiarity for Panic Disorder; S.B.: single breath; D.B.: double breath; MD: medical doctors; SD: standard deviation.

4 Pharmacological modulation of the affective response to CO₂

4.1 Studies in healthy volunteers

The serotonin (5-HT) system plays a modulatory role on CO₂-induced affective response: selective serotonin reuptake inhibitors (SSRIs) like paroxetine inhibit the response to 7.5% CO₂ (Bailey *et al*, 2007), while the administration of the 5-HT antagonist metergoline increased the anxiety provoked by CO₂ inhalation (Ben-Zion *et al*, 1999; Meiri *et al*, 2001). Studies using single breath 35% CO₂ showed that the manipulation of 5-HT precursors availability in healthy volunteers induced no clear effects on the response to single breath 35% CO₂ (Hood *et al*, 2006; Klaassen *et al*, 1998; Miller *et al*, 2000; Schruers *et al*, 2000a). A recent study from our laboratory (see Chapter 5) surprisingly showed that tryptophan depletion inhibited the response to a double-breath 35% CO₂ challenge and “tryptophan loading” (an amino-acid mixture containing 5.15 g l-tryptophan) tended to increase the vulnerability to CO₂. In a separate analysis, a significant positive relationship between plasma tryptophan and intensity of fearful response to CO₂ was found, indicating that a lower availability of 5-HT precursors is associated to a blunted affective response to CO₂. This is contrasting with the results of studies in PD patients (see below) showing that tryptophan depletion increased CO₂ sensitivity in PD patients while the administration of 5-hydroxytryptophan inhibited the response to CO₂ (Schruers *et al*, 2002b).

The pharmacological enhancement of GABA system, with both selective and non-selective benzodiazepine receptor agonists, results in inhibition of the response to CO₂ (Bailey *et al*, 2007; Bailey *et al*, 2009). Similarly, ethanol (another GABA enhancer) infusion also inhibited the response to CO₂ (Cosci *et al*, 2005). Other anxiolytics compounds like the β -blocker propranolol, the histamine receptor antagonist hydroxyzine or the D₂-antagonist flupentixol were not effective in reducing the CO₂-induced anxiety (Papadopoulos *et al*, 2010). The administration of cholecystokinin, an anxiogenic challenge per se, resulted in an inhibitory effect on the anxiety induced by CO₂ challenge (Pols *et al*, 1999; Schruers *et al*, 2000b). Biperiden (Battaglia *et al*, 2001), a muscarinic antagonist, appeared to protect against CO₂-induced anxiety while nicotine transcutaneous administration did not have any effects (Cosci *et al*, 2006).

The only two studies exploring the role of noradrenergic system in modulation of CO₂-response in healthy volunteers showed that premedication with the α_2 -antagonist yohimbine (Pols *et al*, 1994) and the α_2 -partial agonist clonidine (Woods *et al*, 1989) did not alter the response to CO₂. Preliminary indications suggest the novel anxiolytic CRF-antagonist compounds induce a decrease in CO₂-induced symptoms (Bailey *et al*, 2011). Finally, premedication with the opioid antagonist naltrexone did not have any effect on CO₂-vulnerability, which contrasts with the evidence of increased symptomatic response to a similar panicogenic challenge, lactate, after administration of naloxone (Preter *et al*, 2011).

4.2 Studies in Panic Disorder Patients

As a further confirmation of the validity of CO₂ as a model of panic, drugs that are effective in treating PD, like tricyclic antidepressants and SSRIs, also reduce the anxiety that patients with PD experience when they inhale CO₂. This has been shown for tricyclic antidepressants (Bertani *et al*, 1997; Gorman *et al*, 1997; Perna *et al*, 1997), benzodiazepines (Beckett *et al*, 1986; Nardi *et al*, 1999; Pols *et al*, 1996a; Pols *et al*, 1991; Roth *et al*, 1992; Sanderson *et al*, 1994; Woods *et al*, 1986; Woods *et al*, 1989), SSRIs (Bertani *et al*, 2001; Bertani *et al*, 1997; Perna *et al*, 2004a; Perna *et al*, 2002; Perna *et al*, 1997; Pols *et al*, 1996b), venlafaxine (Bertani *et al*, 2003) and the reversible monoamine-oxidase inhibitor toloxatone (Perna *et al*, 1994b). However, recently in a placebo-controlled study on 32 subjects who had either a past history of panic attacks or a family history of PD, or a panic reaction to CO₂ challenges, escitalopram did not produce greater changes than placebo in panic or anxiety responses after CO₂ exposure (Coryell and Rickels, 2009).

Other pharmacological challenges modulated the response to the challenge in PD patients: the 5-HT reuptake enhancer tianeptine decreased the vulnerability to CO₂ and tryptophan depletion increased CO₂ sensitivity in PD patients (Hood *et al*, 2006; Klaassen *et al*, 1998; Miller *et al*, 2000; Schruers *et al*, 2000a).

4.3 Studies in animal models

There is a relatively limited amount of studies exploring the use of CO₂ as a preclinical model of anxiety. It has been demonstrated that rats exposed to CO₂ showed increased levels of freezing relative to controls (Mongeluzi *et al*, 1996) and that the behavioral response to CO₂ was dose-dependent (Maren, 2009; Mongeluzi *et al*, 2003; Ziemann *et al*, 2009). The anxiogenic properties of CO₂ have also been shown using the open-field test, the aversion test, and context fear conditioning (Maren, 2009; Mongeluzi *et al*, 2003; Ziemann *et al*, 2009).

In a proconflict test in rats, exposure to 35% CO₂ enriched air significantly decreased the drinking behaviour associated to the delivery of response-dependent punishment, indicating increased anxiety. This effect was abolished with pre-treatment with alprazolam but not with flumazenil (Cuccheddu *et al*, 1995). Another study reported that CO₂ decreased the function of the GABA-A receptor complex in rat brain (Concas *et al*, 1993).

5. Putative mechanisms of CO₂-induced affective states

The neurobiological mechanisms underlying CO₂ anxiogenic properties still need to be elucidated, however in the last ten years a few studies have provided a number of very important clues which contributed to gain a better understanding of the relationship between CO₂ and affect: these clues are 1) the neuroimaging evidence of limbic and paralimbic activation during CO₂ inhalation; 2) the in-vitro demonstration of the existence of midbrain CO₂-chemosensitive serotonergic neurons, projecting to the brain regions involved in affect regulation; 3) the in-vitro/in-vivo evidence that amygdala is a chemosensitive region, which triggers fearful responses in response to a fall in pH, as in case of hypercapnic acidosis.

5.1 Neural response to CO₂ inhalation involves limbic and paralimbic activations

The neural activations during CO₂-inhalation have been studied with Positron Emission Tomography (PET) and H₂ [O₁₅] on nine healthy volunteers (Brannan *et al*, 2001; Parsons *et al*, 2001). When compared to the images acquired during inhalation of a N₂/O₂ gas mixture with the same apparatus, and also during paced breathing, and with eyes closed rest, inhalation of a gas mixture containing 8% CO₂ produced changes in cerebral blood flow in a number of brain structures associated with the control of motivational states and emotions: the network of activations included pons, midbrain (mesencephalic tegmentum, parabrachial nucleus, and periaqueductal gray), hypothalamus, limbic and paralimbic areas (amygdala and periamygdalar region), cingulate, parahippocampal and fusiform gyrus, anterior insula, caudate, pulvinar, and the cerebellum as well; strong deactivations were seen in prefrontal cortex and dorsal and posterior cingulate (Brannan *et al*, 2001; Parsons *et al*, 2001). Interestingly, the activations and deactivations were significantly correlated with the feeling of air hunger evoked by CO₂. Furthermore, the neural activations and deactivations were strikingly similar to those observed during other motivational/affective states involved in the regulation of homeostasis of the organism, such as pain, thirst, and hunger.

A recent study in PD patients using double breath 35% CO₂, with electroencephalogram (EEG) being recorded immediately after the inhalation, showed electroencephalographic changes associated to CO₂ – induced panic attacks, indicating a reduction in the frontal cortex activity, a lack of coherence between frontal and occipital areas, and an increased right posterior activity (Lopes *et al*, 2009).

Neuroimaging studies investigating the brain response to acute administration of CO₂ have been limited so far by technical and functional difficulties, and by the presence of artefacts such as head movements and large changes in blood flow produced by CO₂. An fMRI investigation of brain responses to CO₂ challenges in subjects with high and low CO₂–vulnerability is currently undergoing in our laboratory.

5.2 Midbrain serotonergic neurons are CO₂ chemosensitive

Converging evidences indicated the existence of midbrain serotonergic neurons acting as CO₂-chemosensors (see review (Corcoran *et al*, 2009)). A subset of 5-HT neurons is located in the so-called *chemosensitive* zone, the ventrolateral medulla. Serotonergic neurons have a crucial role in the detection of hypercapnic acidosis, as demonstrated by the fact all the raphe neurons stimulated by hypercapnia are serotonergic. Also, 5-HT neurons are associated with large arteries, a strategic position which allow them to faithfully sense CO₂ concentration (Bradley *et al*, 2002). In-vitro studies showed that 5-HT neurons increase their firing rate in response to CO₂ in rodents' brain and that the response is not dependent by inputs from other brain regions (Bradley *et al*, 2002; Severson *et al*, 2003). Studies in freely moving cats demonstrated that a subset of 5-HT raphe neurons increases their firing rate in response to hypercapnia, with some neurons displaying non-linear responses and a large increase in firing rates after response threshold (Veasey *et al*, 1995, 1997). This is supported by experiments using *in vivo* microdialysis showing that increased inhaled CO₂ causes a 2-3 folds increase in extracellular 5-HT levels (Kanamaru and Homma, 2007).

The functional role of these midbrain serotonergic neurons seems not just confined to control exclusively the ventilatory responses to CO₂, instead these neurons may be involved in the regulation of affective behaviors as well. On the basis of the demonstration of projections from midbrain serotonergic neurons to areas like forebrain and limbic system, Richerson proposed that these neurons also mediate non-ventilatory responses to hypercapnia, such as arousal, and feeling of anxiety and suffocation (Richerson, 2004). These observations are in line with the evidence from human studies indicating a modulatory role of the 5-HT system on the affective response to CO₂ (see paragraph 4).

5.3 Amygdala is a CO₂-chemosensor that elicits fear responses

A recent study by Ziemann *et al*. (Ziemann *et al*, 2009) provided a molecular explanation for how CO₂ elicits fearful responses. The work originated by the observation that the molecular channels permeable to Na⁺ and Ca²⁺, acid-sensing ion channel-1a (ASIC1a), are expressed on dendrites and neuronal bodies in the amygdala and are necessary for the expression of normal fearful responses in rodents. Using in-vitro and in-vivo techniques, including in-vivo

pH measurement during CO₂ inhalation, the authors showed that the inhalation of CO₂ reduced amygdalar pH, and that the reduction of pH led to the activation of amygdalar ASIC1a channels. Moreover, the study demonstrated that CO₂ inhalation elicited defensive behaviours such as freezing, increased aversion in the aversion test, reduced preference for open spaces in the open-field test, and context fear conditioning. Notably, the disruption of ASIC1a genes, or the acute inhibition of ASIC1a channels, blunted each of these responses.

These findings, all together, indicate not only that CO₂ directly triggers emotional responses by activating brain areas that control emotions, but also that CO₂ can be detected directly by structures involved both in control of respiration and emotions, such as midbrain and amygdala. These neurobiological evidences are in line with the previously reviewed findings from human studies, indicating that 1) acute inhalation of CO₂ induces an emotion strongly related to respiratory discomfort, which closely resemble natural-occurring panic (Colasanti *et al*, 2008), and that 2) exposure to CO₂ modulates the selective attention to threat in healthy individuals, independently of subjective changes in mood (Garner *et al*, 2011).

In the next section, we will discuss the idea, pointed out by the converging neurobiological evidences described above, that the response to CO₂ might represent an emotion serving an adaptive homeostatic function.

6. CO₂ as the agent of a primal emotion

6.1 Rostral extension of CO₂ sensitivity

Rising CO₂ lowers pH and increases ventilation; a fall in CO₂ increases pH and slows down ventilation. Thus, CO₂ levels regulate two basis elements of aerobic life, oxygen supply and acid base balance. This process is a matter of reflex adjustments mediated by chemosensitive neurons and autonomic centers in phylogenetically ancient brain structures of the rhombencephalon.

We now have evidence that CO₂ also drives specific neurons at higher levels in the central nervous system. Both the midbrain and the limbic system have proven to be CO₂ susceptible.

Midbrain dorsal raphe neurons are CO₂ sensors, which are not mainly, or not at all, involved in ventilatory control (Severson *et al*, 2003). These neurons project rostrally to evolutionarily more recent structures throughout the forebrain. They share 5-HT mediated CO₂ sensitivity with their medullary respiratory counterpart but apparently yield functional effects at the level of limbic structures.

Then comes the recent discovery that the amygdala itself, a keystone in the affective brain, directly senses CO₂ released acidity (Ziemann *et al*, 2009). Thus, CO₂ sensitivity extends into neuronal systems which, as far as we know, have no respiratory function. Once believed to be mainly a factor of reflex functions and the principal parameter of ventilatory control, CO₂ now appears as a potential player in higher functions in the brain.

6.2 Grounds for a suffocation alarm

Observing the behavioural vulnerability of PD subjects, Klein once proposed that panic attacks may be false biological alarms triggered by a suffocation detector that went oversensitive (Klein, 1993). The theory was met with scepticism, namely because ventilatory chemosensitivity proved normal in PD (Papp *et al*, 1995; Zandbergen *et al*, 1991). Yet the new evidence of CO₂ sensors higher up in the brain has changed the perspective.

Besides, CO₂ inhalation has been observed to induce dose dependently panic and anxiety-like affects in healthy individuals (Bailey *et al*, 2005; Griez *et al*, 2007; Schruers *et al*, 2011). This lends more credibility to the idea of an hardwired inborn, CO₂ driven alarm machinery in humans. Finally, it has been found that CO₂-provoked breathlessness caused the activation of limbic and paralimbic areas otherwise closely linked to emotional responses (Brannan *et al*, 2001; Evans *et al*, 2002; Liotti *et al*, 2001). Commenting on these findings, the authors note that the sense of suffocation evokes a strong emotion with a negative valence, and go on speculating that this may serve as an internal alarm in case of disrupted vital function (Liotti *et al*, 2001).

6.3 A particular instance of primal emotion

There is a generally accepted view that emotions have two components: sensation and intention. The former is the emergence of a disturbed bodily function into the stream of consciousness, “the mental representation of physiological changes” (Dolan, 2002). The latter is a move towards restoration of homeostasis. Primal emotions are those where the sensation component is interoceptor driven and linked to the basic functions of life and death such as water, food and air supply or thermal and acid base regulation (Denton, 2006).

In this latter perspective, panic might be considered as a perfect instance of primal emotion. The sense of neuronal CO₂ loading spreads rostrally throughout the brain and emerges into the conscious distress of panic. Biological distress permeates from the primitive neurovegetative rhombencephalon into the affective brain until the cingulate cortex and the painful awareness of a full-blown emotion. In this way, panic is the affective expression of suffocation, a scream for air and therefore a scream for life.

7. Conclusions

The experimental work and historical clinical observations reported in the present review demonstrated that the human organism has a behavioral vulnerability to increasing levels of acute hypercapnia. The subjective response to CO₂ observed in experimental studies has been expressed as a transient affective distress complying with the definition of panic in current psychiatric nosology.

PD patients and their relatives show a hypersensitivity to CO₂, which became considered a genetic marker of vulnerability to panic. However, experimental work in healthy volunteers and preclinical models clearly showed the panicogenic properties of CO₂ are not merely restricted to clinical populations.

The validity of the use of CO₂ in healthy volunteers as a reliable experimental model of panic would open interesting perspectives for its use in future research. Assuming that similar physiologic mechanisms underlie the response to CO₂ inhalation in at least a subset of

PD patients and in healthy volunteers, CO₂ challenges in healthy subjects may have a potential role in clinical research as an early test for novel compounds, and in experimental research as a tool for research on the pathophysiology of PD.

Finally, we have suggested the idea that the affective response to CO₂ and panic might represent an instance of “primal emotion”, a concept proposed by other authors (Denton, 2006; Dolan, 2002) to describe those emotions driven by interoceptors, which are conceived to move the organism towards the restoration of internal homeostasis. Further research would be worth to see whether CO₂ in healthy subjects might indeed represent a valid empirical approach to study primal emotional systems in humans.

Conflict of interest

The authors declare no conflicts of interest.

Acknowledgements

The authors would like to thank Ms Saramicol Viscardi for editing and proofreading the manuscript.

Chapter II

Carbon Dioxide inhalation induces dose-dependent and age-related negative affectivity

Eric Griez ^{1,2}, Alessandro Colasanti ¹, Rob van Diest ¹, Ewa Salamon ¹, Koen Schruers ¹

¹ *Department of Psychiatry and Neuropsychology, University of Maastricht, 6200 MD, NL*

² *Department of Psychiatry and Behavioural Neuroscience, Upstate Medical University, State University of New York, Syracuse, USA.*

Published as: Griez EJ, Colasanti A, van Diest R, Salamon E, Schruers K. Carbon dioxide inhalation induces dose-dependent and age-related negative affectivity. *PLoS ONE* 2007; 2(10):e987.

Abstract

Background

Carbon dioxide inhalation is known to induce an emotion similar to spontaneous panic in Panic Disorder patients. The affective response to carbon dioxide in healthy subjects was not clearly characterized yet.

Methodology/Principal Findings

Sixty-four healthy subjects underwent a double inhalation of four mixtures containing respectively 0, 9, 17.5 and 35% CO₂ in compressed air, following a double blind, cross-over, randomized design. Affective responses were assessed according to DSM IV criteria for panic, using an Electronic Visual Analogue Scale and the Panic Symptom List. It was demonstrated that carbon dioxide challenges induced a dose dependent negative affect ($p < 0.0001$). This affect was semantically identical to the DSM IV definition of panic. Older individuals were subjectively less sensitive to Carbon Dioxide ($p < 0.05$).

Conclusions/Significance

CO₂ induced affectivity may lay on a continuum with pathological panic attacks. Consistent with earlier suggestions that panic is a false biological alarm, the affective response to CO₂ may be part of a protective system triggered by suffocation and acute metabolic distress.

Introduction

Intolerance to carbon dioxide in anxiety prone individuals has been widely documented (Coryell *et al*, 2006; Griez *et al*, 1998; Papp *et al*, 1997). When inhaling hypercapnic gasses, subjects diagnosed with Panic Attacks (PA) shortly sense an instant affect that closely replicates spontaneous panic (Coryell, 1997). Hence Klein inferred that pathological PA's may be false biological alarms, resulting from neuronal misfiring in an evolutionarily evolved, CO₂ driven oversensitive suffocation monitor (Klein, 1993).

In other words it was suggested that panic may be an inborn behavioural response to a metabolic distress. If so, panic must belong to the behavioural repertoire of healthy individuals, the hypersensitive alarm in PD subjects corresponding to a normoresponsive system in others. Accordingly, the very same mechanism firing false alarms in PD patients as a response to moderate CO₂ intake, should be activated in healthy subjects following higher doses of CO₂.

Here we demonstrate in healthy individuals that increasing concentrations of CO₂ dose dependently induce a negative affect and that this affect is semantically identical to panic, as defined in current psychiatric nosology.

Materials and methods

Subjects

Sixty-four volunteers provided their informed consent to participate in the study. There were 33 males and 31 females, aged 35.8 (SD=15.9) and 31.1 (SD=14.4) years respectively.

All potential participants had a complete inventory of medical history and a physical examination. Inclusion criteria were 18 to 65 years of age and a good present and past physical and mental condition. The mental condition was assessed by a structured psychiatric interview (Mini International Neuropsychiatric Interview) performed by a psychologist who was not directly involved in the study. Exclusion criteria included a history of pulmonary or

cardiovascular disease, the presence of hypertension (diastolic >100 mmHg; systolic >170 mmHg), cerebral aneurysm, pregnancy, epilepsy, excessive smoking (>15 cigarettes/day), use of adrenergic receptor blockers and use of psychotropic medication. A history of affective or anxiety disorders within a first-degree relative excluded participation. Participants were also excluded if they reported common specific fears or if there was any suspicion of history of Panic Attacks. The ethics committee of the Academic Hospital of Maastricht approved the study.

Procedure

The inhalation apparatus and the general procedures used in our laboratory have been described elsewhere (Verburg *et al*, 2001).

More specifically, the procedure consisted for each subject in a double inhalation of four mixtures containing respectively 0, 9, 17.5 and 35% CO₂ in compressed air, following a double blind randomized design.

Subjects were instructed in the use of a mask with a demand valve for self-administration of medical gasses and told that they would take a double vital capacity breath of four different concentrations of CO₂ in air, which, though being a harmless physiologic substance, may cause brief neurovegetative responses and arousal or anxiety, depending on the concentration. Subjects were asked to exhale to the maximum, to position the inhalation mask on their face and inhale their full capacity as quickly as possible. Next they were to empty their lungs and refill them immediately with gas, whereupon they had to hold their breath for 5 seconds before exhaling. All inhalations took place within one week, on four separate days but at the same time for each probant. Care was taken that each inhalation represented at least 80% of the subject's vital capacity.

Assessments

Affective responses were assessed with strict reference to the DSM IV (APA, 2000), which refers to a PA as "a discrete period of intense fear or discomfort", in which four (or more)

out of a list of thirteen predefined symptoms develop abruptly and reach a peak within 10 minutes.

Accordingly (Fig. S1) we used an electronic visual analogue scale for affect (eVAAS). The eVAAS was programmed on a Compaq Tablet PC, TC1000, with a 21 cm × 16 cm touch screen having a 1027 × 748 pixel resolution. The VAAS was a 20 cm × 1 cm horizontal bar. Subjects had to mark their anxiety level by tipping on the bar with a stylus, which had a 1 mm diameter spherical tip. The top of the display was labelled “*fear or discomfort*”. The scale was anchored from 0, “no fear/discomfort at all”, to 100, “the worst imaginable fear/discomfort”. This instrument has been validated for use during 35% CO₂ challenges (van Duinen *et al*, 2008).

Panic Symptom List (PSL-IV) was used to evaluate panic symptomatology (Schruiers *et al*, 2000a). It consisted in a questionnaire listing thirteen items, each item representing a DSM-IV panic symptom, to be rated on a five point scale, from 0 (absent) to 4 (very intense) (Fig. S1).

The eVAAS was presented at baseline immediately before inhalation, which was followed after CO₂ by multiple instant assessments, in fact as many as possible, during 60 seconds. This allowed the computation of both a peak value and an area under the curve (AUC). The Panic Symptom List was administered one minute before and after each inhalation. The total PSL score was calculated for each assessment.

Fig. S1) Experimental assessments. DSM IV criteria for Panic Attack; eVAAS for Fear/Discomfort; Panic Symptom List (PSL-IV)

DSM IV CRITERIA	EXPERIMENTAL ASSESSMENTS					
<i>A discrete period of intense fear or discomfort in which four (or more) of the following symptoms developed...</i>	<div> <div>eVAAS: @ Wed May 20 00:00:00 CEST 2016</div> <div>[[0:00:00]]</div> <div>FEAR / DISCOMFORT</div> <div>[[0:00:00]]</div> <div>100</div> <div>0</div> <div></div> <div>OK</div> </div>					
		NOT AT ALL	MILD	MODERATE	SEVERE	EXTREMELY SEVERE
1. Palpitations	PALPITATIONS, POUNDING HEART, OR ACCELERATED HEART RATE					
2. Sweating	SWEATING					
3. Trembling	TREMBLING OR SHAKING					
4. Sensation of shortness of breath or smothering	SENSATION OF SHORTNESS OF BREATH OR SMOTHERING					
5. Feeling of choking	FEELING OF CHOKING					
6. Chest Discomfort	CHEST PAIN OR DISCOMFORT					
7. Nausea or abdominal distress	NAUSEA OR ABDOMINAL DISTRESS					
8. Feeling dizzy, lightheaded or faint	FEELING DIZZY, UNSTEADY, LIGHTHEADED, OR FAINT					
9. Feeling of derealization or depersonalization	DEREALIZATION (FEELING OF UNREALITY) OR DEPERSONALIZATION (BEING DETACHED FROM ONESELF)					
10. Fear of losing control	FEAR OF LOSING CONTROL OR GOING CRAZY					
11. Fear of dying	FEAR OF DYING					
12. Paresthesias	PARESTHESIAS (NUMBING OR TINGLING SENSATIONS)					
13. Chills or hot flushes	CHILLS OR HOT FLUSHES					

Statistical analysis

Statistical analysis was performed on the eVAAS peak values, obtained by subtracting the baseline from the maximum value, and PSL total scores, represented by delta scores (post-pre assessment).

A one-way Manova of repeated measures with eVAAS peak values as the dependent variable and dose (exposure to the four mixtures of CO₂) as the within-subjects factor was used to investigate the affective response to the various CO₂ mixtures. The same analysis was conducted with eVAAS AUC scores and PSL individual and total scores as the dependent variables.

AUC was calculated by the trapezoidal rule extrapolation method. The data were reanalysed using a repeated measures design with eVAAS peak values or PSL value as the dependent variable, age (below and above age 38) as a between-subjects factor and exposure to the four mixtures as the within-subjects factor. In both analyses, orthogonal polynomial trend contrasts were used to search for the presence of significant linear and/or quadratic trends in case of a significant “dose” effect.

Subjects were divided in “responders” and “non-responders”, according to conservative criteria, proposed by others in previous CO₂ challenge studies (Poma *et al*, 2005). Following those criteria an arbitrary eVAAS peak score of 50 was used as threshold to identify the responders (mean of the eVAAS peak scored during AIR+2 SD). In addition responders should report at least one-point increase for at least four of the 13 PSL symptoms.

Results

Results are presented in figures 1-5. eVAAS peak values showed CO₂-triggered affectivity to be dose dependent ($p<0.001$), displaying an increase with concentration, which fits both a significant linear ($p<0.0001$) and quadratic pattern ($p<0.001$) (Fig. 1 a). eVAAS AUC values were also dose related ($p<0.0001$) (Fig. 2 a,b) and exhibited a significant linear and quadratic

pattern ($p<0.0001$). PSL data yielded similar results, with comparable dose-response relationship ($p<0.0001$) and mathematical pattern ($p<0.0001$) (Fig. 3 a).

Changes in individual PSL scores symptoms are presented in Fig. 4. As far as cognitive symptoms are concerned, a PSL score increase >1 in any of CO₂ conditions was shown in 53% of the subjects.

The sum of the symptom scores, defining a cognitive dimension (“derealization-depersonalization” score + “fear of losing control-going crazy” score) (Cox *et al*, 1994; Meuret *et al*, 2006) is presented in Fig. 5. Looking to the cognitive symptoms separately (to which we added fear of dying), 48%, 26%, and 8% of the subjects reported an increase of PSL score respectively, in any of CO₂ condition. A significant CO₂ dose-dependent relationship was evidenced for derealization-depersonalization, and fear of losing control-going crazy ($p<0.0001$), which displayed a linear ($p<0.001$) and quadratic pattern ($p<0.05$). A similar significant dose-effect was found for fear of dying ($p<0.05$), however it appeared to be overall a very rare symptom.

According to above defined criteria there were 4 (6%), 4 (6%), 9 (14%), and 24 (37%) “responders” in the 0, 9, 17.5 and 35% CO₂ conditions respectively ($p\leq 0.0001$).

Dividing the subjects in an older (>38 years) and younger group, analysis revealed a significant difference in eVAAS peak scores ($p<0.05$) (Fig. 1 b). eVAAS peak values in both age groups increase in a significant linear ($p<0.001$) and quadratic pattern ($p<0.001$) and run parallel. PSL scores displayed that age effect was not significant ($p=0.217$) (Fig. 3 b).

Dividing the subjects by gender, no significant differences were found between males and females in any of the assessed parameters (eVAAS peak score, eVAAS AUC score, PSL – IV score).

Fig. 1) Peak scores on the Fear / Discomfort scale in four different CO₂ conditions.

Fig. 1

a) eVAAS: air vs 9% $p=0.44$; air vs 17.5% and vs 35% $p\leq 0.001$; 9% vs 17.5% and vs 35% $p\leq 0.0001$; 17.5% vs 35% $p\leq 0.0001$.

b) Younger versus older subjects: $p<0.05$

Fig. 2) Area under the curve on the Fear / Discomfort scale in four different CO₂ conditions.

Fig. 2

- a)** eVAAS AUC score: air vs 9% $p=0.91$; air vs 17.5% and vs 35% $p\leq 0.005$; 9% vs 17.5% and vs 35% $p\leq 0.001$; 17.5% vs 35% $p\leq 0.0001$.
- b)** Time course of Fear/Discomfort in a single subject after the double inhalation of 0%, 9%, 17.5%, 35% CO₂ respectively.

Fig. 3) Intensity of PSL panic symptoms in four different CO₂ conditions.

- a)** PSL: air vs 9% $p=0.76$; air vs 17.5% and vs 35% $p\leq 0.0001$; 9% vs 17.5% and vs 35% $p\leq 0.0001$; 17.5% vs 35% $p\leq 0.0001$.
- b)** Younger versus older subjects: $p=0.217$.

Fig. 4) DSM panic symptoms intensity in healthy subjects taking four different doses of CO₂.

Fig. 5) Aggregate score of cognitive symptoms induced by four different CO₂ conditions in healthy subjects (“derealization-depersonalization” score + “fear of losing control-going crazy” score).

Discussion

The double breath challenge induced an instant affect with a negative valence. As rated on the eVAAS, the healthy volunteers experienced a significant sense of "fear" or "discomfort" while reporting substantial panic symptomatology on the PSL. Both eVAAS and PSL were strictly based on DSM-IV semantics. The picture as a whole was a mathematical function of CO₂ intake.

It may therefore be inferred that a double breath of increasing concentrations of CO₂ dose dependently induced a condition complying with the formal criteria of panic in current psychiatric nosology.

There has been a wealth of evidence showing that experimental hypercapnia triggers PA's in patients diagnosed with PD (Coryell, 1997; Griez *et al*, 1998; Papp *et al*, 1997), and conditions which are closely related to PD (Caldirola *et al*, 1997; Verburg *et al*, 1994). In contrast, the same procedure failed to affect patients with other disorders (Griez *et al*, 1990b), in particular those with Generalized Anxiety Disorder (Perna *et al*, 1999a; Verburg *et al*, 1995a), Obsessive-Compulsive Disorder (Griez *et al*, 1990a; Perna *et al*, 1995b), Eating Disorders (Perna *et al*, 2004c), Major Depression (Perna *et al*, 1995a) and control groups of healthy volunteers. First-degree relatives of PD patients however share a significant degree of CO₂ vulnerability (Coryell, 1997; Perna *et al*, 1995c; van Beek *et al*, 2000). In fact, the liability to experience panic with CO₂ exposure discriminates between individuals at high and low risk for PD (Coryell *et al*, 2006).

Recent reports have suggested that healthy individuals breathing a low 7% concentration of CO₂ may display signs of generalized anxiety (Bailey *et al*, 2005; Poma *et al*, 2005). Yet, the present results are the first to demonstrate that CO₂ dose dependently activates a condition identical to panic in healthy volunteers, regardless of any constitutional predisposition to psychiatric pathology.

Did CO₂ induce a true emotion? While formally meeting all the criteria of a PA according to modern psychiatric nosology, the CO₂ induced state we observed in our healthy subjects may have been a “phenocopy” of panic, the amalgam of autonomic symptoms of hypercapnia and some resulting physical discomfort. Amongst the 13 PSL items, we therefore separately analyzed the specific cognitive symptoms of “derealization” and “fear of losing control”. Several studies have identified these symptoms as belonging to a specific psychological/cognitive cluster on basis of factor analysis (Cox *et al*, 1994; Meuret *et al*, 2006). Our results show that both “derealization” and “fear of losing control” were linked to the doses of inhaled carbon dioxide in a significant linear and quadratic pattern. Across the procedure, “derealization/depersonalisation” displayed more than one point increase (on a five point scale) in about half of the subjects, and “fear of losing control” in about one fourth of them. Fear of dying did not belong to the cognitive dimension in Meuret and Cox’s studies (Cox *et al*, 1994; Meuret *et al*, 2006), nevertheless, from a conceptual point of view, it may refer to an extreme type of emotion. In the present study “fear of dying” remained very infrequent. However, when reported, we noted a significant dose-response relationship. It should be born in mind that all subjects were in a safe laboratory environment, and all had received ample reassurance regarding the safety of the intervention trough the informed consent procedure. This obviously influenced the psychological impact of CO₂. Yet, modest as they are, cognitive shifts did occur, they were a function of the experimental procedure, and their occurrence was statistically significant.

This lends support to the idea that, beyond a particular threshold, CO₂ may yield genuine psychotropic properties in healthy individuals.

Influential authors have increasingly referred to emotions as evolutionarily derived, “organism-ready solutions” to face major survival problems (Panksepp, 1998), as brain representations of internal body states (Damasio, 1999), and more specifically, as images of the “material me” arising from “the homeostatic condition of each individual’s body” (Craig, 2003). The idea that panic may proceed from a suffocation alarm disrupted by acute CO₂ loading is perfectly consonant with such views. Several pieces of evidence point to a connection between hypercapnia and emotion. For instance, it appears that central chemosensitivity is not restricted to medullary respiratory neurons. Severson and co-workers

(Severson *et al*, 2003) have shown that midbrain raphe serotonergic neurons are CO₂ sensors, and midbrain neurons are not believed to have any direct function in the control of ventilation. Instead these midbrain chemosensors head mainly in the rostral direction. They have been proposed to participate in the homeostasis of the brain via non-respiratory responses to hypercapnia, including behavioural reactions as hyperarousal and anxiety (Richerson, 2004). Liotti and coauthors have produced neuroimaging evidence linking directly CO₂ inhalation with brain structures related to emotions (Liotti *et al*, 2001). Following CO₂ induced breathlessness, healthy volunteers displayed limbic and paralimbic activation, and neuronal firing in the affective brain correlated with the sense of suffocation. The authors comment that this neuronal activity may reflect a primal emotion, in other words "a compelling interoceptor-driven affect, rooted in metabolic distress, and aimed at signalling that the existence of the organism is endangered." In an earlier study on the characteristics of CO₂ induced responses, healthy volunteers spontaneously described their subjective experience as "frightening", "panicky" or "scaring", while authors noted that the sensitivity of the feeling, which was poorly correlated with the ventilatory response, varied threefold among individuals (Banzett *et al*, 1996).

Our study shows that CO₂ intake induces an affective state, which is similar to the psychiatric picture of panic. Within subjects, we observe a significant interaction between the intensity of the affective response and the CO₂ concentration of the inhaled mixture.

We show older subjects to display less behavioural vulnerability to CO₂, compared to younger individuals. To the extent that CO₂ intake is a valid model of panic, this difference between younger and older subjects strikingly evokes the decline of natural PA's and the progressive blunting of panic symptomatology in PD patients when they grow older (Sheikh *et al*, 2004). Most studies have found a lower prevalence of PD amongst elderly people (Krystal *et al*, 1992). The decreased CO₂ susceptibility in the elderly revealed by the present data reminds of a similar age effect found with experimental cholecystokinin provocation of panic (Flint *et al*, 1998). If midbrain serotonergic chemosensors are at work in the chain of events leading from CO₂ to panic, the phenomenon observed in our study might be related to an age dependent decline of serotonergic activity (Lawlor *et al*, 1989; Yamamoto *et al*, 2002).

No gender differences were found. This is somewhat surprising in view of all epidemiological data showing women to be at greater risk for panic than men (Gater *et al*, 1998). Yet, a recent study in a nonclinical population shows women reporting more fear and panic than men after CO₂ administration (Kelly *et al*, 2006). Interestingly, when asked to rate their experience on a "like or dislike" dimension (which dimension has a conceptual overlap with "discomfort"), the gender difference disappeared. This suggests women being more prone than men to report a feeling as "anxiety". Therefore, lumping together anxiety and discomfort in our eVAAS may have blunted a gender effect. It is noteworthy that the few existing reports about sex differences in the so-called condition "non fearful PD", which diagnosis relies on "discomfort" rather than on "anxiety", suggest that both genders have similar prevalence (Bringager *et al*, 2004; Fleet *et al*, 2000).

A final comment applies to the potential of further work with CO₂ challenges in healthy individuals. The panic model of CO₂, in particular the single breath 35% CO₂ procedure, has proven to be both valid and reliable (Verburg *et al*, 1998b). It has undergone extended pharmacological validation (Bertani *et al*, 1997). Assuming that higher doses of CO₂ activate the same physiologic chain of events in panic free individuals, CO₂ challenges in healthy volunteers may have a strong potential as a substitute to early clinical trials in testing novel pharmacological compounds.

In conclusion, it appears that healthy individuals display a distinct behavioural vulnerability to increasing levels of acute hypercapnia. This effect is dose-dependent and shares a striking similarity with the psychiatric condition of panic.

CO₂ susceptibility, sensed as acute affective distress may represent an evolutionarily evolved protective mechanism in case of impending asphyxia.

Chapter III

Carbon Dioxide-induced emotion and respiratory symptoms in healthy volunteers

Alessandro Colasanti ¹, Ewa Salamon ¹; Koen Schruers ¹, Rob van Diest ¹, Marlies van Duinen ¹, Eric J Griez ¹

¹ *Department of Psychiatry and Neuropsychology, University of Maastricht, 6200 AB Maastricht, NL*

Published as: Colasanti A, Salamon E, Schruers K, van Diest R, van Duinen M, Griez EJ. Carbon dioxide-induced emotion and respiratory symptoms in healthy volunteers. *Neuropsychopharmacology*. 2008 Dec;33(13):3103-10.

Abstract

A number of evidences have established that panic and respiration are closely related. Clinical studies indicated that respiratory sensations constitute a discrete cluster of panic symptoms and play a major role in the pathophysiology of panic. The aim of the present study was to explore the phenomenology of an experimental model of panic in healthy volunteers based on the hypothesis that: (1) we can isolate discrete clusters of panic symptoms, (2) respiratory symptoms represent a distinct cluster of panic symptoms, and (3) respiratory symptoms are the best predictor of the subjective feeling of panic, as defined in the DSM IV criteria.

Sixty-four healthy volunteers received a double inhalation of four mixtures containing 0, 9, 17.5, and 35% CO₂, respectively, in a double-blind, cross-over, random design. An electronic visual analogue scale and the Panic Symptom List (PSL) were used to assess subjective “fear/discomfort” and panic symptoms, respectively. Statistical analyses consisted of Spearman’s correlations, a principal component factor analysis of the 13 PSL symptoms, and linear regressions analyses.

The factor analysis extracted three clusters of panic symptoms: respiratory, cognitive, and neurovegetative ($r^2=0.65$). Respiratory symptoms were highly related to subjective feeling of fear/discomfort specifically in the CO₂-enriched condition. Moreover, the respiratory component was the most important predictor of the subjective feeling of “fear/discomfort” ($\beta=0.54$).

The discrete clusters of symptoms observed in this study were similar to those elicited in panic attacks naturally occurring in patients affected by Panic Disorder. Consistent with the idea that respiration plays a crucial role in the pathophysiology of panic, we found that respiratory symptoms were the best predictors the subjective state defined in the DSM IV criteria for panic.

Introduction

Panic attacks (PAs) are defined in the current nosology as discrete periods of intense fear or discomfort accompanied by diverse physical and cognitive symptoms (APA, 2000). The symptomatology includes cardio-respiratory symptoms (dyspnea or breathlessness, palpitations, and chest pain); neurovegetative symptoms (nausea and sweating), and other nonspecific symptoms (trembling, paresthesias, dizziness, and chills). Frequent cognitive symptoms include feelings of derealization or depersonalization, fear of losing control or going crazy, and fear of dying.

Research from the past two decades has focused considerable attention on elucidating the phenomenology of panic, resulting in the recognition that PAs are characterized by inter-individual heterogeneity. Researchers have identified distinct subtypes of Panic Disorder (PD) on the basis of a predominant symptom constellation (Aronson and Logue, 1988; Bass *et al*, 1987; Ley, 1992). Such an approach may contribute to a better understanding of the etiology of panic since dysregulation in different psychobiological mechanisms may underlie phenotypically similar attacks. Gorman and coworkers in 1999 posed a neuroanatomical hypothesis of PD based on the idea that the physiological and behavioral consequences of a panic attack are mediated by a "central fear network" in the brain that is centred in the amygdala and involves its interaction with the hippocampus, medial prefrontal cortex, and hypothalamic and brainstem sites (Gorman *et al*, 2000).

Even though clustering of panic symptoms has not yielded always consistent results, there is general agreement about the existence of a prominent respiratory subtype of panic that is characterized by the prevalence of respiratory symptoms. Briggs and coauthors (1993) analyzed a sample of 1168 PD patients and divided them into two clusters. The first cluster, labelled "respiratory", was characterized by the presence of shortness of breath, choking, fear of dying, chest pain, and tingling; the second "nonrespiratory" cluster was characterized by the absence of respiratory symptoms and the presence of the other symptoms listed in DSM-IV criteria for panic attack. Consistently with Briggs, Argyle and Roth (1989) and De Beurs *et al*. (1994) found a similar "respiratory" cluster in their factor analysis. Cox *et al*. (1994) extracted three factors: a dizziness-related symptom cluster, a cardio-respiratory distress

symptom cluster, and a catastrophic cognition symptom cluster. The cardio-respiratory cluster was primarily characterized by palpitations but also included dyspnea, choking, and fear of dying. Recently, Meuret *et al.* (2006) analyzed 343 PD patients and extracted three “dimensions” interpreted as cardio-respiratory, mixed somatic-autonomic, and cognitive. The cardio-respiratory cluster included shortness of breath, chest pain, fear of dying, palpitations, tingling, and choking. Shioiri *et al.* (1996), in a Japanese study of 207 PD patients, found slightly different results. Their cluster analysis revealed three panic symptom clusters. The first was comprised exclusively of physiological symptoms, among which respiratory symptoms were prominent. The second included mixed panic symptoms, including agoraphobia and anticipatory anxiety, and the third was comprised of fearful cognitive symptoms plus paresthesias and chest pain.

The existence of a distinct “prominent respiratory” subtype of panic seems to be supported by clinical evidence. Briggs *et al.* (1993) demonstrated that patients with the respiratory subtype of panic suffer more spontaneous PAs than patients with the residual subtype and that they respond better to imipramine than to alprazolam. The respiratory subtype has been shown to be associated with increased familial risk of PD (Horwath *et al.*, 1997; Nardi *et al.*, 2003; Nardi *et al.*, 2006a; Nardi *et al.*, 2006b), to be more common among heavy smokers, to have a longer duration and major severity of illness (Biber and Alkin, 1999), and to have a lower resting end-tidal pCO₂ (Moynihan and Gevirtz, 2001) and a higher sensitivity to CO₂ inhalation (Abrams *et al.*, 2006; Biber and Alkin, 1999; Nardi *et al.*, 2006a; Nardi *et al.*, 2006b; Valenca *et al.*, 2002). Other clinical features displayed by PD patients with the respiratory subtype include a later onset of the disease and a faster response to nortriptyline (Nardi *et al.*, 2003; Nardi *et al.*, 2006a; Nardi *et al.*, 2006b), more past traumatic suffocation experiences and respiratory diseases (Bouwer and Stein, 1997; Verburg *et al.*, 1995b), higher levels of anxiety sensitivity, and more panic-agoraphobic spectrum symptoms (Onur *et al.*, 2007).

A strong relation between panic and respiration would be consistent with the high comorbidity of respiratory disorders (asthma, COPD) and PD observed in large, epidemiological studies (Goodwin and Pine, 2002). Taken together, the data emerging from clinical, experimental, and epidemiological studies on panic and respiration suggest that the

neurobiological mechanism underlying PD may involve respiratory control (Battaglia *et al*, 2005; Klein, 1993; Preter *et al*, 2008). Briggs, Meuret, Biber, Nardi and co-workers have suggested that: (1) panic symptoms can be grouped into clusters, (2) respiratory symptoms constitute a distinct and well-defined cluster, and (3) respiratory symptoms play a major role in its pathophysiology.

In the present study, we sought evidence to support these suggestions by analyzing an experimental model of panic. We recently showed that increasing concentrations of CO₂ dose dependently induce a negative affect, which eventually culminates in genuine panic, also in healthy individuals (Griez *et al*, 2007). Accordingly, high doses of CO₂ may be considered as a model of panic in healthy subjects, just as moderate doses are in PD patients. On these premises, we performed a statistical analysis of the symptom pattern observed in our 2007 dose response experiment. In line with the above mentioned authors, we hypothesized that: (1) there are discrete clusters of panic symptoms, (2) respiratory symptoms can be extracted as an independent component, and (3) respiratory symptoms are, indeed, the best predictor of the subjective disturbance defined in the DSM IV criteria for panic.

Materials and methods

Subjects

Students and staff members were recruited by word of mouth from within Vijverdal Psychiatric Hospital in Maastricht and from the University of Maastricht. They received course credit for their participation in the studies. All potential participants provided a complete medical history and underwent a physical examination. Inclusion criteria were age 18-65 years and a good present and past physical and mental condition, based on the results of a structured psychiatric interview (Mini International Neuropsychiatric Interview) performed by a psychologist not directly involved in the study. Exclusion criteria included a history of pulmonary or cardiovascular disease, the presence of hypertension (diastolic >100 mmHg; systolic >170 mmHg), cerebral aneurysm, pregnancy, epilepsy, excessive smoking (>15 cigarettes/day), use of adrenergic receptor blockers, and use of psychotropic

medication. Individuals with a history of affective or anxiety disorders in a first-degree relative were excluded. Individuals with a present or past history of substance-related disorders, including caffeine-related disorder, were excluded. Participants were also excluded if they reported common specific fears or if they had a history of PAs. The ethics committee of the University of Maastricht approved the study. A complete description of the study was given both orally and in written form to the subjects. Those who met the inclusion criteria and who provided written informed consent were included in the study.

Procedure

The study was conducted according to a double-blind, randomized, cross-over design. All subjects received all of the following challenges: air: 0% CO₂, 20% O₂, 80% N₂; low: 9% CO₂, 20% O₂, 71% N₂; medium: 17.5% CO₂, 20% O₂, 62.5% N₂; high: 35% CO₂, 20% O₂, 55% N₂ in randomized order. Each subject underwent the four different challenges on four different days within the same week, at the same hour, to eliminate circadian effects in the challenge response. Every challenge was performed in the morning, between 9:00 and 12:00. The participants were asked to refrain from drinking beverages containing xanthine for at least 8 hours and from eating for at least 2 hours before the test.

The procedure was standardized for all subjects and for all sessions and was performed according to the protocol for 35% CO₂ inhalation used at the Maastricht Academic Anxiety Center (Griez *et al*, 1987a). The different gas mixtures were all delivered through the same nasal-oral exercise self-administration face mask using a double vital capacity inhalation technique. Before the challenge was started, the inspired vital capacity of every subject was evaluated using an analogue respirometer (Wright respirometer Mark 20) connected to the self-administration mask. The same respirometer measured the gas volume delivered at each inhalation. Baseline inspired vital capacity with a double breath of normal air was measured on each occasion, and a test breath was considered adequate if it was more than 80% of the baseline vital capacity. The subjects were then given the self-administration mask and told to hold it in their hands and to exhale as deeply as they could. A double-breath inhalation of a

mixture containing one of the four different concentrations of CO₂ was then delivered to the subjects. They were asked to take a maximal inspiration through the self-administration mouthpiece and to make a complete expiration outside the mouthpiece, immediately followed by a second maximal inspiration through the mouthpiece following the same procedure. At the end of the second inhalation, the subjects were asked to hold their breath for 4 seconds to enhance the alveolar gas exchange.

Measures

Assessments were chosen with strict reference to the definition of PA in the current psychiatric nosology, and specifically the DSM IV TR criteria for PA. These define a PA as a discrete period of intense fear or discomfort followed by the abrupt development of 13 well-defined symptoms. An electronic visual analogue scale for affect (eVAAS) was developed to record the subjective feeling of fear or discomfort. It consists of a Compaq laptop touch screen personal computer interfaced with original eVAAS software, in which the analogue scale is shown on the electronic display and the subject interacts directly via an electronic pen with the touch screen. The top of the display is labelled “fear or discomfort”. The participants were instructed to indicate the amount of the subjective disturbance, in case of feeling either fear or discomfort. The visual analogue scale is represented by a 200-mm bar on the display that ranges from 0 (no fear/discomfort at all) to 100 (the worst imaginable fear/discomfort). This instrument has been validated for use during 35% CO₂ challenges (van Duinen *et al*, 2008).

Before each challenge began, the participants rated their baseline level of fear/discomfort. Panic symptoms were evaluated using the Panic Symptom List (PSL-IV) (Schruers *et al*, 2000a). This consists of a questionnaire listing 13 items, each representing one of the DSM-IV TR symptoms (i.e., palpitations; sweating; trembling; sensations of shortness of breath or smothering; feeling of choking; chest discomfort; nausea or abdominal distress; feeling dizzy, lightheaded, or faint; derealization or depersonalization; fear of losing control; fear of dying; paresthesias; chills or hot flushes). The participants were asked to rate the intensity of each symptom from 0 (absent) to 4 (very intense). The total scores thus ranged from 0 to 52.

Baseline assessment of eVAAS and PSL-IV symptoms were obtained one minute before each double inhalation (baseline score). One minute after the end of each double inhalation, the subjects filled in both the eVAAS and the PSL-IV questionnaire. At that time, they were asked to indicate the worst moment they experienced after inhaling the gas mixture (post-inhalation score).

The post-inhalation change was calculated by subtracting the baseline score from the post-inhalation score.

Statistical analysis

The statistical analyses were performed using SPSS 13.0. First, an ANOVA for repeated measures was conducted on the eVAAS score, total PSL score, and each of PSL symptom scores. The subsequent analysis of the relationship between eVAAS score and PSL symptoms consisted of four steps:

- 1) Spearman's non-parametric correlation analysis between eVAAS score and each of the 13 PSL-IV symptoms;
- 2) First linear regression analysis to determine the relative weight of each PSL-IV symptom in the determination of the eVAAS score. The dependent variable was the eVAAS score and the predicting variables were the PSL-IV symptoms;
- 3) Principal component factor analysis with varimax rotation to obtain variables with very high factor weights in some factors and very low factor weights in others. To insert a variable into a factor, a factor weight of at least 0.5 was selected as the threshold value. Factor scores were then computed as variables, representing a measure of each subject's contribution to each factor.
- 4) Second linear regression analysis to determine the relative weight of each principal component in the determination of the eVAAS score. The dependent variable was the eVAAS score and the predicting variables were the principal factor scores.

The correlation analysis and first linear regression analysis were made separately for each condition (air, low, medium, high). The principal component factor analysis was applied to the 13 PSL-IV symptoms only in the high condition (35% CO₂). The second linear regression analysis was performed only in the high condition.

Results

Sixty-four volunteers were included in the study: 33 males and 31 females aged 35.8 (15.9 SD) and 31.1 (14.4 SD) years, respectively.

PSL-IV scores for each symptom are presented in Table 1. Dizziness, sensation of shortness of breath, feeling of choking, and palpitations had the highest mean scores in all three CO₂ conditions (high, medium, and low). For both the eVAAS score and the PSL-IV total score, a statistically significant dose-response relationship was observed (these results are extensively presented elsewhere) (Griez *et al*, 2007). Each PSL symptom score was significantly dose-dependent ($p < 0.05$).

Table 1) Panic Symptom List scores.

DOSE	AIR		LOW		MEDIUM		HIGH	
	mean	SD	mean	SD	mean	SD	mean	SD
Palpitations	0,47	0,73	0,50	0,70	0,69	0,76	1,31	1,06
Sweating	0,00	0,44	0,10	0,56	0,25	0,54	0,63	0,81
Trembling	0,14	0,43	0,16	0,52	0,30	0,69	0,81	0,97
Shortness of breath	0,30	0,55	0,37	0,73	0,72	0,82	1,47	1,16
Feeling of choking	0,20	0,44	0,40	0,73	0,67	0,79	1,56	1,13
Chest pain	0,02	0,22	0,05	0,28	0,07	0,31	0,39	0,71
Nausea	0,09	0,50	0,05	0,28	0,08	0,33	0,29	0,82
Dizziness	0,72	0,92	0,63	0,71	1,03	0,84	1,74	1,13
Derealization	0,17	0,38	0,18	0,43	0,21	0,58	0,66	0,90
Fear of losing control	0,05	0,21	0,02	0,22	0,16	0,49	0,29	0,66
Fear of dying	0,00	0,00	0,02	0,13	0,02	0,13	0,10	0,39
Paresthesias	0,14	0,39	0,11	0,32	0,20	0,48	0,65	1,03
Chills	0,06	0,24	0,02	0,34	0,08	0,33	0,19	0,54
PSL tot	2,47	3,07	2,60	3,51	4,48	4,01	10,08	7,07
E-VAAS	16,06	17,98	17,66	18,56	26,16	24,19	44,94	26,62

DSM panic symptoms intensity (mean $\pm$ SD) in four different CO₂ conditions.

Correlations

Correlation coefficients are shown in Table 2. A high Spearman's rho coefficient was found between the symptoms "feeling of choking" and "sensation of shortness of breath" in all conditions except air. The symptoms "derealization or depersonalization", "fear of losing control", and "fear of dying" were highly related to each other in all of the conditions.

Correlation coefficients between eVAAS score and PSL-IV scores across the four different doses are presented in Fig. 1. Dizziness and palpitations were strongly related to the eVAAS score in all of the CO₂ conditions, including the air condition. Sensation of shortness of breath and feeling of choking were strongly related to the eVAAS score in all of the CO₂ conditions but not in the air condition.

Regression analysis (1)

A regression analysis was performed to show the weight of each symptom in predicting the eVAAS score. Figure 2 shows the relative weight (β score) of each PSL-IV symptom separately for the four conditions. In the high condition, "feeling of choking" had the highest Beta score. "Sensation of shortness of breath" appeared to be a poor predictor. Looking at the other conditions, it is evident that the weight of "feeling of choking" in predicting the eVAAS score increased with the dose, while the weight of "shortness of breath" decreased with the dose. In the air condition, both respiratory symptoms had a low predicting value (<0) compared to "palpitations", "chest pain", and "dizziness", which had Beta scores higher than 0.3.

Table 2) Correlations between Panic Symptom List scores.

		HIGH													
	VAS	palpitations	sweating	trembling	shortbreath	choking	chestpain	nausea	dizziness	derealization	fear/second	fear/ying	paresthesia	chills	
MED	VAS	1,00	0,49	0,36	0,49	0,40	0,47	0,41	0,19	0,52	0,26	0,38	0,23	0,29	0,31
	palpitations	0,59	1,00	0,51	0,51	0,40	0,29	0,44	0,18	0,43	0,26	0,37	0,11	0,25	0,22
	sweating	0,19	0,10	1,00	0,43	0,47	0,36	0,34	0,16	0,35	0,24	0,39	0,35	0,23	0,33
	trembling	0,29	0,17	0,32	1,00	0,19	0,20	0,54	0,31	0,52	0,30	0,27	0,20	0,43	0,41
	shortbreath	0,56	0,44	0,06	0,19	1,00	0,76	0,42	0,09	0,46	0,28	0,34	0,30	0,27	0,19
	choking	0,38	0,36	0,14	0,21	0,48	1,00	0,39	0,10	0,45	0,26	0,23	0,23	0,16	0,22
	chestpain	0,11	0,32	0,14	0,01	0,22	0,36	1,00	0,30	0,52	0,42	0,27	0,22	0,51	0,45
	nausea	0,39	0,28	0,16	0,28	0,35	0,18	0,11	1,00	0,26	0,34	0,38	0,30	0,22	0,46
	dizziness	0,54	0,49	0,06	0,13	0,38	0,20	0,26	0,31	1,00	0,27	0,24	0,26	0,33	0,24
	derealization	0,34	0,19	0,23	0,06	0,41	0,30	0,15	0,40	0,41	1,00	0,51	0,47	0,42	0,31
	fear/second	0,40	0,30	0,04	0,23	0,56	0,41	0,19	0,51	0,41	0,73	1,00	0,60	0,25	0,28
	fear/ying	0,15	0,08	-0,07	-0,07	0,22	0,23	-0,04	-0,03	0,16	0,33	0,36	1,00	0,34	0,33
	paresthesia	0,21	0,11	0,40	0,19	0,16	-0,06	0,05	0,23	0,28	0,26	0,23	-0,05	1,00	0,37
	chills	0,16	0,13	0,32	0,03	0,35	0,23	0,28	0,15	0,11	0,20	0,25	-0,04	0,35	1,00
LOW	VAS	1,00	0,46	0,27	0,26	0,43	0,38	0,19	0,19	0,62	0,32	0,23	0,21	0,22	0,16
	palpitations	0,46	1,00	0,25	0,32	0,13	0,12	0,16	0,21	0,26	0,18	0,19	0,12	0,06	0,17
	sweating	0,25	0,26	1,00	0,34	0,24	0,13	0,40	0,11	0,21	0,34	0,19	-0,04	0,29	0,45
	trembling	0,28	0,32	0,26	1,00	0,28	0,23	0,22	0,35	0,30	0,15	-0,04	0,37	-0,03	0,00
	shortbreath	0,13	0,32	0,11	0,10	1,00	0,61	0,40	0,17	0,24	0,29	0,35	0,26	0,16	0,00
	choking	0,14	0,36	0,06	0,02	0,28	1,00	0,20	0,16	0,33	0,17	0,35	0,26	0,15	0,09
	chestpain	0,11	0,25	0,15	0,15	-0,04	0,15	1,00	0,18	0,08	0,41	0,25	-0,02	0,49	-0,01
	nausea	0,22	0,11	0,49	0,21	0,02	0,21	0,21	1,00	0,18	0,26	-0,01	-0,02	0,31	0,21
	dizziness	0,50	0,40	0,26	0,22	0,17	0,31	0,10	0,25	1,00	0,44	0,20	0,21	0,34	0,11
	derealization	0,36	0,32	0,27	0,24	0,15	0,22	-0,22	0,22	0,44	1,00	0,20	0,29	0,55	0,14
	fear/second	0,23	0,27	0,29	0,28	0,08	0,26	-0,02	-0,04	0,29	0,49	1,00	0,58	-0,02	0,29
	fear/ying	-	-	-	-	-	-	-	-	-	-	-	1,00	-0,04	-0,02
	paresthesia	0,27	0,24	0,12	0,20	0,33	0,33	0,19	0,26	0,30	0,21	-0,09	-0,04	1,00	0,16
	chills	0,13	0,19	0,08	-0,09	0,13	0,23	-0,02	0,18	0,17	0,22	-0,05	-0,02	0,31	1,00

Spearman's correlation coefficients between DSM panic symptoms in four different CO₂ conditions.

Fig. 1) Correlations between Panic Symptom List scores and eVAAS Fear/Discomfort scores.

Spearman's correlation coefficients between DSM panic symptoms and Fear/Discomfort scores in four different CO₂ conditions. Sensation of shortness of breath and feeling of choking show a high correlation coefficient in all of the CO₂ (high, med, low) conditions but not in the air condition.

Fig. 2) Regression analysis. Dependent variable: eVAAS "Fear/Discomfort" score.

Relative weight (Beta scores) of separate DSM panic symptoms in predicting the intensity of "Fear/Discomfort" after the inhalation of 0% (air), 9% (low), 17.5% (med), and 35% (high) CO₂.

Factor analysis

The factor analysis extracted and rotated three components – respiratory, cognitive, and neurovegetative – which accounted for over 65% of the variance (Table 3). The respiratory component was mainly characterized by “sensation of shortness of breath” and “feeling of choking”. It also included “dizziness”, “sweating”, and “palpitations”. The cognitive component was defined by “fear of dying”, “fear of losing control”, and “derealization”. The neurovegetative component was primarily characterized by “trembling” but also included “chest pain”, “chills”, “nausea”, and “paresthesias”.

Regression analysis (2)

The three principal factor scores were then computed as variables. Regression analysis of factor scores as predicting variables (respiratory, cognitive, neurovegetative) showed that the respiratory component was a better predictor of eVAAS than the cognitive and the neurovegetative components (Beta standardized coefficients $\beta=0.541$; 0.391 ; 0.178 , respectively). The model explained 45% of the total variance ($R=0.67$).

Table 3) Factor analysis of Panic Symptom List scores.

	RESPIRATORY	COGNITIVE	NEURO VEGETATIVE
Shortness of breath	0.856		
Feeling of choking	0.845		
Dizziness	0.606		0.475
Sweating	0.582		
Palpitations	0.551		0.419
Fear of dying		0.906	
Fear of losing control		0.868	
Derealization		0.744	
Trembling			0.781
Chest Pain	0.421		0.756
Chills			0.697
Nausea			0.649
Paresthesias			0.642

Principal component analysis of DSM panic symptoms (performed only in 35% CO₂ condition). Three clusters are extracted: respiratory, cognitive, and neurovegetative. Only factor scores >0.4 are shown.

Discussion

In the present study, we analyzed the phenomenology of the CO₂-induced reaction in healthy volunteers. The symptoms reported by the subjects after the inhalations could be clustered into three distinct components. This confirms the first hypothesis that panic symptoms can be

subgrouped in discrete clusters. The clusters were labelled “respiratory”, “neurovegetative”, and “cognitive”, according to the most prominent symptoms. The respiratory cluster was determined mainly by the feelings of shortness of breath and choking (second hypothesis). Moreover, a strong relation was demonstrated between the respiratory symptoms and the subjective feeling evoked by the CO₂ challenge, which, according to the DSM criteria for PA, was labelled “fear or discomfort”. Our third hypothesis was that respiratory symptoms were the best predictor of the subjective disturbance defined in the DSM IV criteria for panic. The CO₂-induced emotion was specifically correlated with the respiratory sensations, and these symptoms were indeed the best predictors of the subjective fear/discomfort.

Fear and discomfort are two separate emotional entities but they appear together in the definition of Panic Attack provided by DSM-IV (APA, 2000). Consistently, in order to adhere as strictly as possible to the current psychiatric nosology, the subjects were asked to indicate the amount of the subjective experienced feeling, either it was fear or discomfort. The subjects were not instructed to specifically recognize the type of emotion they were feeling, in order to minimize a cognitive interpretation of their emotional experience.

The factor analysis of the present study extracted three components. The respiratory component was mainly characterized by shortness of breath and choking; it also included dizziness, sweating, and palpitations. The neurovegetative component was primarily characterized by trembling, but also included chest pain, chills, nausea, and paresthesias. The cognitive factor was characterized by fear of dying, fear of losing control, and derealization.

To the best of our knowledge, this is the first factor analysis performed on CO₂-induced panic symptoms in healthy subjects. Previous reports on PD patients (Argyle *et al*, 1989; Briggs *et al*, 1993; Cox *et al*, 1994; de Beurs *et al*, 1994; Meuret *et al*, 2006; Shioiri *et al*, 1996) generally agreed on several clusters, one representing a respiratory component. The similarity between our clusters, extracted in a normal sample, and clusters found in studies on PD patients supports the idea that the CO₂ challenge in healthy volunteers may be a valid model to study the phenomenology of clinical panic.

Specifically, the most recent analysis by Meuret *et al*. (2006) found a cardio-respiratory cluster that is strikingly similar to our respiratory cluster with regard to the presence of

dyspnea, feeling of choking, and palpitations. However, it is slightly different for other symptoms, like dizziness and sweating, which, in Meuret's PD patient sample, were included in the autonomic/somatic cluster. Instead, in our study sweating, dizziness, and palpitations loaded on the respiratory component. Sweating showed high coefficients of correlations to many other panic symptoms (Table 2) and might represent an unspecific reaction, which occur in presence of general distress, including cases of respiratory distress. Palpitations may be considered related to a cardio-respiratory dimension, since changes in heart rate and cardiac output can be secondary to changes in respiratory drive. Dizziness may be considered part of a hyperventilation cluster therefore it may be explainable why it loaded on the RESPIRATORY component in our study. Moreover, dizziness might also be secondary to a transient cerebral hypoperfusion, secondary to bradycardia. Unfortunately we do not have any physiological measurement in the present study however, according to the studies of Argyropoulos *et al.* (2002) and Kaye *et al.* (2005) on the effects of CO₂ in healthy volunteers, the expected cardiovascular reaction to CO₂ consists in a bradycardic response accompanied by an activation of the sympathetic system with an increase in blood pressure. The bradycardia appears to be regulated independently of the pressor response and most likely involves the direct activation of brainstem vagal nuclei by CO₂. Palpitations might also derive from the same changes in heart rate and the consequent activation the baroreceptor reflex. Therefore, since both dizziness and palpitations are strongly related to the activation of the autonomic system, it may be explainable why a substantial secondary loading for dizziness and palpitations was also present on the neurovegetative component (Table 3).

The majority of factor analyses performed on clinical samples found that fear of dying loaded with the cardio-respiratory symptoms (Argyle *et al.*, 1989; Briggs *et al.*, 1993; Cox *et al.*, 1994; de Beurs *et al.*, 1994; Meuret *et al.*, 2006), while in the present analysis it was the core symptom of the cognitive cluster. Such a difference may reflect a different cognitive elaboration of cardio-respiratory symptoms by PD patients compared to a non-clinical sample in that most PD patients tend to "catastrophize" bodily symptoms whereas healthy subjects are not expected to have developed this cognitive pattern.

As far as the third hypothesis is concerned, the most important finding of the study was that of the respiratory component as the best predictor of the negative affective response to CO₂

challenges. CO₂ inhalation significantly induced almost every panic symptoms listed in the DSM IV. However, we showed that subjective fear/discomfort was specifically associated with an increase in respiratory symptoms. Feeling of choking, shortness of breath, dizziness, and palpitations had the highest scores (mean score >1 in the high condition) and the highest correlation coefficients with regard to the CO₂-evoked subjective disturbance, represented by the eVAAS score. Yet, while dizziness and palpitations were related to the eVAAS score in every condition, including the air condition, the respiratory symptoms had high correlation coefficients specifically in the CO₂-enriched conditions, that is only in the low, medium, and high conditions.

Most of the clinical studies referred to above have provided support for the idea that respiratory symptoms are clinically relevant in PD. The respiratory subtype of panic has a specific profile of pharmacological sensitivity, it is associated with familial risk of PD, and it may predict a greater severity of illness (Biber *et al*, 1999; Briggs *et al*, 1993; Nardi *et al*, 2003; Nardi *et al*, 2006a; Nardi *et al*, 2006b; Onur *et al*, 2007). Epidemiological studies indicate that the presence of respiratory disorders, such as COPD (Goodwin *et al*, 2002), increases the likelihood of developing PD. Moreover, the link between panic and respiration is strengthened by the finding that PD patients have higher levels of irregularity and complexity of respiratory patterns (Caldirola *et al*, 2004).

Some authors have suggested that not only respiratory symptoms, but also the cognitive cluster, represented by catastrophic misinterpretations, seems to correlate quite well with the severity of PD (Cox *et al*, 1991; McNally *et al*, 1995; Telch *et al*, 1989; Vickers and McNally, 2005). However, as the authors themselves admit, a possible limitation of those studies is the retrospective self-report design, which may have overestimated cognitive symptoms. In addition, even if the severity of cognitive misinterpretations does correlate with the severity of the disorder, the direction of causality from cognitive misinterpretations to the severity of PA has not yet been convincingly demonstrated. It is perfectly conceivable that the development of catastrophic misinterpretation may be secondary to the severity of attacks, rather than the severity of attacks being secondary to the self-generated misinterpretations.

Having demonstrated, that in experimental panic, subjective fear/discomfort is more correlated to respiratory sensations than to cognitions, we provide support for the idea that respiratory control, rather than cognitions, plays a major role in the pathophysiology of panic. An interesting hypothesis put forward by Klein some years ago (Klein, 1993; Preter *et al*, 2008) inferred that PAs might derive from an abnormal “suffocation alarm”, an evolved, survival-oriented, inner physiological mechanism that erroneously signals the lack of useful air and the danger of impending suffocation, thus leading to urgency to breathe.

If, indeed, from an evolutionary point of view, panic emerged as an emotion to alert the subject of a biological danger, then it seems logical that a subjective sensation of panic (or discomfort) goes along with the severity of respiratory sensations. This is exactly what we observed in our results, which perfectly fit the core idea proposed by Klein, but also fit the function of emotions as expressed by such authors as Damasio (1999) and Panksepp (1998).

One apparent peculiarity of our results may need further comment. We observed that, in the high condition, “feeling of choking” was the best predictor of the fear/discomfort score while “sensation of shortness of breath” appeared to be a poor predictor (Fig. 1). The opposite behavior was observed in the low condition. The importance of choking in predicting the eVAAS score increased with the dose while the importance of shortness of breath decreased. Recently, Ietsugu and coworkers (2007) examined the relationship between the severity of PA and individual symptoms reported by a clinical sample. Shortness of breath was a predictor of moderate severity of PAs, while choking was a good predictor of high severity. Our results in experimental panic seem to be in line with Ietsugu’s results in clinical panic. It may be proposed that the feeling of choking is more closely related to a stronger sense of suffocation, which is more likely to be evoked by the higher doses, while the sensation of shortness of breath may reflect milder symptoms of dyspnea.

In conclusion, the present study explored the phenomenology of an experimental model of panic in healthy volunteers. We found that the discrete clusters of symptoms observed in this study were similar to those elicited in naturally occurring panic. Consistent with the idea that respiration plays a crucial role in the pathophysiology of panic, we found that respiratory symptoms best predicted the subjective state defined in the DSM IV criteria for panic.

Chapter IV

Multidimensional characterization of respiratory symptoms in CO₂-elicited panic in healthy volunteers

Alessandro Colasanti ¹, Gabriel Esquivel ¹, Erik den Boer ¹, Eric J Griez¹, Koen Schruers ¹

¹ *Research Institute Mental Health and Neuroscience, Maastricht University, NL*

² *Centre for Neuropsychopharmacology, Division of Brain Sciences, Imperial College, London, UK*

Abstract

We characterized the emotional response to CO₂ in healthy volunteers using a multidimensional instrument that measures the sensorial and affective components of respiratory discomfort, the Multidimensional Dyspnea Profile (MDP). All the dimensions of respiratory discomfort were affected by the CO₂ challenge. We found that the rating of respiratory discomfort was strongly correlated to the intensity of the CO₂-induced panic feeling, showing a higher predictive power relative to that of all non-respiratory DSM-IV panic symptoms. MDP scores were able to accurately discriminate between responders and non-responders to the CO₂ challenge. By demonstrating that a scale rating respiratory discomfort could be successfully applied as a tool to evaluate the subjective response to CO₂, we provide support to the idea that respiratory symptoms are a central phenomenon in experimental panic induced by CO₂.

Introduction

Panic Disorder (PD) and respiration are closely inter-related. Respiratory discomfort (or dyspnea), is a central phenomenon in the experience of a Panic Attack (PA) (Schruers *et al*, 2004b). A “respiratory” subtype of panic, characterized by the prevalence of respiratory symptoms, is associated to specific clinical features, a specific profile of pharmacological sensitivity, and a higher sensitivity to carbon dioxide (CO₂) inhalation (Biber *et al*, 1999; Briggs *et al*, 1993; Freire *et al*, 2010; Horwath *et al*, 1997). As a further confirmation of the link between panic and respiration, epidemiological studies evidenced high comorbidity of PD and respiratory disorders (asthma, chronic obstructive pulmonary disease) (Goodwin *et al*, 2002). It has been also hypothesized that the neurobiological mechanisms underlying PD may involve respiratory control (Battaglia *et al*, 2005; Esquivel *et al*, 2010; Klein, 1993; Preter *et al*, 2008).

The hypersensitivity to CO₂ displayed by PD patients and their first-degree relatives is well recognized (Coryell *et al*, 2006; Perna *et al*, 1996; Roberson-Nay *et al*, 2010; van Beek *et al*, 2005). In addition to its use as a disease-specific biomarker of PD, the CO₂ challenge can be used as an experimental model of PAs in healthy volunteers, as increasing concentrations of CO₂ dose-dependently induce a negative affect, compliant with the definition of PA, also in healthy individuals (Griez *et al*, 2007). This finding suggests that high doses of CO₂ can elicit panic in healthy subjects, as moderate doses do in PD patients.

The panic response induced by CO₂ challenge has been classically assessed following the definition of PA in the DSM diagnostic criteria (APA, 2000). Subjects are asked to rate their subjective feeling (fear or discomfort) and their panic symptoms, which include both somatic and cognitive symptoms. It has been previously showed in healthy volunteers that PA symptoms, elicited by high-dose CO₂ inhalation, can be grouped in distinct dimensions, namely respiratory, neurovegetative, and cognitive, and that the respiratory dimension was the best predictor of the emotional response to CO₂ (Colasanti *et al*, 2008). These findings suggest that a careful analysis of the CO₂-induced respiratory symptoms is important to elucidate the phenomenology of the emotion elicited by the CO₂ challenge.

Respiratory discomfort consists of qualitatively distinct sensations, and it has been well demonstrated that it comprises sensorial and affective dimensions that can be measured as separate entities (Lansing *et al*, 2009). There is experimental evidence that different stimuli produce distinct kinds of respiratory discomfort (Banzett *et al*, 2008). Therefore, a careful assessment of the CO₂-induced respiratory symptoms should be multidimensional, and should take into account both the affective and sensorial components.

The scope of the present study is to characterize a focused and specific, multidimensional instrument to measure respiratory discomfort, in terms of its potential application as a tool to rate the subjective response to CO₂ challenges. The Multidimensional Dyspnea Profile (MDP) has been designed to measure different dimensions of respiratory discomfort: unpleasantness, sensory intensity, and emotional response (Banzett *et al*, 2008).

We aim to 1) assess the response to acute high dose CO₂ inhalation using the MDP in healthy volunteers and 2) test whether and how accurately the rating of respiratory discomfort can predict the intensity of the panic-like feeling induced by CO₂, and discriminate between responders and non-responders to the challenge. Furthermore, we want to characterize how the different dimensions of respiratory discomfort differentially contribute in discriminating the response to acute CO₂ inhalation. We hypothesize that the MDP, a respiratory rating instrument, will be able to accurately predict the emotional response to CO₂. As the response to CO₂ is recognized as a valid human model of PAs, this would support the hypothesis that respiratory symptoms are central in the phenomenology of panic.

Materials and methods

Subjects

The study is part of a larger research aimed to investigate the neurobiological mechanisms underlying the response to CO₂ inhalation. The other results, concerning the effects of dietary manipulations on CO₂-induced emotion, have been published elsewhere (Colasanti *et al*, 2011). Healthy volunteers were recruited among students or staff, through advertisements from within Vijverdal Psychiatric Hospital in Maastricht and from the Maastricht University. The ethics committee of Maastricht University approved the study and the subjects have been paid for their participation to the experiment. A complete description of the study was given both orally and in written form to the subjects. The volunteers underwent collection of medical history and physical examination. Inclusion criteria were: an age ranging between 18 and 65 years and a good present and past physical and mental condition, based on the results of a structured psychiatric interview (Mini International Neuropsychiatric Interview) (Sheehan *et al*, 1998) performed by a physician. Exclusion criteria were: current psychopharmacological or psychological treatment, presence of alcohol, substance or caffeine-related disorders, excessive smoking (>10 cigarettes a day), respiratory or cardiovascular disease, hypertension (diastolic>100 mmHg; systolic >170 mmHg), personal or familiar history of cerebral aneurysm, pregnancy, and epilepsy. Individuals were also excluded if they reported common specific fears or if they had a history of PAs, or a history of PD in a first-degree relative. Those who met the inclusion and exclusion criteria and who provided written informed consent were included in the study.

Carbon Dioxide challenge

The procedure was standardized for all subjects and for all sessions and was performed according to the protocol for 35% CO₂ inhalation used at the Maastricht Academic Anxiety Center (Griez *et al*, 1987a). A gas mixture containing 35% CO₂ / 65% O₂ was delivered through a nasal-oral exercise self-administration facemask using a double vital capacity inhalation technique. Before the challenge was started, the inspired vital capacity of every

subject was evaluated using an analogue respirometer (Wright respirometer Mark 20) connected to the self-administration mask. The same respirometer measured the gas volume delivered at each inhalation. Baseline inspired vital capacity with a double breath of air was measured on each occasion, and a test breath was considered adequate if it was more than 80% of the baseline vital capacity. The subjects were then given the self-administration mask and told to hold it in their hands and to exhale as deeply as they could. A double-breath inhalation of the 35% CO₂ / 65% O₂ mixture was then delivered to the subjects (Griez *et al*, 2007). They were asked to take a maximal inspiration through the self-administration facemask and to make a complete expiration outside the facemask, immediately followed by a second maximal inspiration through the facemask following the same procedure. At the end of the second inhalation, the subjects were asked to hold their breath for 4 seconds to enhance the alveolar gas exchange.

Assessments

We used a visual analogue scale for affect (VAAS) labelled ‘fear or discomfort’, ranging from 0 (no fear/discomfort at all) to 100 (the worst imaginable fear/discomfort). The participants were instructed to indicate the amount of the subjective disturbance, in case of feeling either fear or discomfort following an established procedure (Colasanti *et al.*, 2008).

Panic symptoms were evaluated using the Panic Symptom List (PSL-IV) (Schruers *et al*, 2000b). This consists of a questionnaire listing 13 items, each representing one of the DSM-IV symptoms (palpitations; sweating; trembling; sensations of shortness of breath or smothering; feeling of choking; chest discomfort; nausea or abdominal distress; feeling dizzy, lightheaded, or faint; derealisation or depersonalization; fear of losing control; fear of dying; paresthesias; chills or hot flushes). The participants were asked to rate the intensity of each symptom from 0 (absent) to 4 (very intense). The total scores thus ranged from 0 to 52.

To assess dyspnea, we used the MDP (Banzett *et al*, 2008). This instrument is designed to measure immediate unpleasantness (A1), sensory qualities (SQ), and emotional responses (A2). A1 is an individual item, while SQ and A2 are composed of categories. The scales

comprising all integers from 0 to 10, equally spaced, were presented for ratings. For the A1 item, in addition to the numbers, words descriptive of magnitude and dimension were ranged along the scale to improve consistency among subjects; the score 0 was associated with the description “neutral”, scores between 1 and 3 were associated with “slightly unpleasant”, 4 and 5 were described “annoying”, while between 6 and 8 were “distressing”. The upper end of the SI scale (scores 9 and 10) was labelled “maximum,” whereas the upper end of the A1 scale was labelled “unbearable”.

The five categories of SQ were: “My breathing requires muscle work or effort”; “I am not getting enough air, I feel hunger for air, or, I am smothering”; “My breathing requires mental effort or concentration”; “My chest and lungs feel tight or constricted”; “I am breathing a lot; (breathing rapidly, deeply, heavily)”. Subjects rated how much of each sensation quality they felt, from 0 (“none”) to 10 (“as intense as I can imagine”).

A2 was rated through a list of five negative emotions: depression, anxiety, frustration, anger and fear and two positive emotions, happiness and contentedness. Subjects rated how much of each emotion they experienced on a scale ranging from 0 (“none”) to 10 (“the most I can imagine”).

All the assessments were administered 10 minutes before (pre-CO₂) and immediately after CO₂ challenge (post-CO₂). Post-CO₂ scores indicated the worst moment experience by subjects after inhaling the gas mixture.

Data analysis

The statistical analyses were performed using SPSS 17.0. All the data are presented as means $\pm$ SD. Changes in VAAS, PSL, and MDP scores were calculated with the formula: Δ scores = post-CO₂ – pre-CO₂ scores.

A MDP total score was generated by adding A1 and each SQ scores to the A2 scores related to negative emotions (depression, anxiety, frustration, anger and fear). The two positive emotions, happiness and contentedness, were not included in the MDP Total Score as they

are unlikely to contribute to the negative affect associated to respiratory discomfort. The positive emotions have been included by the authors of the scale to help subjects to pay attention to the items (personal communication).

A “responder” to CO₂ inhalation was defined accordingly to previously applied conservative criteria (Griez et al., 2007), which indicate as responder a subject reporting both Δ VAAS scores >50 and Δ PSL subscores >1 in at least four PSL symptoms.

The accuracy of each rating scales (MDP and PSL subscales) in discriminating responders from non-responders has been determined using Receiving Operator Characteristics (ROC) curves. The ROC curves have been obtained by plotting the true positive rates (sensitivity of the test) and false positive rates (1 – specificity), with each point of the curve corresponding to different true positive and false positive rates. The overall accuracy of the test performance has been summarized by the area under the curve (AUC) obtained by connecting the points. The AUC value could range from 0.5, indicating no better than chance test performance (sensitivity and specificity = 50%), to 1.0, with sensitivity and specificity = 100%, indicating perfect test discrimination. The significance of the differences between the ROC curve and the true diagonal (Reference Line) has been tested assuming a non-parametric distribution. The null hypothesis was that AUC of the variable of interest was equal to that of the Reference Line (AUC=0.5).

The statistical analysis was aimed to test the following hypothesis:

1. CO₂ inhalation results in significant increases in MDP Total Score and subscales scores.
2. MDP Total Score significantly predicts Δ VAAS fear/discomfort scores and significantly discriminate responders from non-responders to the challenge.
3. MDP Total Score predictive power (in predicting Δ VAAS and identifying responders) is at least equal to that of PSL.

Additionally, we aimed to test which sensorial and affective dimensions of dyspnea significantly discriminate responders from non-responders in an optimal way.

Accordingly, we have performed the following statistical analyses:

1. A one-tailed T-test for Paired Samples to compare pre- and post-CO₂ MDP Total and MDP subscales scores.
2. Linear regression analysis using Δ VAAS scores as dependent variable and either
 - a. each of Δ MDP A1, SQ, and A2 scores *or*
 - b. each of individual Δ PSL scores (with or without respiratory symptoms) as predicting variables.
3. ROC curves to classify responders and non-responders generated for Total Δ MDP Scores and Total Δ PSL Scores, respectively. The significance of the difference between their AUC and Reference Line has been tested.
4. ROC curves to classify responders and non-responders generated for each Δ MDP A1, SQ and A2 scores. The significance of the difference between their AUC and Reference Line has been tested.

Results

We analyzed data from 96 CO₂ challenges performed in 57 subjects (30 males) included in the study. The mean age was 24.6 ± 6.1 years.

CO₂ inhalation induced a significant change in all MDP ratings, demonstrated by a significant post-CO₂ vs pre-CO₂ increase in Total scores, A1, all SI subscales ($p < 0.0001$), and all A2 subscales scores with negative valence [anxiety, fear, frustration ($p < 0.0001$), anger ($p < 0.001$), and depression ($p < 0.05$)], and by a significant decrease in the A2 subscale scores with positive valence [happiness ($p < 0.0001$) and contentedness ($p < 0.05$)]. The frequency distribution of post-CO₂ MDP subscale ratings is represented in Fig. 1. With regard to “unpleasantness” (A1) scores, the experience was rated at least “distressing” (post-CO₂ A1 scores ≥ 6) in 39 cases (40.6%).

There was a significant increase in VAAS scores (mean Δ VAAS = 38.7 ± 25.3), total PSL scores (mean total Δ PSL score = 11.5 ± 6) and all individual PSL scores ($p < 0.0001$) except

“nausea or abdominal distress” and “fear of dying”. In 33 cases (34.4%) the subjects were responders to the CO₂ challenges. Among those who were responders, 72.7% rated post-CO₂ MDP A1≥6 (“distressing or unbearable”).

Fig. 1) Frequency of post-CO₂ MDP scores.

MDP scores 6 to 10 were labelled with the descriptors “distressing” (6 to 8), or “unbearable” (9 and 10). MDP scores 1-5 were labelled with the descriptors “slightly unpleasant” (1 to 3), or “annoying” (4 and 5). The score 0 was labelled with the descriptor “neutral”. A1: unpleasantness; SQ: sensory qualities; A2: emotional responses.

Linear regression

The linear regression analysis showed that the regression model which included all Δ MDP sub-scores as predictor variables, was significantly able to predict Δ VAAS scores ($R^2=0.553$; $F=7.793$; $p<0.0001$). The model which included all PSL scores as predictor variables was less effective in predicting Δ VAAS scores ($R^2=0.391$; $F=4.051$; $p>0.0001$), and the only significant regression coefficient displayed by the PSL regressors was that of

shortness of breath. The same model, after removing PSL respiratory symptoms (sensation of shortness of breath and feeling of choking), was a relatively weak predictor of Δ VAAS scores ($R^2=0.255$; $F=2.610$; non-significant), and there were no statistically significant regression coefficients among PSL symptoms.

ROC curves

ROC curves for Total Δ MDP and Total Δ PSL scores are presented in Fig. 2. Both AUCs were significantly different from that of the asymptotic curve ($p<0001$), indicating that the null hypothesis is rejected. AUCs are similar between the two classifiers (0.815 and 0.792, respectively for Total Δ MDP and Total Δ PSL scores), indicating that they are equally effective in discriminating between responders and non-responders to CO₂.

With regard to the SQ scores (Table 2, Fig. 4), all the dimensions were significantly different from the asymptotic curve in discriminating between responders and non-responders, however the SQ with the highest discriminating power was air hunger/sensation of smothering or suffocating.

ROC curves for individual affective dimensions (Δ MDP A1 score and individual Δ MDP A2 scores) are showed in Table 1 and Fig. 3. Δ MDP A1 (unpleasantness) displays the highest AUC, followed by anxiety and fear, and frustration (0.835, 0.759, 0.722, 0.674, respectively). Depression, happiness, anger and contentedness' AUCs were not significantly different from that of the asymptotic curve.

Fig. 2) ROC curve of Total Δ MDP and Total Δ PSL scores.

Table 1. AUC of individual affective dimensions of respiratory discomfort (Δ MDP A1 score and individual Δ MDP A2 scores).

Affective dimensions	AUC	SE	Sig.	95% CI	
unpleasantness	.835	.044	.000	.748	.921
depression	.550	.063	.425	.427	.673
anxiety	.759	.053	.000	.656	.863
contentedness	.597	.061	.120	.477	.716
frustration	.674	.061	.005	.555	.793
anger	.596	.063	.124	.472	.720
happiness	.511	.063	.865	.388	.633
fear	.722	.057	.000	.611	.833

Fig. 3) ROC curve of individual affective dimensions of respiratory discomfort (Δ MDP A1 score and individual Δ MDP A2 scores).

Table 2. AUC of individual sensory qualities of respiratory discomfort (Δ MDP SQ scores)

Sensory Qualities	AUC	SE	Sig.	95% CI	
Muscle Work	.697	.055	.002	.590	.805
Air Hunger/Smothering	.779	.048	.000	.685	.874
Mental effort	.726	.054	.000	.619	.833
Chest tightness	.626	.067	.043	.494	.758
Breathing a lot	.757	.050	.000	.660	.855

Fig. 4) ROC curve of individual sensory qualities of respiratory discomfort (Δ MDP SQ scores).

Discussion

We characterized the respiratory discomfort in response to CO₂ inhalation, an acute panicogenic challenge, in healthy volunteers using the multidimensional scale MDP. By investigating whether a scale rating respiratory discomfort could be successfully applied as a tool to evaluate the subjective response to CO₂, we aimed to support the idea that respiratory symptoms are a central phenomenon in experimental panic.

We have found that 1) all the MDP dimensions were strongly affected by the CO₂ challenge; 2) the rating of respiratory discomfort was associated with the intensity of the CO₂-induced panic feeling, showing a higher predictive power relative to that of all non-respiratory DSM-IV panic symptoms; 3) the rating of respiratory discomfort was able to discriminate between responders and non-responders to the CO₂ challenge; 4) the respiratory dimensions that better

discriminated responders from non-responders were unpleasantness among the affective dimensions, and sensation of air hunger/smothering among the sensorial dimensions.

If all the published literature on the relationship between panic and CO₂ challenges is right (Griez *et al*, 1998; Griez *et al*, 2007; Papp *et al*, 1997) in claiming that the CO₂ challenge is a valid experimental model of panic, then it appears from the present findings that a respiratory instrument designed by physiologists is better in grasping panic than a psychiatric instrument rating all the DSM-IV symptoms of panic (the PSL). This leads to the thought that panic is essentially a respiratory phenomenon, at least from a phenomenological point of view.

These findings also suggest that MDP can be implemented to monitor the subjective response to CO₂ challenges. The accurate assessment of respiratory discomfort induced by CO₂ provides important information to investigate the phenomenology of CO₂-induced emotion and to further understand the relationship between respiratory sensations and panic.

The results of this study replicate and extend our previous findings obtained by clustering CO₂-induced panic symptoms, which indicated that a cluster of respiratory symptoms of panic could be extracted in the experimental panic similarly to the naturally occurring panic. It was also shown that the respiratory dimension was the best predictor of the affective response to CO₂ inhalation (Colasanti *et al*, 2008).

In the present study, we observed that the CO₂ inhalation significantly affected the rating of all respiratory dimensions measured with MDP and that the immediate feeling induced by CO₂ (unpleasantness of respiration, or A1) was rated as at least “distressing” in more than 40% of the cases and in more than 70% of the responders to the challenge. MDP was strongly associated to the intensity of the affective response to CO₂ (measured with VAAS) and discriminated between responders and non-responders to the challenge at least with the same accuracy as the PSL did. Furthermore, a regression model including all MDP subscales was more powerful in predicting the affective response than a model including the other, non-respiratory, panic symptoms. This is consistent with another study that examined dimensions of dyspnea evoked by 35% CO₂ challenge in PD patients and demonstrated that

breathing effort and sense of suffocation discriminated patients who did and did not have CO₂-induced PAs (Perna *et al*, 2004b).

These results are in line with the clinical evidence pointing that respiratory symptoms are central in the phenomenology and clinical course of PD. The presence of prominent respiratory symptoms is associated with a distinct profile of pharmacological sensitivity (Briggs *et al*, 1993), a familial risk of PD (Horwath *et al*, 1997; Nardi *et al*, 2003; Nardi *et al*, 2006a), a longer duration and a greater severity of illness (Biber *et al*, 1999; Onur *et al*, 2007). Other clinical features displayed by PD patients with prominent respiratory symptoms include a higher sensitivity to CO₂ inhalation (Abrams *et al*, 2006; Biber *et al*, 1999; Nardi *et al*, 2006a; Valenca *et al*, 2002), more past traumatic suffocation experiences and respiratory diseases (Bouwer *et al*, 1997; Verburg *et al*, 1995b), higher levels of anxiety sensitivity, and more symptoms of the panic-agoraphobic spectrum (Onur *et al*, 2007). Epidemiological studies indicate that the presence of respiratory disorders, such as chronic obstructive pulmonary disease (Goodwin *et al*, 2002a), increases the likelihood of developing PD.

We found that the affective dimension of respiratory discomfort that best discriminated between responders and non-responders to the CO₂ challenge was the immediate experience of unpleasantness, rather than emotional responses which require a more extensive cognitive evaluation, such as anxiety, fear and frustration. The latter are “secondary” emotions, which involve the broader context of a person’s life experience and personal situation, and other cognitive inputs (Lansing *et al*, 2009). Instead, unpleasantness is an immediate “feeling state”, more primitive, non-reflective, and more directly related to the homeostatic urge of breathing. We hypothesize that this finding is consistent with the nature of the CO₂-induced emotion.

Increased CO₂ levels are sensed by central and peripheral CO₂/H⁺ chemoreceptors, which provide rapid feedback to the brainstem respiratory control system concerning the adequacy of alveolar ventilation relative to metabolism and also monitor the balance of arterial CO₂, cerebral blood flow, and cerebral metabolism. Recent findings demonstrated that central chemoreception is a distributed property of different groups of midbrain neurons, which also include midbrain serotonergic neurons (Severson *et al*, 2003). These have been proposed to

mediate non-respiratory responses to hypercapnic acidosis, such as intense feeling of anxiety. Also, the amygdala, a key region in processing affective stimuli, is intrinsically CO_2/H^+ chemosensitive, and its chemosensitive properties regulates the expression of fearful behavioural responses in rodents (Ziemann *et al*, 2009). Based on these evidences, it appears that the *emotional* brain respond directly to hypercapnic acidotic stimuli. Behavioural evidence in humans, showing that acutely increased CO_2 levels dose-dependently elicit an emotional distress (Griez *et al*, 2007), and neuroimaging evidence, showing limbic neural activation correlating with CO_2 -induced distress (Liotti *et al*, 2001), support this idea. The emotion elicited by CO_2 could represent the subjective-affective element of an instinct critical for survival, that is the urge of breathing. Denton proposed that hunger for air is an instance of a primal or primordial emotion, similar in nature to those emotions experienced during states of pain, thirst, and hunger, when the sensation component is interoceptor-driven and linked to the basic homeostatic functions of life (Denton *et al*, 2009). It is not surprising that in our study the emotional response to CO_2 was better described as an immediate and non-reflective “feeling state” of unpleasantness rather than a more complex secondary type of emotion.

We found that all the sensorial dimensions discriminated between responders and non-responders to the challenge, however the dimension which better predicted the response was “not getting enough air, hunger for air, smothering”. Klein proposed the existence of an inborn CO_2 -driven alarm in humans, aimed to protect the organism in case of impending suffocation (Klein, 1993; Preter *et al*, 2008). It is conceivable that panic is part of the human emotional repertoire and is elicited by suffocation cues to signal to the body the need of more air. Our findings support this theory.

In the present study, the CO_2 inhalation induced a significant change in all affective dimensions of MDP, including depression and anger, which are not directly related to panic. Other experimental studies have indicated that emotions other than panic can be elicited by CO_2 inhalation. In a study in PD patients, depressive and aggressive symptoms were provoked by CO_2 inhalation, particularly in those subjects also suffering from Major Depression (Overbeek *et al*, 2005). Prolonged 7.5% CO_2 breathing has been described to elicit reductions in happiness and relaxation ratings, and increases in fear, anxiety, tension,

nervousness, irritability, and worrying in healthy volunteers (Bailey *et al*, 2005). Consistently with the profile of provoked symptoms 7.5% CO₂ has been used as an experimental model of GAD, rather than PD (Bailey *et al*, 2007).

Conclusions

We have characterized the emotional response to CO₂ using a multidimensional instrument which measures the sensorial and affective components of respiratory discomfort. Our results suggest that MDP could be successfully used to evaluate the subjective response to CO₂ and that could be extended to assessments of clinical populations. Also, additional research is worth to test whether it is a sensitive instrument to detect the effects of panicolytic agents on the subjective response to CO₂.

In conclusion, the ability of a respiratory instrument to capture the expression of experimental panic is paradigmatic of the important link existing between respiration and panic.

Chapter V

Effects of tryptophan depletion and tryptophan loading on the affective response to high-dose CO₂ challenge in healthy volunteers

Alessandro Colasanti,^{1,2}; Gabriel Esquivel,¹; Erik den Boer¹; Annerieke Horlings¹; Abdul Dandachi,¹; Jeff L Oostwegel,³; Eva L van Donkelaar,¹; Eric J Griez,¹; Koen Schruers,¹

¹ *Department of Psychiatry and Neuropsychology, Faculty of Health, Medicine and Life Sciences, School for Mental Health and Neuroscience, Maastricht University, Maastricht, NL*

² *Centre for Pharmacology and Therapeutics, Division of Experimental Medicine, Department of Medicine, Imperial College London, UK*

³ *Apotheek Ten Horn, Service Pharmacy, Maastricht, NL*

Published as: Colasanti A, Esquivel G, den Boer E, Horlings A, Dandachi A, Oostwegel JL, van Donkelaar EL, Griez EJ, Schruers K. Effects of tryptophan depletion and tryptophan loading on the affective response to high-dose CO₂ challenge in healthy volunteers. *Psychopharmacology* (Berl). 2011 Jun;215(4):739-48.

Abstract

It has been reported that in Panic Disorder (PD), tryptophan depletion enhances the vulnerability to experimentally induced panic, while the administration of serotonin precursors blunts the response to challenges. Using a high dose Carbon Dioxide (CO₂) challenge, we aimed to investigate the effects of acute tryptophan depletion (ATD) and acute tryptophan loading (ATL) on CO₂-induced panic response in healthy volunteers.

Eighteen healthy volunteers participated in a randomized, double-blind placebo-controlled study. Each subject received ATD, ATL, and a balanced condition (BAL) in separate days, and a double-breath 35% CO₂ inhalation 4.5 h after treatment. Tryptophan (Trp) manipulations were obtained adding 0 g (ATD), 1.21 g (BAL), and 5.15 g (ATL) of l-tryptophan to a protein mixture lacking Trp. Assessments consisted of a Visual Analogue Scale for Affect (VAAS) and Panic Symptom List (PSL). A separate analysis on a sample of 55 subjects with a separate-group design has also been performed to study the relationship between plasma amino acid levels and subjective response to CO₂.

CO₂-induced subjective distress and breathlessness were significantly lower after ATD compared to BAL and ATL ($p < 0.05$). In the separate-group analysis, Δ VAAS scores were positively correlated to the ratio Trp: Σ LNAA after treatment ($r = 0.39$; $p < 0.05$).

The present results are in line with preclinical data indicating a role for the serotonergic system in promoting the aversive respiratory sensations to hypercapnic stimuli (Richerson, 2004). The differences observed in our study, compared to previous findings in PD patients, might depend on an altered serotonergic modulatory function in patients compared to healthy subjects.

Introduction

In patients affected by Panic Disorder (PD), acute tryptophan depletion (ATD) enhances the response to a number of panicogenic agents. This effect of ATD has been shown in studies which used inhalation of 35% and 5% Carbon Dioxide (CO₂) (Miller *et al*, 2000; Schruers *et al*, 2000a) and infusion of flumazenil (Bell *et al*, 2002; Davies *et al*, 2006) as challenges to induce panic, but no effect has been observed using infusion of cholecystokinin tetrapeptide (CCK-4) (Toru *et al*, 2006). Pre-treatment with 5-hydroxytryptophan (5-HTP), the immediate precursor of serotonin (5-HT), has been shown to blunt the response to 35% CO₂ challenge, indicating a “protective” effect on experimentally induced panic (Schruers *et al*, 2002b). These findings seem to indicate that, in PD patients, fear or anxiety provoked by some panicogenic challenges is negatively correlated to the availability of 5-HT precursors.

Studies in healthy volunteers yielded inconclusive findings: reports showed that ATD failed to modify the panicogenic effects of CCK-4 (Koszycki *et al*, 1996) as well as the effects of 5% CO₂ inhalation (Miller *et al*, 2000) or the Read rebreathing test (Struzik *et al*, 2002). Two studies have tested the effects of 35% CO₂ in tryptophan (Trp) depleted subjects, one showing an increase of CO₂-induced neurovegetative symptoms but not subjective anxiety (Klaassen *et al*, 1998), while the other did not find any significant difference between ATD condition and placebo with regard to CO₂-provoked subjective effects (Hood *et al*, 2006). Administration of 5-HTP in healthy volunteers was shown to reduce CCK-4-induced panic attacks and panic-related cognitive symptoms specifically in females (Maron *et al*, 2004) but had no effects on the response to CO₂ (Schruers *et al*, 2002b).

The discrepancies observed between PD patients and healthy controls, in terms of the effects of ATD on the subjective response to challenges might be due to the relative low sensitivity exhibited by healthy subjects to panicogenic agents. We have previously showed in healthy volunteers that the inhalation of CO₂ dose-dependently induces panic-like symptoms, and that high doses of CO₂ (double-breath of 35% CO₂) in healthy subjects might be as effective as moderate doses of CO₂ are in PD patients (Griez *et al*, 2007; Schruers *et al*, 2004b). Here we intended to perform a study in healthy subjects using a high dose CO₂ challenge in order to test whether we can reproduce in a non-clinical population the same modulating effects of

5-HT manipulation observed in PD patients on experimental panic response; for this purpose, we investigated the effects of ATD on CO₂-induced panic response in healthy volunteers.

Additionally, since the Trp suppletion studies with panicogenic challenges conducted in healthy subjects gave inconclusive results (Maron *et al*, 2004; Schruers *et al*, 2002b), we also tested the effects of acute tryptophan loading (ATL) on subjective response to CO₂ challenge.

Material and Methods

Subjects

Healthy volunteers were recruited amongst students or staff, through advertisements from within the Vijverdal Psychiatric Hospital Maastricht (Mondriaan Zorggroep) and throughout the Maastricht University locations. The Medical Ethics Committee of the Academic Hospital Maastricht and Maastricht University approved the study and the subjects were paid for their participation in the experiment. After a complete description of the study, a written informed consent was obtained from the subjects. The volunteers underwent collection of medical history and physical examination. Inclusion criteria were age between 18 and 65 years and a good present and past physical and mental condition. The latter was established using a structured psychiatric interview (Mini International Neuropsychiatric Interview) performed by a physician. Exclusion criteria were current psychopharmacological or psychological treatment, recent alcohol intake, substance or caffeine-related disorders, excessive smoking (>10 cigarettes a day), respiratory or cardiovascular disease, hypertension (diastolic>100 mmHg; systolic>170 mmHg), personal or familiar history of cerebral aneurysm, pregnancy, and epilepsy. Individuals were also excluded if they reported common specific fears or if they had a history of panic attacks, or a history of PD in a first-degree relative.

Design

Subjects were randomized in double-blind placebo-controlled cross-over study design. The subjects received three different gelatin-based mixtures (GBM) on three different days, in a randomized order, to induce respectively the ATD condition, a balanced condition (BAL) and the ATL condition. On each day, after GBM administration, they underwent a double-breath CO₂ challenge.

A separate analysis has been conducted on a larger sample of subjects in a randomized separate-group design, in order to investigate the relationship between the ratio Trp to the sum of large neutral amino acids in plasma (Trp:ΣLNAA) and the subjective response to CO₂. Subjects were randomly assigned to one of the three groups: ATD condition, BAL condition, and ATL condition. This sample also included subjects who were enrolled in the cross-over study for which only the first study day was taken into consideration in the analysis.

Procedure

The subjects arrived at the clinic after an overnight fast. Blood was drawn to measure plasma Trp and LNAA levels. GBM were administered in the morning at about 9.30. After drinking the GBM, the subjects remained on the ward and were allowed to read or watch a nature documentary on video. Subjects had ad libitum access to mineral water but they were asked to refrain from eating and drinking any xanthine beverages. At 4.5 h after GBM administration other blood samples were collected to monitor plasma Trp and LNAA levels. Ten minutes later, the subjects underwent a double-breath inhalation of a gas mixture containing 35% CO₂ and 65% O₂.

Gelatin-based mixtures

The gelatin consists of a hydrolysate collagen-protein comprising the entire range of amino acids in the form of peptides, but completely lacking Trp. After administration, these peptides are decomposed into amino acids, and the mechanism of depletion is identical to

that of the “classic” amino acid mixture (Sambeth *et al*, 2009). The GBM was kindly provided by PB Gelatins (Tessenderlo Group, Belgium) in form of powder. Amino acid composition of the GBM can be found in Table 1. The drink was prepared mixing 100 g of the powder with 200 ml water at 50-70°C. The drink was kept refrigerated at 4°C and then kept at room temperature for the 30 min before administration. The three GBM were identical in composition except that 1.15 g of l-tryptophan and 5.15 g of l-tryptophan were added to the mixtures for the BAL and ATL conditions, respectively. No l-tryptophan was added for the ATD condition. The three GBM had the same colour and taste.

Table 1. Amino-acid spectrum

Amino acid spectrum (typical weight % on ds protein)	
Alanine	8.4
Arginine	7.7
Aspartic Acid/Asparagine	4.5
Cysteine	0.0
Glutamic Acid/Glutamine	10.0
Glycine	23.3
Histidine	0.9
Hydroxylysine	1.5
Hydroxyproline	12.3
Isoleucine	1.2
Leucine	2.6
Lysine	3.3
Methionine	0.9
Phenylalanine	1.6
Proline	13.7
Serine	3.4
Threonine	1.9
Tryptophan	0.0
Tyrosine	0.6
Valine	2.2

Carbon Dioxide challenge

The 35% CO₂-inhalation procedure was performed in accordance to a standardized protocol developed at the Maastricht Academic Anxiety Center (Griez *et al*, 1987a; Griez *et al*, 1998). A gas mixture containing 35% CO₂/65% O₂ was delivered through a nasal-oral exercise self-administration facemask using a double vital capacity inhalation technique. Before the challenge, the inspired vital capacity of every subject was measured using an analogue respirometer (Wright respirometer Mark 20) connected to the self-administration mask. The same respirometer measured the gas volume delivered at each inhalation. The inspired vital capacity with a double breath of air was measured on each occasion, and a challenge was considered adequate if it was more than 80% of the baseline vital capacity. The subjects were then given the self-administration mask and asked to exhale as deeply as possible. They were asked to take a maximal inspiration through the mask and to make a complete expiration outside the mask, immediately followed by a second maximal inspiration. At the end of the second inhalation, the subjects were asked to hold their breath for 4 seconds, to enhance the alveolar gas exchange, and finally make a complete expiration outside the mask again.

Amino acid analysis

Samples for determination of plasma amino acid levels were taken at baseline (T0) and 4.5 h after GBM administration (T1). Blood (10 ml) was collected by venepuncture in sodium heparin tubes at each time point, immediately after the rating of subjective assessments. After collection, the blood samples were immediately centrifuged at 4°C (10 min at 4000 rpm). Subsequently, 100 µl of plasma was mixed with 8 mg of sulphasalicyl acid and frozen at -80°C until the amino acid analysis was performed (van Eijk *et al*, 1993). Plasma amino acids were determined using a fully automated high-performance liquid chromatography (HPLC) system after precolumn derivatization with *o*-phthalaldehyde (OPA). OPA-AA derivatives of the amino acids were quantified with fluorescence detection. The concentrations of plasma amino acids were expressed as µmol/l (van Eijk *et al*, 1993). The ratio of total Trp:ΣLNAA (LNAA: large neutral amino acids, i.e., tyrosine, phenylalanine, leucine,

isoleucine and valine) at baseline and 4.5 h after GBM were used as endpoints to monitor changes in Trp availability.

Assessments

Rating scales to assess panicogenic effects of CO₂ challenge were chosen with reference to the definition of Panic Attack in DSM-IV TR diagnostic criteria (APA, 2000). We used a visual analogue scale for affect (VAAS) labelled “fear or discomfort”, ranging from 0 (no fear/discomfort at all) to 100 (the worst imaginable fear/discomfort). The participants were instructed to indicate the amount of the subjective disturbance, in case of feeling either fear or discomfort following an established procedure (Colasanti *et al*, 2008).

Panic symptoms were evaluated using the Panic Symptom List (PSL-IV) (Schruiers *et al*, 2000a). This consists of a questionnaire listing 13 items, each representing one of the DSM-IV TR symptoms (i.e., palpitations; sweating; trembling; sensations of shortness of breath or smothering; feeling of choking; chest discomfort; nausea or abdominal distress; feeling dizzy, lightheaded, or faint; derealization or depersonalization; fear of losing control; fear of dying; paresthesias; chills or hot flushes). The participants were asked to rate the intensity of each symptom from 0 (absent) to 4 (very intense). The total scores thus ranged from 0 to 52.

VAAS and PSL-IV were administered at baseline (T0; pre-GBM administration), 1.5 H hrs (T1), 3 hrs (T2), 4.5 h post-GBM administration (T3), and after CO₂ challenge (Post-CO₂). Post-CO₂ scores indicated the worst moment experienced by the subjects after inhaling the gas mixture.

Mood states were measured with the shortened 32-item validated version of the Dutch translation of the Profile of Mood States Scale (POMS) (Wald and Mellenbergh, 1990), which consists of 5 mood scales (depression, tension/anxiety, vigor, anger/hostility, and fatigue). The POMS was administered at T0, T1, T2, and T3. Subjects were asked to rate the scale according to how they felt at that moment.

Data analysis

All the data are presented as mean $\pm$ standard deviation (SD). Percentage changes in Trp: Σ LNAA ratio ($\Delta\%$ Trp: Σ LNAA ratio) after GBM (T3) compared to baseline (T0) were calculated by the formula $T3-T0/T0 \times 100$. CO₂-induced changes in VAAS and PSL scores were expressed as Δ scores (obtained by the formula: POST-CO₂ scores - T3 scores). In the cross-over sample, all data were analyzed with analysis of variance (ANOVA) for repeated measures with time and treatment condition as within-subjects factors. The effects of time $\times$ treatment condition interaction were studied to investigate the influence of GBM condition (ATD, BAL, ATL) on the subjective response to CO₂ measured with VAAS and PSL scores. The analysis of VAAS scores has been repeated after controlling for gender, and the interaction time $\times$ treatment condition $\times$ gender has been studied using ANOVA per repeated measures.

To investigate the influence of GBM conditions on POMS scores, the effects of time per se and time $\times$ treatment condition interaction were studied with ANOVA per repeated measures.

If indicated by a significant ANOVA condition effect, time effect, or time $\times$ condition interaction effect, a subsequent evaluation on difference between individual conditions and between individual time points was done by within-subject repeated contrasts. The level of significance was set at 0.05. For the separate-groups analysis the principal statistical analysis consisted of Spearman's non-parametric correlation between Δ VAAS scores and Trp: Σ LNAA levels. A partial correlation analysis between these two variables was repeated after controlling for gender. Moreover, baseline differences between treatments/groups were analyzed by one-way ANOVA for continuous variables (age, weight, Trp: Σ LNAA ratio, VAS and PSL scores) and chi-square for non-parametric variables (gender distribution).

Results

Eighteen healthy volunteers (10 male) completed the cross-over study (mean age 25 ± 5.5 years). One subject was excluded because she reported nausea and vomiting after the administration of GBM.

Amino acid levels

Plasma amino acid levels are presented in Fig.1. Total Trp:ΣLNAA ratio at T0 did not significantly differ between treatment conditions ($F=0.88$, $p=0.42$). A significant time X condition interaction was found, with Δ% Trp:ΣLNAA ratio (from T0 to T3) being different between conditions ($F=106.6$; $p<0.0001$). ATD resulted in a decrease of $61.35\pm15.6\%$ in Trp:ΣLNAA ratio compared to baseline, while ATL resulted in an increase of $361.53\pm154.05\%$. A $17.76\pm19\%$ post-GBM increase was found in the BAL condition. Within-subject contrasts evidenced significant differences between changes in Trp:ΣLNAA ratio between ATD and BAL, between ATL and BAL, and between ATD and ATL ($F=106.6$; $p<0.0001$). In three cases of ATD condition, we observed a decrease in Trp:ΣLNAA ratio $<50\%$ and in one case of BAL condition, an increase in Trp:ΣLNAA ratio $>50\%$ was observed. For all the other subjects, we found Trp:ΣLNAA changes $>50\%$ in ATD condition, $<50\%$ in balanced condition, $>100\%$ in the ATL condition. The analyses reported in the following sections have also been performed after exclusion of those three subjects, obtaining the same results as with the complete sample.

Fig. 1) Plasma amino-acid levels

Plasma Trp:LNA ratio at baseline and 4.5 h after treatment across conditions: acute tryptophan depletion (ATD), balanced condition (BAL), acute tryptophan loading (ATL); time $\times$ condition interaction: $p < 0.0001$; Trp:LNA ratio ($\mu\text{mol/l}$) is presented on logarithmic scale.

Subjective measures

VAAS scores (fear/discomfort) between conditions, at different time points, are presented in Fig. 2. There were no significant differences in VAAS scores at T0, T1, T2, and T3 between conditions. No effect of GBM administration per se was observed on VAAS scores, as no significant difference was found between any of pre- CO_2 challenge time points (T3, T2, T1) and T0, in any condition. CO_2 inhalation was followed by an increase in VAAS scores in all the conditions ($F = 57.49$; $p < 0.0001$). A significant time $\times$ condition interaction was found,

indicating that Δ VAAS scores were significantly lower in ATD compared to BAL and ATL (33.89 $\pm$ 26.18 vs 43.78 $\pm$ 25.5 and 44.17 $\pm$ 23.88, respectively; $F=5.79$ and $F=6.58$, $p<0.05$). No significant differences were found between BAL and ATL conditions. The findings remained identical after controlling for gender and no effects of time X gender X condition interaction have been found.

Fig. 2) VAAS scores for fear/discomfort

Fig. 2) VAAS scores for fear/discomfort at 0, 1.5, 3, 4.5 h after treatment, and after CO₂ inhalation, across treatment conditions: acute tryptophan depletion (ATD), balanced condition (BAL), acute tryptophan loading (ATL); change in VAAS scores was significantly lower in ATD compared to BAL and ATL (time $\times$ condition interaction: $p<0.05$).

There were no significant differences in PSL scores between conditions at any time point. Total PSL scores did not change at T1, T2, and T3 compared to T0, but significantly increased after CO₂ inhalation, relative to T3 ($F=97.51$; $p<0.0001$). Δ PSL scores were similar between conditions (ATD: 11.11 ± 6.35 ; BAL: 11.06 ± 4.87 ; TL: 11.22 ± 4.32 ; NS). Analyzing individual PSL items separately, the only significant effect of treatment conditions on Δ PSL scores was evident for the item “sensation of shortness of breath”, indicating that Δ PSL scores after CO₂ were lower in ATD condition than in BAL and ATL conditions ($F=4.11$; $p<0.05$) (Fig. 3).

Fig. 3) PSL scores for sensation of shortness of breath

Fig. 3) Change in PSL scores for shortness of breath after CO₂ inhalation relative to T3, across treatment conditions: acute tryptophan depletion (ATD), balanced condition (BAL), acute tryptophan loading (ATL); change in PSL scores was significantly lower in ATD compared to BAL and ATL (time $\times$ condition interaction: $p<0.05$).

No order effect was found and Δ VAAS and Δ PSL scores were not affected by the order of administration of GBM conditions.

There was a significant effect of time on POMS-vigor ($p<0.0001$) and POMS-tension ($p<0.05$) scores, and within-subjects contrasts indicated that POMS-vigor scores were significantly higher at T0 relative to T1 ($p<0.01$), and significantly lower at T2 compared to T3 ($p<0.01$). POMS-tension scores were higher at T0 compared to T1 ($p<0.05$). There was no significant effect of the time $\times$ treatment condition interaction on POMS scores.

Separate-group study

Fifty-five volunteers were enrolled in the separate group study. Treatment groups consisted in 19 subjects (8 male; age: 24.84 ± 5.33 years) in ATD condition, 19 subjects (10 male; age: 23.32 ± 4.46 years) in BAL condition, and 17 subjects (10 male; 24.65 ± 5.32) in ATL condition. Age, gender distribution, and weight did not significantly differ between groups. Trp: Σ LNAA ratio at T0 was similar between conditions and baseline VAAS scores and PSL scores did not significantly differ between groups either. The relationship between Trp: Σ LNAA ratio and Δ VAAS scores is presented in Figs. 4 and 5. Δ VAAS scores were positively correlated to $\Delta\%$ Trp: Σ LNAA ratio and Trp: Σ LNAA ratio at T3 [Spearman's rho= 0.395 ($p<0.005$) and 0.381 ($p<0.005$), respectively], indicating that higher VAAS scores were associated with larger increases in the ratio Trp: Σ LNAA. No correlation was found between total PSL scores and $\Delta\%$ Trp: Σ LNAA ratio or Trp: Σ LNAA ratio at T3.

Fig. 4) Correlation between $\Delta\%$ Trp: Σ LNAA ratio and Δ VAAS scores

Fig. 4) Relationship between % change in Trp: Σ LNAA ratio after treatment and change in VAAS scores after CO₂ inhalation; change in VAAS scores after CO₂ inhalation was positively correlated to % change in Trp: Σ LNAA ratio [Spearman's rho= 0.395, $p<0.005$]

Fig 5) Correlation between Trp:ΣLNAA ratio at T3 and Δ VAAS scores.

Fig. 5) Relationship between Trp:ΣLNAA ratio at T3 (4.5 h post-treatment) and change in VAAS scores after CO₂ inhalation; change in VAAS scores after CO₂ inhalation was positively correlated to Trp:ΣLNAA ratio at T3 [Spearman's rho=0.381, $p<0.005$]; Trp:ΣLNAA ratio (μmol/l) is presented on logarithmic scale.

Discussion

To investigate whether the amount of available 5-HT precursors influence the vulnerability to a panicogenic challenge, we tested the subjective response to a 35% CO₂ inhalation after acute Trp depletion, Trp loading, and placebo in healthy volunteers. We found a mild, but significant effect of treatment condition on the subjective scores of fear/discomfort, indicating that ATD is associated to a reduced response to a CO₂ inhalation relative to placebo and ATL. The same effect was also evident for scores on the panic symptom “shortness of breath”. The analysis of the other separate individual symptoms and the total composite score of panic symptoms induced by CO₂ did not show any significant difference between conditions. In a separate analysis, we also investigated the relationship between Trp availability (Trp:ΣLNAA ratio) and subjective response to CO₂, as measured by VAAS scores, in a separate-group design. We found a relatively weak, but significant positive correlation between the Trp:ΣLNAA ratio and CO₂-induced changes in VAAS scores, indicating that lower availability of 5-HT precursors is associated to a blunted affective response to CO₂.

These findings are in contrast with previous results found in studies by our laboratory (Klaassen *et al*, 1998; Schruers and Griez, 2004a; Schruers *et al*, 2000a; Schruers *et al*, 2002a; Schruers *et al*, 2002b) and in other CO₂ challenge studies in healthy volunteers (Hood *et al*, 2006) and in PD patients (Miller *et al*, 2000). First, we will discuss potential explanations for the divergent findings observed in this study compared to other studies with inhaled CO₂ and other panicogenic agents in both healthy volunteers and PD patients. Furthermore, we will try to interpret our findings in the context of the complex relationship between panic, 5-HT and CO₂, also in light of the recent data, which suggest that 5-HT neurons are sensitive to acute changes in CO₂ concentration. Methodological issues and limitations relative to the technique used to manipulate 5-HT precursors will be finally addressed.

Tryptophan depletion/suppletion studies in healthy volunteers and PD patients

A large body of evidence suggests that manipulation of 5-HT precursors availability has an influence in modulating panic and anxiety (see review by (Maron *et al*, 2008). However, some of the findings from experimental studies, both in healthy volunteers and PD patients, are divisive and indicate that the role of 5-HT might not be unique.

Hood *et al.* (2006) and Klaassen *et al.* (1998) tested the effects of ATD on the response to single-breath 35% CO₂ challenge in healthy subjects. In a study on 14 healthy volunteers, no significant differences were found in subjective measures between ATD and balanced conditions, although ATD resulted in an increased CO₂-induced elevation of cortisol compared to the balanced condition (Hood *et al*, 2006). Klaassen's study (Klaassen *et al*, 1998), including 15 volunteers, found a significant increase in CO₂-induced neurovegetative symptoms after ATD. In that study sample, mean net increases in total PSL scores and VAAS scores after CO₂ were <7 and <7, respectively (Klaassen *et al*, 1998). Subjective CO₂-induced anxiety was, therefore, very mild, hence indicating that single-breath 35% CO₂ in healthy subjects did not evoke "real" panic. In the present study, using double breath CO₂, we found a more than 30% higher increase in PSL scores and more than 500% higher increase in VAAS scores after CO₂ compared to Klaassen's (1998) study. Average VAAS and PSL scores in the present double-breath 35% CO₂ study are comparable to those normally found in PD patients after single-breath 35% CO₂ (Verburg *et al*, 1998b). Other challenges in healthy volunteers found no significant effect of ATD on responses to anxiogenic challenges. This has been showed using a 5% CO₂ challenge (Miller *et al*, 2000) and the hypercapnic Read rebreathing technique (Struzik *et al*, 2002), a Simulated Public Speaking challenge (Monteiro-dos-Santos *et al*, 2000), and CCK-4 (Koszycski *et al*, 1996). In contrast, a study by (Goddard *et al*, 1995) showed increased nervousness in response to yohimbine challenge after ATD compared to yohimbine alone.

To enhance 5-HT availability in healthy subjects, Maron and coworkers (2004) administered 5-HTP (direct precursor of 5-HT) and used CCK-4 as panicogenic challenge in 32 healthy volunteers. They observed a significant reduction compared to placebo in CCK-4-induced panic attacks and cognitive symptoms only in females whereas in males only a decrease in

somatic symptoms was observed. In Schruers *et al.*'s study, 5-HTP did not alter the response to 35% CO₂ compared to placebo (Schruers *et al*, 2002b). Taken together, these data and our results indicate that the effects of Trp depletion in healthy volunteers largely depend on the type of challenge and its relative potency, and might be additionally confounded by gender effects.

Studies in PD patients demonstrated that ATD increased the response to single breath 35% CO₂ (Schruers *et al*, 2000a) and 5% CO₂ anxiety (Miller *et al*, 2000), and administration of 5-HTP blunted the response to single breath 35% CO₂ (Schruers *et al*, 2002b)

ATD also increased the response to flumazenil infusion in PD patients successfully treated with selective serotonin reuptake inhibitors (SSRI) (Bell *et al*, 2002; Davies *et al*, 2006) or CBT (Bell *et al*, 2011). In contrast, subjective response to CCK-4 is not influenced by ATD (Toru *et al*, 2006) in SSRI-treated PD patients. Also, ATD did not have significant effects on the subjective response to anxiogenic challenges in OCD (Barr *et al*, 1994; Kulz *et al*, 2007) and in GAD SSRI-treated patients (Hood *et al*, 2010). It is interesting to note that in the latest study of Hood and colleagues (2010), using 7.5% CO₂ challenge, some subjective measures of anxiety ("something bad is going to happen", "anxious", "secure"), seemed to indicate an anxiolytic effect of ATD rather than anxiogenic, however pairways comparison was not significantly different between conditions.

As a further confirmation of the role of 5-HT in modulating experimental panic, serotonergic drugs that are effective in treating Panic Disorder, like SSRI and tricyclics, also reduce the fear that patients with PD experience when they inhale CO₂ (Bertani *et al*, 2001; Bertani *et al*, 1997; Perna *et al*, 2004a; Perna *et al*, 2002; Perna *et al*, 1997; Pols *et al*, 1996b).

In summary, a number of studies in PD indicate that availability of 5-HT precursors is inversely related to vulnerability to CO₂ challenges, which is at odds with the present results. However, overall findings in anxiety disorder patients suggest that the effects of Trp manipulation specifically depend on the diagnosis and the type of anxiogenic challenge.

Panic, 5-HT and CO₂: A complex relationship

Accumulating evidence from clinical and experimental research, and genetic studies suggest a substantial role for the 5-HT system on the neurobiology of PD (Maron and Shlik, 2006). The relationship between 5-HT and panic is complex, as exemplified by the notion that SSRI are effective in reducing panic, but they may exacerbate anxiety during the initial phase of treatment (Sinclair *et al*, 2009). It has been hypothesized that panic is associated to either 5-HT excess (Iversen, 1984) and 5-HT deficit (Deakin and Graeff, 1991). Deakin and Graeff proposed that the 5-HT system plays a dual role in the modulation of anxiety by inhibiting panic responses, but contributing to anticipatory or generalized anxiety. Our findings presented here are not in line with this theory, as in our experimental design increased 5-HT availability did not suppress CO₂-induced panic responses in healthy volunteers. However, recent studies suggest that other factors should be taken into account in understanding the relationship between 5-HT, CO₂ and anxiety: a subset of 5-HT neurons, located in the chemosensitive zone (ventrolateral medulla and raphe) and associated with large arteries, are intrinsically chemosensitive in vitro (Severson *et al*, 2003) and are stimulated by hypercapnia in vivo in unanaesthetized animals (Veasey *et al*, 1995, 1997). Furthermore, experiments using in vivo microdialysis showed that increasing inhaled CO₂ causes an increase in 5-HT release (Kanamaru *et al*, 2007). Interestingly, mice selectively lacking 5-HT neurons display a blunted respiratory response to CO₂, indicating that 5-HT neurons are required for normal central chemoreception (Hodges and Richerson, 2008). Richerson (2004) proposed that medullary 5-HT neurons control ventilatory responses to CO₂ and project to areas like forebrain and limbic system that are involved in affective regulation. Taking into account the panicogenic properties of CO₂, we have previously speculated that these neurons could be part of an adaptive protective mechanism alerting the organism against the risk of impending asphyxia (Griez *et al*, 2007). Taken all these preclinical findings together, it appears that acute hypercapnia stimulates serotonergic neurons and 5-HT release and that conversely, disruption of the 5-HT system blunts the neuronal response to CO₂.

Our data are in line with the above preclinical evidence; we have effectively reduced availability of 5-HT precursors and we have used CO₂ as a panicogenic challenge. In

agreement with Hodges and Richerson's (2008) data, we found that depletion of 5-HT precursors blunted the subjective response to CO₂, particularly the respiratory sensations, and Trp availability was positively correlated with the intensity of the subjective responses.

Methodological limitations

Some methodological considerations regard the validity of Trp manipulations to alter 5-HT availability. Trp depletion and Trp loading are relatively easy procedures to rapidly and reversibly change, decrease and increase respectively, the levels of 5-HT precursors (Hood *et al*, 2005). The first step in 5-HT biosynthesis is the conversion of Trp to 5-HTP by Trp hydroxylase. In the brain, this enzyme is only 50% saturated and the rate at which 5-HT is synthesized is limited only by substrate (Trp) availability. The LNAA transport system at the blood-brain barrier has a high affinity for all the LNAAs, including Trp. Therefore, the ratio Trp:ΣLNAA in plasma is generally used to predict the availability of Trp to the brain. A large body of literature provides evidence that manipulations of the levels of Trp in plasma results in a substantial and parallel alteration of 5-HT synthesis in the brain and availability of 5-HT and its metabolite in humans and animals (Biggio *et al*, 1974; Carpenter *et al*, 1998; Gessa *et al*, 1974; Leathwood, 1987; Lieben *et al*, 2004; Williams *et al*, 1999). However, an altered release of 5-HT efflux (thought to reflect synaptic release, i.e., 5-HT neuronal activity) was only reported after chronic Trp depletion (Fadda *et al*, 2000) or after ATD in combination with 5-HT reuptake inhibition (Bel and Artigas, 1996), but not after ATD alone (van der Plasse *et al*, 2007). In vitro studies suggest that an increase in Trp availability determines dose-dependent changes in 5-HT release under conditions of increased serotonergic neuronal activity but not on basal output of 5-HT (Sharp *et al*, 1992; Wolf and Kuhn, 1986).

We assume that the alterations in the Trp:ΣLNAA ratio of the present study were followed by changes in brain 5-HT availability and synthesis in the same direction. However, at present, we cannot assure that Trp depletion and Trp loading actually influenced 5-HT release. Nevertheless, the possibility exists that the manipulations in the present study did

affect 5-HT neuronal release, based on the above-mentioned notions that acute hypercapnia stimulates serotonergic neurons and induces 5-HT release, and that Trp manipulations seem to be effective in altering 5-HT release only in stimulated neurons.

A number of other methodological issues need to be addressed. To manipulate brain Trp availability, the studies in healthy volunteers of both Klaassen *et al.* (1998) and Hood *et al.* (2006) included the use of the classic amino-acid mixture (Young *et al.*, 1985), the former including an addition of carbohydrates and fat. In these studies, similarly to ours, ATD appeared to be as effective and resulted in a significantly decrease of plasma Trp levels. However, the magnitude of the depletion seems difficult to compare with that in our study due to some methodological differences: in the study of Klaassen *et al.* (1998), no baseline Trp plasma levels were collected, and in the study of Hood *et al.* (2006), free Trp plasma levels instead of total TRP levels were used for calculation of the Trp:ΣLNAA ratio. It is still debated whether total Trp or free Trp levels in plasma are the most reliable indirect measures of brain Trp availability (Pardridge, 1998). Therefore, methodological differences might account for the divergent findings in our study compared to previous studies in healthy volunteers.

Conclusions

It is recognized that 5-HT system plays a complex role in the regulation of the panic responses to CO₂, as different serotonergic mechanisms can coexist, either inhibiting panic (Deakin *et al.*, 1991) or promoting the aversive respiratory sensations to hypercapnic stimuli. The differences observed in our study in healthy volunteers, compared to previous findings in PD patients, might depend on the different relative contribution of these mechanisms in different populations.

Chapter VI

The affective response to CO₂: a true primal emotion?

Colasanti A ^{1,2}, Schruers KR ¹, Griez EJ ¹

¹ *Research Institute Mental Health and Neuroscience, Maastricht University, NL*

² *Centre for Neuropsychopharmacology, Division of Brain Sciences, Imperial College, London, UK*

The present thesis is based on a series of studies investigating the phenomenological characteristics and pharmacological modulation of the emotion induced by Carbon Dioxide (CO₂) administration in healthy humans. Before we provide the conclusive remarks on the studies related to the characterization of the CO₂-induced emotion, presented in chapters 2 to 5, it is worth to step back, and carefully address the most delicate and sensitive question of the thesis: “did CO₂ really evoke an emotion?”.

This is a question of crucial importance in relation to our studies. We based our investigation on the hypothesis that CO₂-induced emotion may constitute an instance of primal (or primordial) emotion. However, if it’s relatively easy to find evidence supporting the ‘primordially’ of response to CO₂ (i.e. its ancient phylogenetic roots, the adaptive survival value, the deep subcortical neural processing, etc.), it is not similarly immediate to find satisfactory arguments to support the statement that the subjective response to CO₂ indeed represents an emotion.

With this problem in mind, we focused our attention on the nature of the emotional response to CO₂ in the first part of the thesis, with Chapter 1 reviewing a large number of cases of acute exposure to CO₂ to search any hint suggesting an ‘affective’ component in the subjective hypercapnic responses, and with Chapter 2 directly investigating the emotional response to CO₂ in an experimentally-controlled setting.

These studies confirmed our hypothesis as they pointed out that CO₂ does induce a dose-dependent affective response, observable in healthy human subjects, as well as in clinical populations. However, it is necessary to acknowledge a potential important caveat pertinent to those studies, which relates to the definition of emotion.

How do we define emotion? Which criteria do we apply to establish that CO₂ induced a real emotion?

In our studies, to test our hypothesis that the subjective response to CO₂ was a real emotion, we used rating scales based on DSM-IV criteria for panic attack, a clinical state characterized by an intense emotional component. We argued that if we could find evidence that CO₂ induces a subjective experience similar to panic, and assuming that panic is an emotion, than

it was logical to believe that that experience qualified as an emotion as well. Nevertheless, we should be cautious in using this reasoning as the unique unequivocal proof that what we were measuring was an emotion indeed. In our studies we have applied a limited range of assessments (Visual Analogue Scales and Panic Symptom List), and although part of them were indeed reflective of emotions, these instruments may have not been sufficient to undoubtedly state that the subjective state elicited by CO₂ is an emotion. We need first to clearly identify a set of criteria defining an emotion, and only then apply these to the observations of our studies, to test if the subjective response to CO₂ satisfies the criteria that such definition implies.

Moreover, we need to formulate a null hypothesis that needs to be more specific and plausible than just stating the CO₂-induced response is not an emotion. If the experience induced by the inhalation of CO₂ is not an emotion, what could it be instead?

Based on our knowledge of the physiology of response to CO₂, there is no doubt that the inhalation of CO₂ is associated to an experience of increased breathing, secondary to a chemosensor-driven ventilatory reflex. Hence, without an affective component the subjective response to CO₂ would be purely the experience of arousal, increased ventilation and other physiological phenomena driven by chemosensors. In other words, the null hypothesis could be formulated as follows:

“The subjective response to CO₂ is merely the experience, or the perception, of a physiological reflex driven by interoceptors”.

Defining an emotion

Providing a definition of emotion is difficult, and according to some authors a definition of emotion, which could be even superficially acceptable, does not exist at all (Mandler, 1984). Often the term emotion is defined with a reference to a list: anger, disgust, fear, joy, etc. Kleinginna and Kleinginna categorized 92 different definitions from the literature and 9 sceptical statements related to the definition of emotion (Kleinginna and Kleinginna, 1981),

looking for a consensual definition. They propose that “the emotion is a complex set of interactions among subjective and objective factors, mediated by neural/hormonal systems, which can (a) give rise to affective experiences such as feelings of arousal, pleasure/displeasure; (b) generate cognitive processes such as emotionally relevant perceptual effects, appraisals, labelling processes; (c) activate widespread physiological adjustments to the arousing conditions; and (d) lead to behaviour that is often, but not always, expressive, goal-directed, and adaptive”. Oatley describes emotions as characteristic mental states that normally happen in response to identifiable conditions of elicitation, have distinctive aspects and recognizable consequences (Oatley, 1992). In 1890, William James, that much influenced current theories in affective neuroscience and philosophy of mind, such as those by Jaak Panksepp (Panksepp, 1998) and Antonio Damasio (Damasio, 1999), hypothesized that emotion is *just* the feeling of bodily changes as they occur in response to a relevant stimulus (James, 1890). These various definitions underline different characteristics of the triggers and the circumstances that accompany emotions. However, they do not tell us much about what is the mental experience taking place during emotion, other than describing it in generic terms such as “feeling of arousal, pleasure/displeasure” (Kleinginna *et al*, 1981), “characteristic mental state” (Oatley, 1992), “feeling of bodily changes” (James, 1890).

In a paper published in 2002, Cabanac focused on the characteristics of the mental experience that takes place during emotions and applied a four-dimensional mathematical description of emotion (Cabanac, 2002), following up a definition of consciousness previously formulated using a similar model (Cabanac, 1996). Cabanac proposes that any mental experience (Ψ) taking place in consciousness could be described by a mathematical equation that includes the dimensions: duration (axis t), quality (axis x), intensity (axis y), and pleasure/displeasure (axis z) (Equation 1).

$$\Psi = f(x[t], y[t], z[t]) \quad \text{Equation 1}$$

With regard to the axis x (qualitative dimension), what emotions have in common is that they are “aroused by exposure of the subject to situations more or less related to motivation [...] resulting in a behaviour oriented towards, or away, from the stimulus” (Cabanac, 2002).

Stimuli can be sensorial or resulting from imagination or memory. With regard to the y-axis (intensive dimension), the author proposes that high intensity is a prerequisite for emotions. This seems in agreement with the view on emotion of other authors, for instance Griffiths (“emotion is an irruptive motivational complex in higher cognition”) (Griffiths, 1997) and, even more clearly, with Denton’s idea of primal emotions (“[...] they can reach intensity which gives total occupancy of the stream of consciousness and plenipotentiary power over behaviour”) (Denton, 2006). Intensity is a necessary but not sufficient condition, as a mental event of high intensity does not qualify as an emotion if it does not have a hedonic component. That component, the hedonic or pleasure/displeasure dimension, represents the axis z. Damasio proposed that the pleasure is the dimension of consciousness that motivates the subject towards useful behaviours (Damasio, 1994). The hedonic dimension serves to rank priorities and ensure that the most urgent motivation has first access to the behavioural common path. In other words, pleasure is a sign of usefulness. If emotion is an integrative response whose biological function is primarily homeostatic, we expect all emotions to be highly hedonic, either positively or negatively, and indeed no mental state commonly recognized as emotion is hedonically indifferent (for instance fear, anger, desire, sadness, disgust, love, joy, etc.). All these emotions are intense mental events aroused by exposure to situations related to motivation, either positive or negative but all resulting in a behaviour oriented to, or away from, the stimulus. Finally, as any other mental event, emotion has a limited duration (axis t), which is closely related to the stimulus that aroused it.

In conclusion, emotion is a mental experience and possesses the four dimensions of consciousness: quality, intensity, hedonicity, and duration. Cabanac summarizes and concludes that emotion is any mental experience with high intensity and high hedonicity (Cabanac, 2002).

Based on the above, the null hypothesis can be refined as:

“The subjective response to CO₂ is merely the experience, or the perception, of a physiological reflex driven by interoceptors and is characterized by either low intensity or low hedonicity.”

Application of the definition of emotion to the subjective response to CO₂

We take for granted that the subjective response to CO₂ is a mental state. We then examine each of the dimensions individually, and test if each criterion of the definition of emotion provided by Cabanac (Cabanac, 2002) is applicable to our studies.

Axis X: Quality

Definition: Emotions are aroused by exposure of the subject to stimuli, sensorial or mental, more or less related to motivation.

By definition, the mental state elicited in our studies is aroused by inhalation of gas mixture containing high concentration of CO₂. The type of stimulus is entirely sensorial; it has a strong motivational value, and correlate strongly with respiratory sensations (see Chapters 3 and 4).

Axis Y: Intensity

Definition: Emotions are characterized by high intensity.

We have observed that the feeling induced by CO₂ is dependent on the dose of CO₂ administered (see Fig. 1). There is a high inter-subject variability of the response. The peak intensity reported by the subjects receiving the highest dose (double breath 35% CO₂) reached the score of 50 (in a scale between 0 and 100 where 100 indicated the worst imaginable fear/discomfort) in more than 44% of the subjects.

Fig. 1) Dose-response relationship between CO₂ and induced fear/discomfort.

Axis Z: Hedonicity

Definition: *Emotions need to be highly hedonic, either positively or negatively.*

In our first study (see Chapter 2), we used a visual analogue scale labelled fear/discomfort, which identify a mental state with a negative valence. After the highest dose, 1 subject over 64 reported no increase from baseline, and 1 reported a decrease of 1 point score from baseline. Over 84% of subjects reported at least an increase of 10 from baseline after 35% CO₂. In our last study (see Chapter 5), we have assessed various affective dimensions of respiratory sensations induced by CO₂, and observed a significant increase relative to

baseline in anxiety, fear and frustration ($p<0.0001$), anger ($p<0.001$), and depression ($p<0.05$), and a significant decrease in happiness ($p<0.0001$) and contentedness ($p<0.05$). Thus, the hedonic component of the mental state induced by CO₂ appears to be negative.

Axis T: Duration

Definition: *Emotion has a limited duration, closely related to the stimulus that aroused it.*

In the majority of the cases, the duration of CO₂-elicited mental state lasted less than one minute. The duration of the state was closely dependent on the dose administered (see Fig. 2).

Fig. 2) Time course of CO₂-induced fear/discomfort across different CO₂ doses.

In summary, the analysis of the four dimensions of emotions, according to Cabanac's definition, indicates that the subjective response observed in our studies:

- 1) *is a mental state elicited by a purely sensorial stimulus, CO₂ inhalation, which correlates with respiratory discomfort;*
- 2) *is characterized by an intensity which is dependent on the dose and becomes very intense with the highest CO₂ doses;*
- 3) *is characterized by high hedonicity with a negative valence;*
- 4) *is characterized by limited duration (less than 1 minute), related to CO₂ administration.*

In conclusion, the null hypothesis that the subjective response to CO₂ is merely the experience, or the perception, of a physiological reflex driven by interoceptors and is characterized by low intensity and low hedonicity, can be rejected, based on the evidence that administration of CO₂, at sufficiently high doses evokes a powerful mental state with a negative valence in a significant proportion of subjects. Hence, we are confident that CO₂ truly induced a genuine emotion.

Other views on primal emotions

Several influential authors have agreed about the existence of a type of emotions evoked by internal body states and whose evolutionary-based function is to motivate behaviour aimed at maintaining the body's internal balance. However, different names and definitions have been used to indicate these emotional states.

Denton's definition of primordial emotions has been already extensively discussed in the introduction (Denton, 2006). Other influential theories were proposed by Bud Craig, Antonio Damasio, and Jaak Panksepp.

Craig (Craig, 2003) focused his interest on the description of an anatomical pathway of afferents that innervate all tissues of the body, terminate monosynaptically in lamina I of the spinal and trigeminal dorsal horns, and conduct information regarding all types of

physiological conditions, including the mechanical, thermal, chemical, metabolic, and hormonal status of skin, muscle, joints, teeth, and viscera. According to Craig (2003), two separate pathways exist: a phylogenetically ancient one, and a more recently-evolved pathway, present in primates only. In all mammals, the projections from lamina I and the NTS pass through parabrachial nucleus and reach the anterior cingulate and insular cortices by way of the medial thalamic nuclei and the basal ventral medial nucleus of the thalamus. In humans and anthropoid primates instead, lamina I neurons and the NTS project directly to a specific thalamocortical relay nucleus in the posterolateral thalamus and eventually terminate to the interoceptive cortex in the posterior insula and the ACC. The direct activation of these structures by the distinct homeostatic modalities corresponds to the simultaneous generation of both a feeling/sensation dimension represented in the anterior insula and a motivation dimension represented in the ACC. As a consequence, a full homeostatic emotion arises. Craig believes these sites are activated in virtually every human emotions and provide an image of the physical self as a feeling (sentient) entity, which is a characteristic of human consciousness (Craig, 2003). He states that the subjective image of the 'material me' is formed on the basis of the sense of the homeostatic condition of each individual's body.

In his most recent book, Damasio (2010) acknowledges the existence of primordial feelings, which he defines as spontaneous reflections of the state of the living body, or images of an organism's internal state. These are supposedly based on the operation of upper-brain-stem nuclei and are part and parcel of the life-regulation machinery. These are feelings that tell the individual that his own body exists, and it is present, independently of any object with which it interacts. These have a definite quality and a valence and, according to the author, they constitute the basis of all feelings, including those caused by interactions between organism and external objects, which become the extension of the primordial feelings. Damasio proposes that primordial feelings are produced by the simplest stage of self-consciousness, which he defines "protoself" (Damasio, 1999, 2010).

Panksepp agrees with the existence of states related to homeostasis (Panksepp, 1998). He defines these as 'need' states, motivations, or regulatory urges. He distinguishes breathing regulation from other motivations as the needed resource, oxygen, under most circumstances is readily available. He acknowledges that when there is an impairment of rhythmic

breathing a regulatory crisis occurs, and a powerful emotional panic-like state arises. According to Panksepp (1998), other motivations such as the need for food or sex can be fulfilled only by an active exploratory and search behaviours, which are generated by an emotional system labelled 'seeking system', which can motivate organisms to pursue a diversity of distinct reward in the environment. However, it is not clear whether the author considers these states as real emotions. He acknowledges that they are affective feelings, however he states these does not fully qualify as emotions, as for instance, they do not fulfil the criterion that neural activity of all emotive systems is expected to outlast the precipitating circumstances.

Summary and concluding remarks

The findings reported in the present thesis demonstrate that CO₂ induces dose-dependent acute emotional distress in healthy volunteers, as measured with self-report subjective assessments. The distress resembles a panic attack when CO₂ doses are increased to an adequate level (Chapters 1 and 2). This is consistent with the notion of a human instinctual response to exposure of high concentrations of CO₂, with subjective elements which are phenomenologically similar to panic. Indeed, a principal component analysis showed that CO₂-induced symptoms cluster in dimensions analogous to the clusters of symptoms identified in clinical panic (Chapter 3).

A respiratory component was clearly identified among three extracted symptom dimensions. The respiratory dimension was the best correlate of subjective distress, indicating that the emotional response to CO₂ was specifically associated to respiratory sensations (Chapter 3). Furthermore, a multidimensional rating of respiratory discomfort was shown to be a stronger correlate of subjective distress compared to the rating of all non-respiratory panic symptoms. The level of respiratory discomfort could accurately discriminate between responders and non-responders to the CO₂ challenge (Chapter 4).

Finally, we observed that dietary manipulation of serotonin precursors influenced the affective response to CO₂, as lower availability of tryptophan was associated to lower subjective distress. The direction of the observed modulation appeared to be consistent with previously published preclinical data, indicating a role for the midbrain serotonergic system in promoting the aversive respiratory sensations to hypercapnic stimuli (Chapter 5). These findings, taken together with the recent discovery that the amygdala itself, a keystone in the affective brain, directly “senses” CO₂-released acidity, suggest that CO₂ plays an active role in the emotional regulation of the brain, and is not just a parameter of ventilatory control.

When reviewing his observations of behavioural vulnerability of patients with Panic Disorder, Klein proposed that panic attacks might be false biological alarms (Klein 1993) triggered by a ‘suffocation detector’ that is oversensitive. Our findings provide grounds for the existence of a hardwired inborn, CO₂ driven alarm machinery in humans. The sense of neuronal CO₂ loading, emerging into the conscious distress of panic to alert the organism

about the threat of imminent suffocation, fits perfectly with the idea that the affective response to CO₂ represents an instance of a primal emotion (Denton 2006).

The experimental paradigm presented in this thesis may represent a valid, reproducible, and safe empirical approach to study primal emotional systems in humans. Our work adds to the existing literature by stimulating a novel perspective on future CO₂-related affective neuroscientific research. In fact, we believe that the application of CO₂ challenges may go beyond the diagnostic boundaries set by DSM criteria for mental disorders. Studying the response to CO₂ may highlight not only the vulnerability to Panic Disorder, but in addition it could represent a tool to probe a primordial defensive response that is part of the human emotional repertoire. The application of our approach in neuropsychopharmacological research may be exciting: novel anxiolytic compounds could be assessed in very early phases of translation to clinical use on the basis of their ability to modulate response to CO₂ in healthy volunteers. Furthermore, psychopathology research would benefit from a dimensional approach based on the objective and reliable assessments of basic emotional systems, rather than solely relying on the current categorical/nosological paradigms.

It is attractive to speculate about the use of similar emotional challenges in the future. These could emerge as tools that can contribute towards a more personalized psychiatry, where pharmacological treatments are based on each individual characteristic, conceptualized as an ensemble of basic objectively-measurable biologically-rooted emotional traits, rather than focusing on diagnostic criteria based on overlapping syndromes of symptoms and aberrant behaviours. In other words, in our view the aim of testing primordial defensive responses in psychiatric patients would not be related primarily to diagnostic purposes, but instead it could be potentially useful to identify sensible biological targets for treatment at the individual level.

Further research on the biological mechanisms underlying primal emotional systems is needed before an application of models of CO₂-induced distress can be realised in translational medicine. Our work presented in this thesis and other recent studies have generated a set of new hypothesis that can be tested and potentially falsified. For instance, it would be important to test in humans the finding that limbic structures of the rodent brain

directly senses CO₂ released acidity (Ziemann et al. 2009). [³¹P] magnetic resonance spectroscopy is an imaging technique that allows the in-vivo monitoring of regional brain pH. This technique is well suited to test if 1) CO₂ challenges truly induce a decrease in brain pH in the human brain and 2) if the subjective emotional response corresponds to the intensity of brain acidity. Another example of future potential research pertains to the investigation of synaptic neurotransmitters, in particular to answer the question which neurochemicals are released in response to CO₂ challenges. Molecular imaging with PET using radiotracers that are sensitive to displacement by endogenous neurotransmitters can be used to successfully detect and quantify the release of endogenous ligands at synaptic level, such as dopamine (Laruelle 2000) and opioids (Colasanti et al., 2012) in response to pharmacological challenges. These neurotransmitters, and in particular opioids, are promising candidates to try to modulate the brain response to CO₂ challenges due to the well-recognized link existing between CO₂, respiration and the opioid system, and between opioids and defensive behaviours (Colasanti et al. 2010). A PET study with [¹¹C]carfentanil is being planned to investigate the endogenous opioid response to CO₂ challenges.

Samenvatting en conclusies

De bevindingen beschreven in deze thesis demonstreren een dosis-afhankelijk effect van CO₂ op acuut emotioneel leed in gezonde proefpersonen. Het leed vertoont overeenkomst met die van een paniekaanval, wanneer CO₂ doseringen voldoende worden verhoogd (hoofdstuk 1 en 2). Dit is consistent met de veronderstelling dat er in mensen een instinctuele respons bestaat in antwoord op blootstelling aan hoge concentraties CO₂, en dat het subjectieve element van deze respons fenomenologisch gelijk is aan paniek. Een ‘principal component analysis’ toonde aan dat CO₂-geïnduceerde symptomen clusteren in dimensies die analoog zijn aan het cluster van symptomen die gerelateerd zijn in klinische paniek (hoofdstuk 3).

Onder 3 ge-extraheerde symptoomdimensies werd duidelijk een respiratorische component geïdentificeerd. De respiratorische dimensie correleerde het beste met de subjectieve maten van ongemak, wat suggereert dat de emotionele respons door CO₂ specifiek geassocieerd was met respiratorische sensaties (hoofdstuk 3). Bovendien was een multidimensionele beoordeling van respiratorisch ongemak een sterkere correlaat van de subjectieve ongemak, in vergelijking met de beoordeling van alle non-respiratorische panieksymptomen, en dit was in staat om accuraat een onderscheiding te maken tussen responders en nonresponders van de CO₂ toediening (hoofdstuk 4).

Tot besluit hebben we geobserveerd dat een diëetmanipulatie van de serotonine voorloper de affectieve respons van CO₂ beïnvloedt, en dat de richting van de geobserveerde modulatie consistent blijkt te zijn met preklinische data, die aangaf dat het mid-brein serotonine systeem een rol speelt in het bevorderen van de aversieve respiratorische sensaties van hypercapnische stimuli (hoofdstuk 5). Deze bevindingen, samen genomen met de recente ontdekking dat de amygdala (een hoeksteen in het affectieve brein) zelf direct reageert op het zuur van CO₂, suggereert dat CO₂ een rol speelt in affective delen van het brein, en niet alleen een parameter is van ademhalingscontrole.

Naar aanleiding van een gedragsexperiment waarin de kwetsbaarheid van patiënten met paniekstoornis naar voren kwam, stelde Klein voor dat een paniekaanval een biologische vorm van vals alarm is (Klein 1993) veroorzaakt door een overgevoelige benauwdheidsdetector. Onze bevindingen geven bewijs voor het bestaan van een aangeboren, CO₂-aangestuurd biologisch alarmsysteem. The sensatie van CO₂, voortvloeiend

in een bewust gevoel van paniek om het organisme te waarschuwen voor naderend zuurstofgebrek en verstikking, is uitstekend te verenigen met het idee van dat een affectieve respons op CO₂ een oer-emotie is (Denton 2006).

Het experimentele paradigma dat in deze thesis is gepresenteerd zou een valide, reproduceerbaar, en veilige empirische benadering kunnen bieden om oer-emotionele systemen in mensen te bestuderen. Ons werk verrijkt de bestaande literatuur door een nieuw perspectief te bieden op toekomstig CO₂-gerelateerd affectief neurowetenschappelijk onderzoek. Metterdaad zijn we ervan overtuigd dat de toepassing van CO₂ toedieningen de grenzen kan overschrijden van de DSM criteria voor mentale stoornissen. Door de respons van CO₂ te bestuderen zou men niet alleen de kwetsbaarheid voor paniekstoornissen kunnen uitlichten, maar bovendien een methode bieden om evolutionair gezien oude verdedigingsmechanismen te onderzoeken die deel uitmaken van het repertoire van menselijke emoties. De toepassing van onze benadering in neuropsychopharmacologisch onderzoek heeft potentieel: nieuwe psychoactieve stoffen zouden kunnen worden geevalueerd in de vroege fase van de translatie naar klinisch gebruik op basis van hun mogelijkheid om de respons op CO₂ in gezonde proefpersonen te moduleren. Bovendien zou psychopathologisch onderzoek baat hebben bij een dimensionele benadering gebaseerd op objectieve en betrouwbare beoordelingen van basale emotionele systemen, in plaats van voornamelijk afhankelijk te zijn van de huidige categorische/nosologische paradigma's.

Het is aantrekkelijk om te speculeren over het gebruik van gelijkwaardige emotionele challenges in de toekomst, als middelen die kunnen contribueren aan een meer persoonsgebonden psychiatrie, waar farmacologische behandelingen gebaseerd zijn op elke individuele eigenschap, geconceptualiseerd als een bijeenvoeging van basale objectief meetbare, biologisch diepgewortelde emotionele trekken, geen te focussen op diagnostische criteria die gebaseerd zijn op overlappende syndromen van symptomen en afwijkend gedrag. Met andere woorden, het doel van het testen van verdedigingsmechanismen in psychiatrische patienten zou niet primair gericht zijn op diagnostiek, maar om potentiële biologische doelen te identificeren voor behandeling op individueel niveau.

Vervolgonderzoek is nodig om de biologische mechanismen van basale emotionele systemen te verduidelijken, voordat toepassing van CO₂-geïnduceerd ongemak kan worden gerealiseerd. Ons werk, en ander recent onderzoek, heeft een nieuwe set hypotheses gegenereerd die kunnen worden getest en eventueel kunnen worden gefalsificeerd. Het zou bijvoorbeeld belangrijk zijn om de preclinische bevinden te testen in mensen, specifiek de hypothese dat de limbische structuren van het brein direct een CO₂ vrijgegeven zuur kunnen 'voelen'. ³¹P MRS is een nuttige beeldvormende techniek waarmee in-vivo de regionale pH in de hersen kan worden gemeten. Het zou waardevol zijn om te testen of 1) CO₂ toediening inderdaad een daling van pH in het menselijk brein veroorzaken en 2) of the emotionele respons correspondeert met de intensiteit van de zuurgraad. Een ander voorbeeld van potentieel toekomstig onderzoek betreft de vraag welke synaptische neurotransmitters worden vrijgegeven na CO₂ toediening. Moleculaire beeldvormende technieken zoals PET met radioliganden die sensitief genoeg zijn om de verplaatsing van endogene neurotransmitters van de receptor te detecteren en quantificeren zouden bijvoorbeeld dopamine (Laruelle 2000) of opioïden (Colasanti et al, 2012) niveaus kunnen meten na farmacologische challenge. Deze neurotransmitters, en vooral opioïden, zijn veelbelovende mechanismen in het brein om te moduleren na toediening van CO₂. Dit borduurt voort op eerder gepubliceerd onderzoek waarin we een link hebben aangetoond tussen CO₂, ademhaling en het opioïd systeem, en tussen opioïds een verdedigend gedrag (Colasanti et al, 2010). Een PET experiment met [¹¹C]carfentanil is gepland om endogene opioïds te bestuderen na toediening van CO₂.

References

- Abrams K, Rassovsky Y, Kushner MG (2006). Evidence for respiratory and nonrespiratory subtypes in panic disorder. *Depress Anxiety* **23**(8): 474-481.
- Antony MM, Brown TA, Barlow DH (1997). Response to hyperventilation and 5.5% CO₂ inhalation of subjects with types of specific phobia, panic disorder, or no mental disorder. *Am J Psychiatry* **154**(8): 1089-1095.
- APA (2000). *DSM-IV-TR Diagnostic and Statistic Manual of Mental Disorders, Fourth Edition, Text Revision.* , 4th edn. American Psychiatric Association: Washington, D.C.
- Arena J, Drew R (1986). *Poisoning, Toxicology, Symptoms, Treatment. 5th ed.*: Springfield.
- Argyle N, Roth M (1989). The definition of panic attacks, Part I. *Psychiatr Dev* **7**(3): 175-186.
- Argyropoulos SV, Bailey JE, Hood SD, Kendrick AH, Rich AS, Laszlo G, *et al* (2002). Inhalation of 35% CO₂ results in activation of the HPA axis in healthy volunteers. *Psychoneuroendocrinology* **27**(6): 715-729.
- Aronson TA, Logue CM (1988). Phenomenology of panic attacks: a descriptive study of panic disorder patients' self-reports. *J Clin Psychiatry* **49**(1): 8-13.
- Bailey JE, Argyropoulos SV, Kendrick AH, Nutt DJ (2005). Behavioral and cardiovascular effects of 7.5% CO₂ in human volunteers. *Depress Anxiety* **21**(1): 18-25.
- Bailey JE, Kendrick A, Diaper A, Potokar JP, Nutt DJ (2007). A validation of the 7.5% CO₂ model of GAD using paroxetine and lorazepam in healthy volunteers. *J Psychopharmacol* **21**(1): 42-49.
- Bailey JE, Papadopoulos A, Diaper A, Phillips S, Schmidt ME, van der Ark P, *et al* (2011). Preliminary evidence of anxiolytic effects of the CRF1 receptor antagonist R317573 in the 7.5% CO₂ proof-of-concept experimental model of human anxiety. *J Psychopharmacol.* **25**(9): 1199-1206.
- Bailey JE, Papadopoulos A, Seddon K, Nutt DJ (2009). A comparison of the effects of a subtype selective and non-selective benzodiazepine receptor agonist in two CO₂ models of experimental human anxiety. *J Psychopharmacol* **23**(2): 117-122.
- Banzett RB, Lansing RW, Brown R, Topulos GP, Yager D, Steele SM, *et al* (1990). 'Air hunger' from increased PCO₂ persists after complete neuromuscular block in humans. *Respir Physiol* **81**(1): 1-17.
- Banzett RB, Lansing RW, Evans KC, Shea SA (1996). Stimulus-response characteristics of CO₂-induced air hunger in normal subjects. *Respir Physiol* **103**(1): 19-31.

Banzett RB, Pedersen SH, Schwartzstein RM, Lansing RW (2008). The affective dimension of laboratory dyspnea: air hunger is more unpleasant than work/effort. *Am J Respir Crit Care Med* **177**(12): 1384-1390.

Barr LC, Goodman WK, McDougle CJ, Delgado PL, Heninger GR, Charney DS, *et al* (1994). Tryptophan depletion in patients with obsessive-compulsive disorder who respond to serotonin reuptake inhibitors. *Arch Gen Psychiatry* **51**(4): 309-317.

Bass C, Kartsounis L, Lelliott P (1987). Hyperventilation and its relationship to anxiety and panic. *Integr Psychiatry* **5**: 279-291.

Battaglia M, Bertella S, Ogliari A, Bellodi L, Smeraldi E (2001). Modulation by muscarinic antagonists of the response to carbon dioxide challenge in panic disorder. *Arch Gen Psychiatry* **58**(2): 114-119.

Battaglia M, Ogliari A (2005). Anxiety and panic: from human studies to animal research and back. *Neurosci Biobehav Rev* **29**(1): 169-179.

Battaglia M, Ogliari A, Harris J, Spatola CA, Pesenti-Gritti P, Reichborn-Kjennerud T, *et al* (2007). A genetic study of the acute anxious response to carbon dioxide stimulation in man. *J Psychiatr Res* **41**(11): 906-917.

Battaglia M, Perna G. The 35% CO₂ challenge in panic disorder: optimization by receiver operating characteristics (ROC) analysis. *J Psychiatr Res* **29**: 111-119.

Battaglia M, Pesenti-Gritti P, Spatola CA, Ogliari A, Tambs K (2008). A twin study of the common vulnerability between heightened sensitivity to hypercapnia and panic disorder. *Am J Med Genet B Neuropsychiatr Genet* **147B**(5): 586-593.

Beckett A, Fishman SM, Rosenbaum JF (1986). Clonazepam blockade of spontaneous and CO₂ inhalation-provoked panic in a patient with panic disorder. *J Clin Psychiatry* **47**(9): 475-476.

Bel N, Artigas F (1996). Reduction of serotonergic function in rat brain by tryptophan depletion: effects in control and fluvoxamine-treated rats. *J Neurochem* **67**(2): 669-676.

Bell C, Forshall S, Adrover M, Nash J, Hood S, Argyropoulos S, *et al* (2002). Does 5-HT restrain panic? A tryptophan depletion study in panic disorder patients recovered on paroxetine. *J Psychopharmacol* **16**(1): 5-14.

Bell C, Hood S, Potokar J, Nash J, Adrover M, Frampton C, *et al* (2011). Rapid tryptophan depletion following cognitive behavioural therapy for panic disorder. *Psychopharmacology (Berl)* **213**(2-3): 593-602.

Bellodi L, Perna G, Caldirola D, Arancio C, Bertani A, Di Bella D (1998). CO₂-induced panic attacks: a twin study. *Am J Psychiatry* **155**(9): 1184-1188.

Ben-Zion IZ, Meiri G, Greenberg BD, Murphy DL, Benjamin J (1999). Enhancement of CO₂-induced anxiety in healthy volunteers with the serotonin antagonist metergoline. *Am J Psychiatry* **156**(10): 1635-1637.

Bertani A, Bellodi L, Bussi R, Caldirola D, Cucchi M, Perna G (2003). The effect of one-week treatment with venlafaxine on 35% CO₂ hyperreactivity in patients with panic disorder: an open study. *J Clin Psychopharmacol* **23**(1): 106-108.

Bertani A, Caldirola D, Bussi R, Bellodi L, Perna G (2001). The 35% CO₂ hyperreactivity and clinical symptomatology in patients with panic disorder after 1 week of treatment with citalopram: an open study. *J Clin Psychopharmacol* **21**(3): 262-267.

Bertani A, Perna G, Arancio C, Caldirola D, Bellodi L (1997). Pharmacologic effect of imipramine, paroxetine, and sertraline on 35% carbon dioxide hypersensitivity in panic patients: a double-blind, random, placebo-controlled study. *J Clin Psychopharmacol* **17**(2): 97-101.

Biber B, Alkin T (1999). Panic disorder subtypes: differential responses to CO₂ challenge. *Am J Psychiatry* **156**(5): 739-744.

Biggio G, Fadda F, Fanni P, Tagliamonte A, Gessa GL (1974). Rapid depletion of serum tryptophan, brain tryptophan, serotonin and 5-hydroxyindoleacetic acid by a tryptophan-free diet. *Life Sci* **14**(7): 1321-1329.

Blechert J, Wilhelm FH, Meuret AE, Wilhelm EM, Roth WT (2010). Respiratory, autonomic, and experiential responses to repeated inhalations of 20% CO enriched air in panic disorder, social phobia, and healthy controls. *Biol Psychol* **84**(1): 104-111.

Bouwer C, Stein DJ (1997). Association of panic disorder with a history of traumatic suffocation. *Am J Psychiatry* **154**(11): 1566-1570.

Brackett NC, Jr., Cohen JJ, Schwartz WB (1965). Carbon Dioxide Titration Curve of Normal Man. Effect of Increasing Degrees of Acute Hypercapnia on Acid-Base Equilibrium. *N Engl J Med* **272**: 6-12.

Bradley SR, Pieribone VA, Wang W, Severson CA, Jacobs RA, Richerson GB (2002). Chemosensitive serotonergic neurons are closely associated with large medullary arteries. *Nat Neurosci* **5**(5): 401-402.

Brannan S, Liotti M, Egan G, Shade R, Madden L, Robillard R, *et al* (2001). Neuroimaging of cerebral activations and deactivations associated with hypercapnia and hunger for air. *Proc Natl Acad Sci U S A* **98**(4): 2029-2034.

- Briggs AC, Stretch DD, Brandon S (1993). Subtyping of panic disorder by symptom profile. *Br J Psychiatry* **163**: 201-209.
- Bringager CB, Dammen T, Friis S (2004). Nonfearful panic disorder in chest pain patients. *Psychosomatics* **45**(1): 69-79.
- Brown C (1982). Cardiovascular aspects of in-water blackout. In: Lanthier E (ed). *The unconscious diver: respiratory control an other contributing factor*. Undersea Medical Society, Inc.: Bethesda, pp. 30-36.
- Brown EW (1930). The physiological effects of high concentrations of Carbon Dioxide. *US Navy Med Bull* **28**(271).
- Bunaciu L, Feldner MT, Babson KA, Zvolensky MJ, Eifert GH (2011). Biological sex and panic-relevant anxious reactivity to abrupt increases in bodily arousal as a function of biological challenge intensity. *J Behav Ther Exp Psychiatry* **43**(1): 526-531.
- Cabanac M (1996). On the origin of consciousness, a postulate and its corollary. *Neurosci Biobehav Rev* **20**(1): 33-40.
- Cabanac M (2002). What is emotion? *Behav Processes* **60**(2): 69-83.
- Caldirola D, Bellodi L, Caumo A, Migliarese G, Perna G (2004). Approximate entropy of respiratory patterns in panic disorder. *Am J Psychiatry* **161**(1): 79-87.
- Caldirola D, Perna G, Arancio C, Bertani A, Bellodi L (1997). The 35% CO₂ challenge test in patients with social phobia. *Psychiatry Res* **71**(1): 41-48.
- Carpenter LL, Anderson GM, Pelton GH, Gudín JA, Kirwin PD, Price LH, *et al* (1998). Tryptophan depletion during continuous CSF sampling in healthy human subjects. *Neuropsychopharmacology* **19**(1): 26-35.
- Cavallini MC, Perna G, Caldirola D, Bellodi L (1999). A segregation study of panic disorder in families of panic patients responsive to the 35% CO₂ challenge. *Biol Psychiatry* **46**(6): 815-820.
- Cohen ME, White PD (1951). Life situations, emotions, and neurocirculatory asthenia (anxiety neurosis, neurasthenia, effort syndrome). *Psychosom Med* **13**: 335-357.
- Colasanti A, Esquivel G, den Boer E, Horlings A, Dandachi A, Oostwegel JL, *et al* (2011). Effects of tryptophan depletion and tryptophan loading on the affective response to high-dose CO₂ challenge in healthy volunteers. *Psychopharmacology (Berl)*; **215**(4): 739-748.
- Colasanti A, Rabiner EA, Lingford-Hughes A, Nutt DJ (2010). Opioids and Anxiety. *J Psychopharmacol* **25**(11): 1415-1433.

Colasanti A, Salamon E, Schruers K, van Diest R, van Duinen M, Griez EJ (2008). Carbon Dioxide-Induced Emotion and Respiratory Symptoms in Healthy Volunteers. *Neuropsychopharmacology*. **33**(13): 3103-3110.

Colasanti A, Searle GE, Long CJ, Hill SP, Reiley RR, Quelch D, *et al* (2012). Endogenous opioid release in the human brain reward system induced by acute amphetamine administration. *Biol Psychiatry* **72**(5): 371-377.

Concas A, Sanna E, Cuccheddu T, Mascia MP, Santoro G, Maciocco E, *et al* (1993). Carbon dioxide inhalation, stress and anxiogenic drugs reduce the function of GABAA receptor complex in the rat brain. *Prog Neuropsychopharmacol Biol Psychiatry* **17**(4): 651-661.

Corcoran AE, Hodges MR, Wu Y, Wang W, Wylie CJ, Deneris ES, *et al* (2009). Medullary serotonin neurons and central CO₂ chemoreception. *Respir Physiol Neurobiol* **168**(1-2): 49-58.

Coryell W (1997). Hypersensitivity to carbon dioxide as a disease-specific trait marker. *Biol Psychiatry* **41**(3): 259-263.

Coryell W, Fyer A, Pine D, Martinez J, Arndt S (2001). Aberrant respiratory sensitivity to CO₂ as a trait of familial panic disorder. *Biol Psychiatry* **49**(7): 582-587.

Coryell W, Pine D, Fyer A, Klein D (2006). Anxiety responses to CO₂ inhalation in subjects at high-risk for panic disorder. *J Affect Disord* **92**(1): 63-70.

Coryell W, Rickels H (2009). Effects of escitalopram on anxiety and respiratory responses to carbon dioxide inhalation in subjects at high risk for panic disorder: a placebo-controlled, crossover study. *J Clin Psychopharmacol* **29**(2): 174-178.

Cosci F, Abrams K, Schruers KR, Rickelt J, Griez EJ (2006). Effect of nicotine on 35% CO₂-induced anxiety: A study in healthy volunteers. *Nicotine Tob Res* **8**(4): 511-517.

Cosci F, De Gooyer T, Schruers K, Faravelli C, Griez E (2005). The influence of ethanol infusion on the effects of 35% CO₂ challenge. A study in panic disorder patients and healthy volunteers. *Eur Psychiatry* **20**(3): 299-303.

Cox BJ, Endler NS, Swinson RP (1991). Clinical and nonclinical panic attacks: an empirical test of a panic-anxiety continuum. *J Anxiety Disord* **5**: 21-34.

Cox BJ, Swinson RP, Endler NS, Norton GR (1994). The symptom structure of panic attacks. *Compr Psychiatry* **35**(5): 349-353.

Craig AD (2003). Interoception: the sense of the physiological condition of the body. *Curr Opin Neurobiol* **13**(4): 500-505.

Cuccheddu T, Floris S, Serra M, Porceddu ML, Sanna E, Biggio G (1995). Proconflict effect of carbon dioxide inhalation in rats. *Life Sci* **56**(16): PL321-324.

Damasio AR (1994). *Descartes' error: emotion, reason and the human brain*. Picador, 1995: London, xix, p. 312.

Damasio AR (1999). *The feeling of what happens : body and emotion in the making of consciousness*, 1st edn. Harcourt Brace: New York, xii, p. 386.

Damasio AR (2010). *Self comes to mind: constructing the conscious brain*, 1st ed. edn. Pantheon Books: New York, xi, p. 367.

Davies SJ, Hood SD, Argyropoulos SV, Morris K, Bell C, Witchel HJ, *et al* (2006). Depleting serotonin enhances both cardiovascular and psychological stress reactivity in recovered patients with anxiety disorders. *J Clin Psychopharmacol* **26**(4): 414-418.

Davison MA, H. (1965). *The evolution of anesthesia*: Baltimore.

de Beurs E, Garssen B, Buikhuisen M, Lange A, van Balkom A, Van Dyck R (1994). Continuous monitoring of panic. *Acta Psychiatr Scand* **90**(1): 38-45.

De Coninck L (1963). Effets, sur l'organisme humain, de l'inhalation d'air contenant de l'anhydride carbonique. *Annales des Mines de Belgique* **5**: 578-583.

Deakin J, Graeff F (1991). 5-HT and mechanisms of defence. *J Psychopharmacol* **5**: 305-315.

Denton D (2006). *The primordial emotions: The dawning of consciousness*. Oxford University Press.

Denton DA, McKinley MJ, Farrell M, Egan GF (2009). The role of primordial emotions in the evolutionary origin of consciousness. *Conscious Cogn* **18**(2): 500-514.

Diaper A, Nutt DJ, Munafo MR, White JL, Farmer EW, Bailey JE (2012). The effects of 7.5% carbon dioxide inhalation on task performance in healthy volunteers. *J Psychopharmacol* **26**(4):487-496.

Dolan RJ (2002). Emotion, cognition, and behavior. *Science* **298**(5596): 1191-1194.

Dripps RD, Comroe JH (1947). The respiratory and circulatory response of normal man to inhalation of 7.6 and 10.4 per cent CO₂. *Am J Physiol* **149**(1): 43-51.

Edmonds CL, C. & Pennefather, J. (1992). *Diving and Subaquatic Medicine*. 3rd ed., pp. 404-406..

EPA (2000). *Carbon dioxide as a fire suppressor: examining the risks.*: Washington, DC.

Esquivel G, Schruers KR, Maddock RJ, Colasanti A, Griez EJ (2010). Acids in the brain: a factor in panic? *J Psychopharmacol* **24**(5): 639-647.

Evans KC, Banzett RB, Adams L, McKay L, Frackowiak RS, Corfield DR (2002). BOLD fMRI identifies limbic, paralimbic, and cerebellar activation during air hunger. *J Neurophysiol* **88**(3): 1500-1511.

Fadda F, Cocco S, Rossetti ZL, Melis G, Stancampiano R (2000). A tryptophan-free diet markedly reduces frontocortical 5-HT release, but fails to modify ethanol preference in alcohol-preferring (sP) and non-preferring (sNP) rats. *Behav Brain Res* **108**(2): 127-132.

Fleet RP, Martel JP, Lavoie KL, Dupuis G, Beitman BD (2000). Non-fearful panic disorder: a variant of panic in medical patients? *Psychosomatics* **41**(4): 311-320.

Flint AJ, Koszycki D, Vaccarino FJ, Cadieux A, Boulenger JP, Bradwejn J (1998). Effect of aging on cholecystokinin-induced panic. *Am J Psychiatry* **155**(2): 283-285.

Foregger R (1957). Joseph Black and the identification of carbon dioxide. *Anesthesiology* **18**: 257-264.

Freire RC, Perna G, Nardi AE (2010). Panic disorder respiratory subtype: psychopathology, laboratory challenge tests, and response to treatment. *Harv Rev Psychiatry* **18**(4): 220-229.

Fyer MR, Uy J, Martinez J, Goetz R, Klein DF, Fyer A, *et al* (1987). CO₂ challenge of patients with panic disorder. *Am J Psychiatry* **144**(8): 1080-1082.

Garner M, Attwood A, Baldwin DS, James A, Munafo MR (2011). Inhalation of 7.5% carbon dioxide increases threat processing in humans. *Neuropsychopharmacology* **36**(8): 1557-1562.

Gater R, Tansella M, Korten A, Tiemens BG, Mavreas VG, Olatawura MO (1998). Sex differences in the prevalence and detection of depressive and anxiety disorders in general health care settings: report from the World Health Organization Collaborative Study on Psychological Problems in General Health Care. *Arch Gen Psychiatry* **55**(5): 405-413.

Gessa GL, Biggio G, Fadda F, Corsini GU, Tagliamonte A (1974). Effect of the oral administration of tryptophan-free amino acid mixtures on serum tryptophan, brain tryptophan and serotonin metabolism. *J Neurochem* **22**(5): 869-870.

Gibbons HL (1977). Carbon dioxide hazards in general aviation. *Aviat Space Environ Med* **48**(3): 261-263.

Gill JR, Ely SF, Hua Z (2002). Environmental gas displacement: three accidental deaths in the workplace. *Am J Forensic Med Pathol* **23**(1): 26-30.

Goddard AW, Charney DS, Germine M, Woods SW, Heninger GR, Krystal JH, *et al* (1995). Effects of tryptophan depletion on responses to yohimbine in healthy human subjects. *Biol Psychiatry* **38**(2): 74-85.

Goodwin RD, Pine DS (2002). Respiratory disease and panic attacks among adults in the United States. *Chest* **122**: 645-650.

Gorman JM, Askanazi J, Liebowitz MR, Fyer AJ, Stein J, Kinney JM, *et al* (1984). Response to hyperventilation in a group of patients with panic disorder. *Am J Psychiatry* **141**(7): 857-861.

Gorman JM, Browne ST, Papp LA, Martinez J, Welkowitz L, Coplan JD, *et al* (1997). Effect of antipanic treatment on response to carbon dioxide. *Biol Psychiatry* **42**(11): 982-991.

Gorman JM, Fyer MR, Goetz R, Askanazi J, Liebowitz MR, Fyer AJ, *et al* (1988). Ventilatory physiology of patients with panic disorder. *Arch Gen Psychiatry* **45**(1): 31-39.

Gorman JM, Kent J, Martinez J, Browne S, Coplan J, Papp LA (2001). Physiological changes during carbon dioxide inhalation in patients with panic disorder, major depression, and premenstrual dysphoric disorder: evidence for a central fear mechanism. *Arch Gen Psychiatry* **58**(2): 125-131.

Gorman JM, Kent JM, Sullivan GM, Coplan JD (2000). Neuroanatomical hypothesis of panic disorder, revised. *Am J Psychiatry* **157**(4): 493-505.

Gorman JM, Papp LA, Martinez J, Goetz RR, Hollander E, Liebowitz MR, *et al* (1990). High-dose carbon dioxide challenge test in anxiety disorder patients. *Biol Psychiatry* **28**(9): 743-757.

Graver D (1993). *Scuba diving*: Champaign (IL).

Griez E, de Loof C, Pols H, Zandbergen J, Lousberg H (1990a). Specific sensitivity of patients with panic attacks to carbon dioxide inhalation. *Psychiatry Res* **31**(2): 193-199.

Griez E, Lousberg H, van den Hout MA, van der Molen MG (1987a). CO₂ vulnerability in panic disorder. *Psychiatry Res* **20**: 87-95.

Griez E, Schruers K (1998). Experimental pathophysiology of panic. *J Psychosom Res* **45**(6): 493-503.

Griez E, van den Hout MA (1982). Effects of carbon dioxide-oxygen inhalations on subjective anxiety and some neurovegetative parameters. *J Behav Ther Exp Psychiatry* **13**(1): 27-32.

Griez E, Zandbergen J, Pols H, de Loof C (1990b). Response to 35% CO₂ as a marker of panic in severe anxiety. *Am J Psychiatry* **147**(6): 796-797.

Griez EJ, Colasanti A, van Diest R, Salamon E, Schruers K (2007). Carbon dioxide inhalation induces dose-dependent and age-related negative affectivity. *PLoS ONE* **2**(10): e987.

Griez EJ, Lousberg H, van den Hout MA, van der Molen GM (1987b). CO₂ vulnerability in panic disorder. *Psychiatry Res* **20**(2): 87-95.

Griffiths PE (1997). *What emotions really are*. The University of Chicago Press: Chicago.

Harrison WM, Sandberg D, Gorman JM, Fyer M, Nee J, Uy J, *et al* (1989). Provocation of panic with carbon dioxide inhalation in patients with premenstrual dysphoria. *Psychiatry Res* **27**(2): 183-192.

Henning R, Sauter S, Lanphier E, Reddan W (1990). Behavioral effects of increased CO₂ load in divers. *Undersea Biomedical Research* **17**(2): 109-120.

Hickman HH (ed) (1965). *Suspended animation*: Charles C. Thomas, Springfield, IL, pp. 282-285.

Hodges MR, Richerson GB (2008). Contributions of 5-HT neurons to respiratory control: neuromodulatory and trophic effects. *Respir Physiol Neurobiol* **164**(1-2): 222-232.

Holt PE, Andrews G (1989). Provocation of panic: three elements of the panic reaction in four anxiety disorders. *Behav Res Ther* **27**(3): 253-261.

Hood SD, Bell CJ, Nutt DJ (2005). Acute tryptophan depletion. Part I: rationale and methodology. *Aust N Z J Psychiatry* **39**(7): 558-564.

Hood SD, Hince DA, Davies SJ, Argyropoulos S, Robinson H, Potokar J, *et al*. Effects of acute tryptophan depletion in serotonin reuptake inhibitor-remitted patients with generalized anxiety disorder. *Psychopharmacology (Berl)* **208**(2): 223-232.

Hood SD, Hince DA, Robinson H, Cirillo M, Christmas D, Kaye JM (2006). Serotonin regulation of the human stress response. *Psychoneuroendocrinology* **31**(9): 1087-1097.

Horwath E, Adams P, Wickramaratne P, Pine D, Weissman MM (1997). Panic disorder with smothering symptoms: evidence for increased risk in first-degree relatives. *Depress Anxiety* **6**(4): 147-153.

Ietsugu T, Sukigara M, Furukawa TA (2007). Evaluation of diagnostic criteria for panic attack using item response theory: findings from the National Comorbidity Survey in USA. *J Affect Disord* **104**(1-3): 197-201.

Iversen SD (1984). 5-HT and anxiety. *Neuropharmacology* **23**(12B): 1553-1560.

James W (1890). *The principles of psychology* H. Holt and company: New York.

James W (1918). *The principles of psychology (1890)* Henry Holt and Co.: New York.

Kanamaru M, Homma I (2007). Compensatory airway dilation and additive ventilatory augmentation mediated by dorsomedial medullary 5-hydroxytryptamine 2 receptor activity and hypercapnia. *Am J Physiol Regul Integr Comp Physiol* **293**(2): R854-860.

Kaye J, Buchanan F, Kendrick A, Johnson P, Lowry C, Bailey J, *et al* (2004). Acute carbon dioxide exposure in healthy adults: evaluation of a novel means of investigating the stress response. *J Neuroendocrinol* **16**(3): 256-264.

Kaye JM, Corrall RJ, Lightman SL (2005). A new test for autonomic cardiovascular and neuroendocrine responses in diabetes mellitus: evidence for early vagal dysfunction. *Diabetologia* **48**(1): 180-186.

Kelly MM, Forsyth JP, Karekla M (2006). Sex differences in response to a panicogenic challenge procedure: an experimental evaluation of panic vulnerability in a non-clinical sample. *Behav Res Ther* **44**(10): 1421-1430.

Kent JM, Papp LA, Martinez JM, Browne ST, Coplan JD, Klein DF, *et al* (2001). Specificity of panic response to CO₂ inhalation in panic disorder: a comparison with major depression and premenstrual dysphoric disorder. *Am J Psychiatry* **158**(1): 58-67.

Klaassen T, Klumperbeek J, Deutz NE, van Praag HM, Griez E (1998). Effects of tryptophan depletion on anxiety and on panic provoked by carbon dioxide challenge. *Psychiatry Res* **77**(3): 167-174.

Klein DF (1993). False suffocation alarms, spontaneous panics, and related conditions. An integrative hypothesis. *Arch Gen Psychiatry* **50**(4): 306-317.

Kleinginna PR, Kleinginna AM (1981). A categorized list of emotion definitions, with suggestions for a consensual definition. *Motivat Emot* **5**: 345-379.

Kling GW, Clark MA, Wagner GN, Compton HR, Humphrey AM, Devine JD, *et al* (1987). The 1986 Lake Nyos Gas Disaster in Cameroon, West Africa. *Science* **236**(4798): 169-175.

Koszycki D, Zacharko RM, Le Melleo JM, Young SN, Bradwejn J (1996). Effect of acute tryptophan depletion on behavioral, cardiovascular, and hormonal sensitivity to cholecystokinin-tetrapeptide challenge in healthy volunteers. *Biol Psychiatry* **40**(7): 648-655.

Kreiss K, Rao CY, Harrison JM, Kaydos-Daniels SC, Benaise LG (2003). Brief report: Investigation of a home with extremely elevated Carbon Dioxide Levels. *MMWR* **53**: 1181-1182.

Krystal JH, Leaf PJ, Bruce ML, Charney DS (1992). Effects of age and alcoholism on the prevalence of panic disorder. *Acta Psychiatr Scand* **85**(1): 77-82.

Kulz AK, Meinzer S, Kopasz M, Voderholzer U (2007). Effects of tryptophan depletion on cognitive functioning, obsessive-compulsive symptoms and mood in obsessive-compulsive disorder: preliminary results. *Neuropsychobiology* **56**(2-3): 127-131.

Langford NJ (2005). Carbon dioxide poisoning. *Toxicol Rev* **24**(4): 229-235.

Lansing RW, Gracely RH, Banzett RB (2009). The multiple dimensions of dyspnea: review and hypotheses. *Respir Physiol Neurobiol* **167**(1): 53-60.

Laruelle M (2000). Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. *J Cereb Blood Flow Metab* **20**(3): 423-451.

Laverne A (1953). Rapid coma technique of carbon dioxide inhalation therapy. *Diseases of the Nervous System* **14**: 141-144.

Lawlor BA, Sunderland T, Hill JL, Mellow AM, Molchan SE, Mueller EA, *et al* (1989). Evidence for a decline with age in behavioral responsivity to the serotonin agonist, m-chlorophenylpiperazine, in healthy human subjects. *Psychiatry Res* **29**(1): 1-10.

Leake CG, Guedel AE, Botsford ME (1929). The stimulating effect of carbondioxide inhalations in dementia praecox catatonia. *California West Medical Journal* **31**: 20.

Leathwood PD (1987). Tryptophan availability and serotonin synthesis. *Proc Nutr Soc* **46**(1): 143-156.

Ley R (1992). The many faces of Pan: psychological and physiological differences among three types of panic attacks. *Behav Res Ther* **30**(4): 347-357.

Lieben CK, van Oorsouw K, Deutz NE, Blokland A (2004). Acute tryptophan depletion induced by a gelatin-based mixture impairs object memory but not affective behavior and spatial learning in the rat. *Behav Brain Res* **151**(1-2): 53-64.

Liotti M, Brannan S, Egan G, Shade R, Madden L, Abplanalp B, *et al* (2001). Brain responses associated with consciousness of breathlessness (air hunger). *Proc Natl Acad Sci U S A* **98**(4): 2035-2040.

Loevenhart AL, WF; Waters, R (1929). Cerebral stimulations. *Journal of the American Medical Association* **11**: 880-883.

Lopes FL, Oliveira MM, Freire RC, Caldirola D, Perna G, Bellodi L, *et al* (2009). Carbon dioxide-induced panic attacks and quantitative electroencephalogram in panic disorder patients. *World J Biol Psychiatry* **11**(2 Pt 2): 357-363.

MacKinnon DF, Craighead B, Hoehn-Saric R (2007). Carbon dioxide provocation of anxiety and respiratory response in bipolar disorder. *J Affect Disord* **99**(1-3): 45-49.

Mackinnon DF, Craighead B, Lorenz L (2009). Carbon dioxide induces erratic respiratory responses in bipolar disorder. *J Affect Disord* **112**(1-3):193-200.

Mandler G (1984). *Mind and body: psychology of emotion and stress* Norton: New York ; London, xii, p. 330.

Maren S (2009). An acid-sensing channel sows fear and panic. *Cell* **139**(5): 867-869.

Maresh CM, Armstrong LE, Kavouras SA, Allen GJ, Casa DJ, Whittlesey M, *et al* (1997). Physiological and psychological effects associated with high carbon dioxide levels in healthy men. *Aviat Space Environ Med* **68**(1): 41-45.

Maron E, Shlik J (2006). Serotonin function in panic disorder: important, but why? *Neuropsychopharmacology* **31**(1): 1-11.

Maron E, Shlik J, Nutt DJ (2008). Tryptophan Research in Panic Disorder. *International Journal of Tryptophan Research* **1**: 3-12.

Maron E, Toru I, Vasar V, Shlik J (2004). The effect of 5-hydroxytryptophan on cholecystokinin-4-induced panic attacks in healthy volunteers. *J Psychopharmacol* **18**(2): 194-199.

McNally RJ, Hornig CD, Donnell CD (1995). Clinical versus nonclinical panic: a test of suffocation false alarm theory. *Behav Res Ther* **33**(2): 127-131.

Meduna L (1955). *Carbon Dioxide Therapy. A neurophysiologic treatment of nervous disorders.*: Springfield, Illinois.

Meiri G, Ben-Zion IZ, Greenberg BD, Murphy DL, Benjamin J (2001). Influence of the serotonin antagonist, metergoline, on the anxiogenic effects of carbon dioxide, and on heart rate and neuroendocrine measures, in healthy volunteers. *Hum Psychopharmacol* **16**(3): 237-245.

Meuret AE, White KS, Ritz T, Roth WT, Hofmann SG, Brown TA (2006). Panic attack symptom dimensions and their relationship to illness characteristics in panic disorder. *J Psychiatr Res* **40**(6): 520-527.

Miller HE, Deakin JF, Anderson IM (2000). Effect of acute tryptophan depletion on CO₂-induced anxiety in patients with panic disorder and normal volunteers. *Br J Psychiatry* **176**: 182-188.

Mongeluzi DL, Rosellini RA, Caldarone BJ, Stock HS, Abrahamsen GC (1996). Pavlovian aversive context conditioning using carbon dioxide as the unconditional stimulus. *J Exp Psychol Anim Behav Process* **22**(3): 244-257.

Mongeluzi DL, Rosellini RA, Ley R, Caldarone BJ, Stock HS (2003). The conditioning of dyspneic suffocation fear. Effects of carbon dioxide concentration on behavioral freezing and analgesia. *Behav Modif* **27**(5): 620-636.

Monkul ES, Onur E, Tural U, Hatch JP, Alkin T, Yucel B, *et al* (2010). History of suffocation, state-trait anxiety, and anxiety sensitivity in predicting 35% carbon dioxide-induced panic. *Psychiatry Res* **179**(2): 194-197.

Monteiro-dos-Santos PC, Graeff FG, dos-Santos JE, Ribeiro RP, Guimaraes FS, Zuardi AW (2000). Effects of tryptophan depletion on anxiety induced by simulated public speaking. *Braz J Med Biol Res* **33**(5): 581-587.

Moosavi SH, Golestanian E, Binks AP, Lansing RW, Brown R, Banzett RB (2003). Hypoxic and hypercapnic drives to breathe generate equivalent levels of air hunger in humans. *J Appl Physiol* **94**(1): 141-154.

Morgan W (1983). Psychometric correlates of respiration: a review. *Am Ind Hyg Assoc J* **44**: 677-684.

Morgan WP (1995). Anxiety and panic in recreational scuba divers. *Sports Med* **20**(6): 398-421.

Morris LE (2002). Carbon dioxide and anesthesia. *International Congress Series* **1242**: 145-155.

Moynihan JE, Gevirtz RN (2001). Respiratory and cognitive subtypes of panic. Preliminary validation of Ley's model. *Behav Modif* **25**(4): 555-583.

Muhtz C, Daneshi J, Braun M, Kellner M Carbon-dioxide-induced flashback in a healthy man with a history of near-drowning. *Psychother Psychosom* **80**(1): 55-56.

Muhtz C, Yassouridis A, Daneshi J, Braun M, Kellner M (2011). Acute panicogenic, anxiogenic and dissociative effects of carbon dioxide inhalation in patients with post-traumatic stress disorder (PTSD). *J Psychiatr Res* **45**(7): 989-993.

Nardi AE, Freire RC, Zin WA (2008). Panic disorder and control of breathing. *Respir Physiol Neurobiol.* **167**(1): 133-143

Nardi AE, Nascimento I, Valenca AM, Lopes FL, Mezzasalma MA, Zin WA, *et al* (2003). Respiratory panic disorder subtype: acute and long-term response to nortriptyline, a noradrenergic tricyclic antidepressant. *Psychiatry Res* **120**(3): 283-293.

Nardi AE, Valenca AM, Lopes FL, Nascimento I, Veras AB, Freire RC, *et al* (2006a). Psychopathological profile of 35% CO₂ challenge test-induced panic attacks: a comparison with spontaneous panic attacks. *Compr Psychiatry* **47**(3): 209-214.

Nardi AE, Valenca AM, Mezzasalma MA, Lopes FL, Nascimento I, Veras AB, *et al* (2006b). 35% Carbon dioxide and breath-holding challenge tests in panic disorder: a comparison with spontaneous panic attacks. *Depress Anxiety* **23**(4): 236-244.

Nardi AE, Valenca AM, Nascimento I, Zin WA, Versiani M (2002). Carbon dioxide test in respiratory panic disorder subtype. *Can J Psychiatry* **47**(7): 685-686.

Nardi AE, Valenca AM, Zin W, Nascimento I (1999). Carbon dioxide induced panic attacks and short term clonazepam treatment. Preliminary study. *Arq Neuropsiquiatr* **57**(2B): 361-365.

Nillni YI, Berenz EC, Rohan KJ, Zvolensky MJ (2012). Sex differences in panic-relevant responding to a 10% carbon dioxide-enriched air biological challenge. *J Anxiety Disord* **26**(1): 165-172.

Nillni YI, Rohan KJ, Bernstein A, Zvolensky MJ (2010). Premenstrual distress predicts panic-relevant responding to a CO₂ challenge among young adult females. *J Anxiety Disord* **24**(4): 416-422.

Oatley K (1992). *Best laid schemes. The psychology of emotions* Cambridge University Press: Cambridge

Onur E, Alkin T, Tural U (2007). Panic disorder subtypes: further clinical differences. *Depress Anxiety* **24**(7): 479-486.

Orwin A (1973). A new use for CO₂ therapy in the treatment of Phobic conditions: a preliminary report on two cases. *British Journal of Psychiatry* **122**: 171-173.

Overbeek T, Schruers K, van Leeuwen ID, Klaassen T, Griez E (2005). Experimental affective symptoms in panic disorder patients. *Can J Psychiatry* **50**(3): 175-178.

Panksepp J (1998). *Affective Neuroscience. The foundations of human and animal emotions* Oxford University Press.

Papadopoulos A, Rich A, Nutt D, Bailey J (2010). The effects of single dose anxiolytic medication on the CO₂ models of anxiety: differentiation of subjective and objective measures. *J Psychopharmacol* **24**(5):649-56.

Papp LA, Klein DF, Martinez J, Schneier F, Cole R, Liebowitz MR, *et al* (1993). Diagnostic and substance specificity of carbon-dioxide-induced panic. *Am J Psychiatry* **150**(2): 250-257.

Papp LA, Martinez JM, Klein DF, Coplan JD, Gorman JM (1995). Rebreathing tests in panic disorder. *Biol Psychiatry* **38**(4): 240-245.

Papp LA, Martinez JM, Klein DF, Coplan JD, Norman RG, Cole R, *et al* (1997). Respiratory psychophysiology of panic disorder: three respiratory challenges in 98 subjects. *Am J Psychiatry* **154**(11): 1557-1565.

Pardridge WM (1998). Blood-brain barrier carrier-mediated transport and brain metabolism of amino acids. *Neurochem Res* **23**(5): 635-644.

Parsons LM, Egan G, Liotti M, Brannan S, Denton D, Shade R, *et al* (2001). Neuroimaging evidence implicating cerebellum in the experience of hypercapnia and hunger for air. *Proc Natl Acad Sci U S A* **98**(4): 2041-2046.

Perna G, Barbini B, Cocchi S, Bertani A, Gasperini M (1995a). 35% CO₂ challenge in panic and mood disorders. *J Affect Disord* **33**(3): 189-194.

Perna G, Battaglia M, Garberi A, Arancio C, Bertani A, Bellodi L (1994a). Carbon dioxide/oxygen challenge test in panic disorder. *Psychiatry Res* **52**(2): 159-171.

Perna G, Bertani A, Arancio C, Ronchi P, Bellodi L (1995b). Laboratory response of patients with panic and obsessive-compulsive disorders to 35% CO₂ challenges. *Am J Psychiatry* **152**(1): 85-89.

Perna G, Bertani A, Caldirola D, Bellodi L (1996). Family history of panic disorder and hypersensitivity to CO₂ in patients with panic disorder. *Am J Psychiatry* **153**(8): 1060-1064.

Perna G, Bertani A, Caldirola D, Di Pasquale D, Migliarese G, Bellodi L (2004a). Modulation of hyperreactivity to 35% CO₂ after one week of treatment with paroxetine and reboxetine: a double-blind, randomized study. *J Clin Psychopharmacol* **24**(3): 277-282.

Perna G, Bertani A, Caldirola D, Gabriele A, Cocchi S, Bellodi L (2002). Antipanic drug modulation of 35% CO₂ hyperreactivity and short-term treatment outcome. *J Clin Psychopharmacol* **22**(3): 300-308.

Perna G, Bertani A, Gabriele A, Politi E, Bellodi L (1997). Modification of 35% carbon dioxide hypersensitivity across one week of treatment with clomipramine and fluvoxamine: a double-blind, randomized, placebo-controlled study. *J Clin Psychopharmacol* **17**(3): 173-178.

Perna G, Bussi R, Allevi L, Bellodi L (1999a). Sensitivity to 35% carbon dioxide in patients with generalized anxiety disorder. *J Clin Psychiatry* **60**(6): 379-384.

Perna G, Caldirola D, Namia C, Cucchi M, Vanni G, Bellodi L (2004b). Language of dyspnea in panic disorder. *Depress Anxiety* **20**(1): 32-38.

Perna G, Casolari A, Bussi R, Cucchi M, Arancio C, Bellodi L (2004c). Comparison of 35% carbon dioxide reactivity between panic disorder and eating disorder. *Psychiatry Res* **125**(3): 277-283.

Perna G, Cocchi S, Allevi L, Bussi R, Bellodi L (1999b). A long-term prospective evaluation of first-degree relatives of panic patients who underwent the 35% CO₂ challenge. *Biol Psychiatry* **45**(3): 365-367.

Perna G, Cocchi S, Bertani A, Arancio C, Bellodi L (1994b). Pharmacologic effect of toloxatone on reactivity to the 35% carbon dioxide challenge: a single-blind, random, placebo-controlled study. *J Clin Psychopharmacol* **14**(6): 414-418.

Perna G, Cocchi S, Bertani A, Arancio C, Bellodi L (1995c). Sensitivity to 35% CO₂ in healthy first-degree relatives of patients with panic disorder. *Am J Psychiatry* **152**(4): 623-625.

Perna G, di Bella D, Favaron E, Cucchi M, Liperi L, Bellodi L (2004d). Lack of relationship between CO₂ reactivity and serotonin transporter gene regulatory region polymorphism in panic disorder. *Am J Med Genet B Neuropsychiatr Genet* **129B**(1): 41-43.

Pols H, Griez E, Bourin M, Schruers K (1999). Effect of CCK-4 on a 35% carbon dioxide challenge in healthy volunteers. *Prog Neuropsychopharmacol Biol Psychiatry* **23**(8): 1345-1350.

Pols H, Griez E, Verburg K, van der Werf D (1994). Yohimbine premedication and 35% CO₂ vulnerability in healthy volunteers. *Eur Arch Psychiatry Clin Neurosci* **244**(2): 81-85.

Pols H, Verburg K, Hauzer R, Meijer J, Griez E (1996a). Alprazolam premedication and 35% carbon dioxide vulnerability in panic patients. *Biol Psychiatry* **40**(9): 913-917.

Pols H, Zandbergen J, de Loof C, Griez E (1991). Attenuation of carbon dioxide-induced panic after clonazepam treatment. *Acta Psychiatr Scand* **84**(6): 585-586.

Pols HJ, Hauzer RC, Meijer JA, Verburg K, Griez EJ (1996b). Fluvoxamine attenuates panic induced by 35% CO₂ challenge. *J Clin Psychiatry* **57**(11): 539-542.

Poma SZ, Milleri S, Squassante L, Nucci G, Bani M, Perini GI, *et al* (2005). Characterization of a 7% carbon dioxide (CO₂) inhalation paradigm to evoke anxiety symptoms in healthy subjects. *J Psychopharmacol* **19**(5): 494-503.

Preter M, Klein DF (2008). Panic, suffocation, false alarms, separation anxiety and endogenous opioids. *Prog Neuropsychopharmacol Biol Psychiatry* **32**: 603-612.

Preter M, Lee SH, Petkova E, Vannucci M, Kim S, Klein DF (2011). Controlled cross-over study in normal subjects of naloxone-preceding-lactate infusions; respiratory and subjective

responses: relationship to endogenous opioid system, suffocation false alarm theory and childhood parental loss. *Psychol Med* **41**(2): 385-393.

Rapee RM, Brown TA, Antony MM, Barlow DH (1992). Response to hyperventilation and inhalation of 5.5% carbon dioxide-enriched air across the DSM-III-R anxiety disorders. *J Abnorm Psychol* **101**(3): 538-552.

Rassovsky Y, Kushner MG (2003). Carbon dioxide in the study of panic disorder: issues of definition, methodology, and outcome. *J Anxiety Disord* **17**(1): 1-32.

Richerson GB (2004). Serotonergic neurons as carbon dioxide sensors that maintain pH homeostasis. *Nat Rev Neurosci* **5**(6): 449-461.

Roberson-Nay R, Klein DF, Klein RG, Mannuzza S, Moulton JL, 3rd, Guardino M, *et al* (2010). Carbon dioxide hypersensitivity in separation-anxious offspring of parents with panic disorder. *Biol Psychiatry* **67**(12): 1171-1177.

Rogers NR (1955). Psychodynamic Exploration and Psychological Test Data with Carbon Dioxide Therapy. In: Meduna L (ed). *Carbon Dioxide Therapy*: Springfield, Illinois.

Romeo L, Prigioni P, Marcheselli S, Marchiori L, Cerpelloni M, Fiorini C, *et al* (2002). [Acute poisoning with carbon dioxide: report of 2 fatal cases]. *Med Lav* **93**(1): 26-33.

Roth WT, Margraf J, Ehlers A, Haddad JM, Maddock RJ, Agras WS, *et al* (1992). Imipramine and alprazolam effects on stress test reactivity in panic disorder. *Biol Psychiatry* **31**(1): 35-51.

Sambeth A, Riedel WJ, Tillie DE, Blokland A, Postma A, Schmitt JA (2009). Memory impairments in humans after acute tryptophan depletion using a novel gelatin-based protein drink. *J Psychopharmacol* **23**(1): 56-64.

Sanderson WC, Wetzler S, Asnis GM (1994). Alprazolam blockade of CO₂-provoked panic in patients with panic disorder. *Am J Psychiatry* **151**(8): 1220-1222.

Savitz AJ, Kahn TA, McGovern KE, Kahn JP (2011). Carbon dioxide induction of panic anxiety in schizophrenia with auditory hallucinations. *Psychiatry Res*.

Sayers JA, Smith RE, Holland RL, Keatinge WR (1987). Effects of carbon dioxide on mental performance. *J Appl Physiol* **63**(1): 25-30.

Schmidt NB, Storey J, Greenberg BD, Santiago HT, Li Q, Murphy DL (2000). Evaluating gene x psychological risk factor effects in the pathogenesis of anxiety: a new model approach. *J Abnorm Psychol* **109**(2): 308-320.

Schruers K, Esquivel G, van Duinen M, Wichers M, Kenis G, Colasanti A, *et al* (2011). Genetic moderation of CO₂-induced fear by 5-HTTLPR genotype. *J Psychopharmacol* **25**(1): 37-42.

Schruers K, Griez E (2004a). The effects of tianeptine or paroxetine on 35% CO₂ provoked panic in panic disorder. *J Psychopharmacol* **18**(4): 553-558.

Schruers K, Klaassen T, Pols H, Overbeek T, Deutz NE, Griez E (2000a). Effects of tryptophan depletion on carbon dioxide provoked panic in panic disorder patients. *Psychiatry Res* **93**(3): 179-187.

Schruers K, Pols H, Overbeek T, Griez E (2000b). 10 microg CCK-4 premedication and 35% CO₂ challenge in healthy volunteers. *Prog Neuropsychopharmacol Biol Psychiatry* **24**(3): 409-418.

Schruers K, van Diest R, Nicolson N, Griez E (2002a). L-5-hydroxytryptophan induced increase in salivary cortisol in panic disorder patients and healthy volunteers. *Psychopharmacology (Berl)* **161**(4): 365-369.

Schruers K, van Diest R, Overbeek T, Griez E (2002b). Acute L-5-hydroxytryptophan administration inhibits carbon dioxide-induced panic in panic disorder patients. *Psychiatry Res* **113**(3): 237-243.

Schruers KRJ, van der Mortel H, Overbeek T, Griez E (2004b). Symptom profiles of natural and laboratory panic attacks. *Acta Neuropsychiatrica* **16**(2): 101-106.

Schutters SI, Viechtbauer W, Knuts IJ, Griez EJ, Schruers KR (2012). 35% CO₂ sensitivity in social anxiety disorder. *J Psychopharmacol*. **26**(4):479-486.

Sechzer PH, Egbert LD, Linde HW, Cooper DY, Dripps RD, Price HL (1960). Effect of carbon dioxide inhalation on arterial pressure, ECG and plasma catecholamines and 17-OH corticosteroids in normal man. *J Appl Physiol* **15**: 454-458.

Severson CA, Wang W, Pieribone VA, Dohle CI, Richerson GB (2003). Midbrain serotonergic neurons are central pH chemoreceptors. *Nat Neurosci* **6**(11): 1139-1140.

Sharp T, Bramwell SR, Grahame-Smith DG (1992). Effect of acute administration of L-tryptophan on the release of 5-HT in rat hippocampus in relation to serotonergic neuronal activity: an in vivo microdialysis study. *Life Sci* **50**(17): 1215-1223.

Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, *et al* (1998). The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. *J Clin Psychiatry* **59** Suppl 20: 22-33.

Sheikh JI, Swales PJ, Carlson EB, Lindley SE (2004). Aging and panic disorder: phenomenology, comorbidity, and risk factors. *Am J Geriatr Psychiatry* **12**(1): 102-109.

Shioiri T, Someya T, Murashita J, Takahashi S (1996). The symptom structure of panic disorder: a trial using factor and cluster analysis. *Acta Psychiatr Scand* **93**(2): 80-86.

Sinclair LI, Christmas DM, Hood SD, Potokar JP, Robertson A, Isaac A, *et al* (2009). Antidepressant-induced jitteriness/anxiety syndrome: systematic review. *Br J Psychiatry* **194**(6): 483-490.

Struzik L, Duffin J, Vermani M, Hegadoren K, Katzman MA (2002). Effects of tryptophan depletion on central and peripheral chemoreflexes in man. *Respir Physiol Neurobiol* **133**(3): 183-195.

Sweeney L (1993). DAN-injury - fatality report shows diving risks. *Underwater USA* **10**: 10-11.

Talesnik B, Berzak E, Ben-Zion I, Kaplan Z, Benjamin J (2007). Sensitivity to carbon dioxide in drug-naïve subjects with post-traumatic stress disorder. *J Psychiatr Res* **41**(5): 451-454.

Telch MJ, Lucas JA, Nelson P (1989). Nonclinical panic in college students: an investigation of prevalence and symptomatology. *J Abnorm Psychol* **98**(3): 300-306.

Toru I, Shlik J, Maron E, Vasar V, Nutt DJ (2006). Tryptophan depletion does not modify response to CCK-4 challenge in patients with panic disorder after treatment with citalopram. *Psychopharmacology (Berl)* **186**(1): 107-112.

Troisi FM (1957). Delayed death caused by gassing in a silo containing green forage. *Br J Ind Med* **14**(1): 56-58.

Valenca AM, Nardi AE, Nascimento I, Zin WA, Versiani M (2002). Respiratory panic disorder subtype and sensitivity to the carbon dioxide challenge test. *Braz J Med Biol Res* **35**(7): 783-788.

van Beek N, Griez E (2000). Reactivity to a 35% CO₂ challenge in healthy first-degree relatives of patients with panic disorder. *Biol Psychiatry* **47**(9): 830-835.

van Beek N, Schruers KR, Griez EJ (2005). Prevalence of respiratory disorders in first-degree relatives of panic disorder patients. *J Affect Disord* **87**(2-3): 337-340.

van den Hout MA, Griez E (1982). Cardiovascular and subjective responses to inhalation of carbon dioxide. A controlled test with anxious patients. *Psychother Psychosom* **37**(2): 75-82.

Van den Hout MA, Griez E (1984). Panic symptoms after inhalation of carbon dioxide. *Br J Psychiatry* **144**: 503-507.

van der Plasse G, Meerkerk DT, Lieben CK, Blokland A, Feenstra MG (2007). Lack of evidence for reduced prefrontal cortical serotonin and dopamine efflux after acute tryptophan depletion. *Psychopharmacology (Berl)* **195**(3): 377-385.

van Duinen M, Rickelt J, Griez E (2008). Validation of the electronic Visual Analogue Scale of Anxiety. *Prog Neuropsychopharmacol Biol Psychiatry* **32**(4): 1045-1047.

van Eijk HM, Rooyackers DR, Deutz NE (1993). Rapid routine determination of amino acids in plasma by high-performance liquid chromatography with a 2-3 microns Spherisorb ODS II column. *J Chromatogr* **620**(1): 143-148.

Veasey SC, Fornal CA, Metzler CW, Jacobs BL (1995). Response of serotonergic caudal raphe neurons in relation to specific motor activities in freely moving cats. *J Neurosci* **15**(7 Pt 2): 5346-5359.

Veasey SC, Fornal CA, Metzler CW, Jacobs BL (1997). Single-unit responses of serotonergic dorsal raphe neurons to specific motor challenges in freely moving cats. *Neuroscience* **79**(1): 161-169.

Verburg C, Griez E, Meijer J (1994). A 35% carbon dioxide challenge in simple phobias. *Acta Psychiatr Scand* **90**(6): 420-423.

Verburg K, Griez E, Meijer J, Pols H (1995a). Discrimination between panic disorder and generalized anxiety disorder by 35% carbon dioxide challenge. *Am J Psychiatry* **152**(7): 1081-1083.

Verburg K, Griez E, Meijer J, Pols H (1995b). Respiratory disorders as a possible predisposing factor for panic disorder. *J Affect Disord* **33**(2): 129-134.

Verburg K, Klaassen T, Pols H, Griez E (1998a). Comorbid depressive disorder increases vulnerability to the 35% carbon dioxide (CO₂) challenge in panic disorder patients. *J Affect Disord* **49**(3): 195-201.

Verburg K, Perna G, Griez E, J. L. (2001). A case study of the 35 % CO₂ challenge. In: Griez E, J. L., Faravelli C, Nutt D, Zohar J (eds). *Anxiety Disorders. An Introduction to Clinical Management and Research*. Wiley: Chichester, pp. 341-357.

Verburg K, Pols H, de Leeuw M, Griez E (1998b). Reliability of the 35% carbon dioxide panic provocation challenge. *Psychiatry Res* **78**(3): 207-214.

Vickers K, McNally RJ (2005). Respiratory symptoms and panic in the National Comorbidity Survey: a test of Klein's suffocation false alarm theory. *Behav Res Ther* **43**(8): 1011-1018.

von Leupoldt A, Dahme B (2005). Cortical Substrates for the Perception of Dyspnea. *Chest* **128**(1): 345-354.

Wald FD, Mellenbergh GJ (1990). De verkorte versie van de Nederlandse vertaling van de Profile of Mood States (POMS). *Ned Tijdschr Psychol* **45**: 86-90.

Williams HI (1958). Carbon dioxide poisoning: report of eight cases, with two deaths. *Br Med J* **2**(5102): 1012-1014.

Williams WA, Shoaf SE, Hommer D, Rawlings R, Linnoila M (1999). Effects of acute tryptophan depletion on plasma and cerebrospinal fluid tryptophan and 5-hydroxyindoleacetic acid in normal volunteers. *J Neurochem* **72**(4): 1641-1647.

Wolf WA, Kuhn DM (1986). Uptake and release of tryptophan and serotonin: an HPLC method to study the flux of endogenous 5-hydroxyindoles through synaptosomes. *J Neurochem* **46**(1): 61-67.

Wolpe J (1958). *Psychotherapy by reciprocal inhibition.*: Stanford, California.

Woods SW, Charney DS, Goodman WK, Heninger GR (1988). Carbon dioxide-induced anxiety. Behavioral, physiologic, and biochemical effects of carbon dioxide in patients with panic disorders and healthy subjects. *Arch Gen Psychiatry* **45**(1): 43-52.

Woods SW, Charney DS, Loke J, Goodman WK, Redmond DE, Jr., Heninger GR (1986). Carbon dioxide sensitivity in panic anxiety. Ventilatory and anxiogenic response to carbon dioxide in healthy subjects and patients with panic anxiety before and after alprazolam treatment. *Arch Gen Psychiatry* **43**(9): 900-909.

Woods SW, Krystal JH, Heninger GR, Charney DS (1989). Effects of alprazolam and clonidine on carbon dioxide-induced increases in anxiety ratings in healthy human subjects. *Life Sci* **45**(3): 233-242.

Yamamoto M, Suhara T, Okubo Y, Ichimiya T, Sudo Y, Inoue M, *et al* (2002). Age-related decline of serotonin transporters in living human brain of healthy males. *Life Sci* **71**(7): 751-757.

Young SN, Smith SE, Pihl RO, Ervin FR (1985). Tryptophan depletion causes a rapid lowering of mood in normal males. *Psychopharmacology (Berl)* **87**(2): 173-177.

Zandbergen J, Pols H, de Loof C, Griez EJ (1991). Ventilatory response to CO₂ in panic disorder. *Psychiatry Res* **39**(1): 13-19.

Ziemann AE, Allen JE, Dahdaleh NS, Drebot, II, Coryell MW, Wunsch AM, *et al* (2009). The amygdala is a chemosensor that detects carbon dioxide and acidosis to elicit fear behavior. *Cell* **139**(5): 1012-1021.

Acknowledgments

I would like to express my gratitude to Professor Eric Griez, for his patience, guidance, and continuous support. My growing passion for science and research originated and was fed by our long afternoon discussions, after which I always felt enthusiastic and rewarded. I learned from him the importance of honesty and fairness in research and the pleasure of the intellectual speculation. I am particularly grateful to Dr. Koen Schruers for his help and supervision in all the experiments we conducted, and to the whole team of the Academic Anxiety Center for being so warm and welcoming.

Particularly, I would like to express my special thanks to Dr Gabriel Esquivel, who has been really inspiring and caring during my stay in Maastricht. I wish to acknowledge Dr. Erik den Boer, Dr. Ewa Salamon, Dr Rob van Diest, and Dr. Lies Goossens, for their invaluable contributions. A special thank is for Leni Noteborn, her help and support has been fantastic.

I would like to thank Christopher Rieder, who contributed to make my life in Maastricht magic and special; I remember with vivid happiness our visionary discussions on the mind and the body. During all these years, and particularly during my psychiatric training, I felt enormously supported by Dr Massimo Mauri. I have been inspired by his vision and his clinical acuteness. I am grateful to Professor Giampaolo Perna for his enthusiastic advices and for the opportunities he gave me. I would like also to express my appreciation to Professor Altamura for allowing me to undergo research experience abroad.

I wish to thank Prof David Nutt and Dr Ilan Rabiner, who represent now a fantastic source of inspiration and knowledge, and supported me in the completion of this thesis. I wish to express my most sincere thanks to Jasper van der Aart, for his contribution and Dutch translation of the conclusive chapter.

The most special thanks go to my intimate affects: Sara, (she read several times the whole thesis!), my father, my mother, my sister, my unbelievable friends, and my sweet little Leo. For them, I can't find words of appreciation; what I feel are just... primal emotions.

Curriculum Vitae

Alessandro Colasanti was born on March 22, 1979 in Milan, Italy. He enrolled in medical school in 1999 in Milan. He spent his fifth medical school year at Maastricht University in the context of the Erasmus student exchange programme. In 2003, he began research work at the Section of Experimental Psychiatry, Maastricht University, under Professor Griez's supervision. He then completed the medical school and obtained the Medical Degree at the University of Milan in 2004, and began specialist training in psychiatry immediately afterwards. Over the course of the specialist training, he undertook the International Master in Affective Neuroscience from Maastricht University and University of Florence, and graduated in 2007. In 2008 he completed the specialist training in Psychiatry at University of Milan and returned to Maastricht to complete his research work. In 2009 he has been awarded the ECNP grant for young scientists and moved to Imperial College of London. In 2010, he was awarded a 3 years Wellcome Trust training fellowship in Translational Medicine and Therapeutics. He is currently a Clinical Research Fellow at the Division of Brain Sciences at Imperial College of London working on Positron Tomography Imaging research projects focused on the study of the endogenous opioid system and neuroinflammatory processes in the living human brain.

List of publications

Mauri MC, Cerveri G, Volonteri LS, Fiorentini A, Colasanti A, Manfrè S, Borghini R, Pannacciulli E (2005). Parasuicide and drug self-poisoning: analysis of the epidemiological and clinical variables of the patients admitted to the Poisoning Treatment Centre (CAV), Niguarda General Hospital, Milan. *Clin Pract Epidemiol Ment Health* **281**(1): 5.

Mauri M, Volonteri L, De Gaspari I, Colasanti A, Brambilla M, Cerruti L (2006). Substance abuse in first- episode schizophrenic patients: a retrospective study. *Clin Pract Epidemiol Ment Health* **232**: 4.

Mauri MC, Colasanti A, Rossattini M, Moliterno D, Baldi ML, Papa P (2006). A single-blind, randomized comparison of olanzapine at a starting dose of 5 mg versus 20 mg in acute schizophrenia. *Clin Neuropharmacol* **29**(3): 126-131.

Mauri MC, Colasanti A, Rossattini M, Volonteri LS, Dragogna F, Fiorentini A, Valli A, Papa P (2007). Ziprasidone outcome and tolerability: a practical clinical trial with plasma drug levels. *Pharmacopsychiatry* **40**(3): 89-92.

Mauri MC, Volonteri LS, Colasanti A, Fiorentini A, De Gaspari IF, Bareggi SR (2007). Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response. *Clin Pharmacokinet* **46**(5): 359-388.

Griez EJ, Colasanti A, van Diest R, Salamon E, Schruers K (2007). Carbon dioxide inhalation induces dose- dependent and age-related negative affectivity. *PLoS ONE* **2**(10): e987.

Colasanti A, Natoli A, Moliterno D, Rossattini M, De Gaspari IF, Mauri MC (2008). Psychiatric diagnosis and aggression before acute hospitalisation. *Eur Psychiatry* **23**(6):441-448.

Mauri MC, Moliterno D, Rossattini M, Colasanti A (2008). Depression in schizophrenia: Comparison of first- and second-generation antipsychotic drugs. *Schizophr Res* **99**(1-3):7-12.

Colasanti A, Salamon E, Schruers K, van Diest R, van Duinen M, Griez EJ (2008). Carbon dioxide induced emotion and respiratory symptoms in healthy volunteers. *Neuropsychopharmacology*; **33**(13): 3103-3110.

Volonteri LS, Colasanti A, Cerveri G, Fiorentini A, De Gaspari IF, Mauri MC, Valli A, Papa P, Mencacci C (2009). Clinical outcome and tolerability of duloxetine in the treatment of major depressive disorder: a 12-week study with plasma levels. *J Psychopharmacol* **24**(8): 1193-119.

Baldini M, Colasanti A, Orsatti A, Airaghi L, Mauri MC, Cappellini MD (2009). Neuropsychological functions and metabolic aspects in subclinical hypothyroidism: the effects of l-thyroxine. *Prog Neuropsychopharmacol Biol Psychiatry* **33**(5): 854-859.

Esquivel G, Schruers KR, Maddock RJ, Colasanti A, Griez EJ (2010). Acids in the brain: a factor in panic? *J Psychopharmacol* **24**(5): 639-47.

Colasanti A, Rabiner EA, Lingford-Hughes A, Nutt DJ (2011). Opioids and Anxiety. *J Psychopharmacol* **25**(11): 1415-1433.

Mauri MC, Paletta S, Moliterno D, Colasanti A, Altamura AC (2010). Depressive dimension, clinical outcome, and duration of hospitalization in acute schizophrenia. *Asian J Psychiatry* **3**: 121-125.

Schruers K, Esquivel G, van Duinen M, Wichers M, Kenis G, Colasanti A, Knuts I, Goossens L, Jacobs N, van Rosendaal J, Smeets H, van Os J, Griez E (2011). Genetic moderation of CO₂- induced fear by 5-HTTLPR genotype. *J Psychopharmacol* **25**(1): 37-42.

Colasanti A, Paletta S, Moliterno D, Mazzocchi D, Mauri MC, Altamura AC (2010). Symptom dimensions as predictors of clinical outcome, duration of hospitalization, and aggressive behaviours in acutely hospitalized patients with psychotic exacerbation. *Clin Pract Epidem Mental Health* **6**: 72-78.

Colasanti A, Esquivel G, den Boer E, Horlings A, Dandachi A, Oostwegel J, van Donkelaar E, Griez E, Schruers K (2011). Effects of tryptophan depletion and tryptophan loading on the affective response to high dose CO₂ challenge in healthy volunteers. *Psychopharmacology* **215**(4): 739-748.

Colasanti A, Young AH (2011). Major Depressive Episodes in clinical practice: state of the art and new developments in drug therapy. *Hot Topics in Neurology and Psychiatry* **12**:13-21.

Shotbolt P, Tziortzi AC, Searle GE, Colasanti A, van der Aart J, Abanades S, Plisson C, Miller SR, Huiban M, Beaver JD, Gunn RN, Laruelle M, Rabiner EA (2012). Within-subject comparison of [(11)C]-(+)-PHNO and [(11)C]raclopride sensitivity to acute amphetamine challenge in healthy humans. *J Cereb Blood Flow Metab* **32**(1):127-136.

Carhart-Harris RL, Erritzoe D, Williams T, Stone JM, Reed LJ, Colasanti A, Tyacke RJ, Leech R, Malizia AL, Murphy K, Hobden P, Evans J, Feilding A, Wise RG, Nutt DJ (2012). Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. *Proc Natl Acad Sci U S A* **109**(6): 2138-2143.

Colasanti A, Searle GE, Long CJ, Hill SP, Reiley RR, Quelch D, Erritzoe D, Tziortzi AC, Reed LJ, Lingford-Hughes AR, Waldman AD, Schruers KJ, Matthews PM, Gunn RN, Nutt DJ, Rabiner EA (2012). Endogenous opioid release in the human brain reward system induced by acute amphetamine administration. *Biol Psychiatry* **72**(5): 371-377.

Colasanti A, Esquivel G, Schruers K, Griez EJ (2012). On the psychotropic properties of carbon dioxide. *Curr Pharm Des*. Epub 24 may 2012.